var title_f37_9_38032="Ultrasound benign fasciculations";
var content_f37_9_38032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/NEURO/60193/US_benign_fascic_conv.mp4?title=Ultrasound+benign+fasciculations\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound benign fasciculations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a real-time axial image of the abductor hallucis muscle in an individual with benign fasciculations of the feet. Note the random focal twitching in muscle that contrasts with the whole movement of muscle that occurs in normal voluntary contraction (see text for link to movie 'Ultrasound biceps contraction and relaxation'). A combined B-mode and M-mode recording of the same muscle follows this image. M-mode refers to motion, and in this image, one vertical line of the B-mode image, as indicated by the white line, is recorded in the M-mode image and followed over time (the large tick marks at the bottom of the screen represent one second). Note that initially the bulk of fasciculations occur to the left of the white line, so the probe is moved to center the recording line over this area. A single fasciculation is then captured and measured. Note that the M-mode image captures the contraction (110ms) phase of the muscle twitch and its total contraction and relaxation phase (230ms), which are much longer than the action potential duration of a motor unit. Ultrasound measures the mechanical activity of the muscle, rather than the change in membrane potential that is recorded by EMG.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis O Walker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38032=[""].join("\n");
var outline_f37_9_38032=null;
var title_f37_9_38033="Transversus abdominus plane block ultrasound";
var content_f37_9_38033=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Transversus abdominus plane (TAP) block ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient is positioned supine and the ultrasound probe is placed cephalad and parallel to the iliac crest (anterior to midaxillary line). The external oblique, internal oblique and transversalis muscle and peritoneal cavity are visualized. Fascial planes appear hyperechoic relative to the adjacent hypoechoic muscle. The needle tip is visualized as it penetrates the fascial layer between the internal oblique and transversus abdominis where a long-acting local anesthetic is injected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38033=[""].join("\n");
var outline_f37_9_38033=null;
var title_f37_9_38034="Patient information: Colectomy (The Basics)";
var content_f37_9_38034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16724\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/60/13250\">",
"          Diagram of the colon and rectum",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/7/6256\">",
"           Colostomy",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/27/19890\">",
"         Patient information: Colon and rectal cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/38/11875\">",
"         Patient information: Colostomy care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/56/10115\">",
"         Patient information: Crohn's disease in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/59/40882\">",
"         Patient information: Ileostomy care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?41/17/42258\">",
"         Patient information: Ulcerative colitis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/0/6148\">",
"         Patient information: Colon and rectal cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/40/24196\">",
"         Patient information: Crohn's disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/39/10869\">",
"         Patient information: Ulcerative colitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Colectomy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/colectomy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10266582\">",
"      <span class=\"h1\">",
"       What is a colectomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A colectomy is surgery in which your doctor removes part or all of your large intestine. The large intestine is also called the colon (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"mobipreview.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Doctors might do a colectomy to treat problems such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Colon cancer",
"       </li>",
"       <li>",
"        Digestive tract disorders",
"       </li>",
"       <li>",
"        A blockage in the colon",
"       </li>",
"       <li>",
"        An injury to the colon",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10266597\">",
"      <span class=\"h1\">",
"       How do I prepare for a colectomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will tell you how to prepare for your colectomy. You might need to eat certain foods and avoid other foods in the days before your surgery. You should not eat or drink anything after midnight the night before your surgery.",
"     </p>",
"     <p>",
"      Your doctor will tell you if you need to change or stop any of your medicines before the surgery. He or she might give you medicine to take beforehand to empty your intestines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10266611\">",
"      <span class=\"h1\">",
"       What happens during a colectomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before the surgery starts, you will get medicines to make you sleep. You will not be awake for the surgery.",
"     </p>",
"     <p>",
"      There are 2 different ways your doctor can do a colectomy:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Open surgery &ndash; During open surgery, your doctor will make a cut in your belly. He or she will remove some or all of your colon. Your doctor might also remove your rectum, or both your rectum and anus (",
"        <a class=\"graphic graphic_figure graphicRef58531 \" href=\"mobipreview.htm?12/60/13250\">",
"         figure 2",
"        </a>",
"        ). How much your doctor removes depends on the reason for your surgery and how severe your condition is.",
"       </li>",
"       <li>",
"        Laparoscopic surgery &ndash; During laparoscopic surgery, your doctor will make a few small cuts in your belly. Then he or she will insert long, thin tools through the cuts and into your belly. One of the tools has a camera (called a &ldquo;laparoscope&rdquo;) on the end, which sends pictures to a TV screen. Your doctor can look at the screen to know where to cut and what to remove. Then he or she uses the long tools to do the surgery through the small cuts.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After your doctor removes your colon, he or she will make sure there is a way for bowel movements to exit your body. To do this, your doctor will either:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Reconnect your colon or rectum &ndash; If your doctor can reconnect your colon or rectum, you should be able to have bowel movements normally. If your doctor removed your rectum, he or she might make a pouch out of your intestine to take the place of your rectum.",
"       </li>",
"       <li>",
"        Do a procedure called a colostomy or ileostomy &ndash; For both of these procedures, your doctor will make a small hole in your belly. Then he or she will connect your intestine to this opening. If your doctor connects your large intestine to the hole, it&rsquo;s called a colostomy. If your doctor connects your small intestine to the hole, it&rsquo;s called an ileostomy. Your bowel movements will come out through the hole into a bag that is attached to your skin (",
"        <a class=\"graphic graphic_figure graphicRef57774 \" href=\"mobipreview.htm?6/7/6256\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10266626\">",
"      <span class=\"h1\">",
"       What happens after surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After surgery, most people stay in the hospital for 3 to 7 days.",
"     </p>",
"     <p>",
"      Your intestines need to heal before you can eat solid foods again. While your intestines are healing, your doctor might give you nutrition through a vein in your arm. Most people can drink liquids within 1 to 2 days after surgery and eat solid foods soon after that.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10266641\">",
"      <span class=\"h1\">",
"       What problems can happen after a colectomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Although uncommon, there are problems that can happen after a colectomy. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bleeding in the belly",
"       </li>",
"       <li>",
"        Infection in the belly or other parts of the body",
"       </li>",
"       <li>",
"        Blockage in the belly",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10266656\">",
"      <span class=\"h1\">",
"       How will I manage my colostomy or ileostomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A special nurse (called an ostomy nurse) will teach you how to manage your colostomy or ileostomy (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/38/11875?source=see_link\">",
"       \"Patient information: Colostomy care (The Basics)\"",
"      </a>",
"      ). He or she will teach you when and how to change the bag that collects your bowel movements.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10266671\">",
"      <span class=\"h1\">",
"       Will I have my colostomy for the rest of my life?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people do need to have a colostomy for the rest of their life, but others don&rsquo;t. Many people have a colostomy for a short time while their body heals after a colectomy.",
"     </p>",
"     <p>",
"      If you need a colostomy for only a short time, your doctor will do another surgery later to reconnect your colon or rectum. Then you can have bowel movements normally again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10266694\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/27/19890?source=see_link\">",
"       Patient information: Colon and rectal cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/17/42258?source=see_link\">",
"       Patient information: Ulcerative colitis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/56/10115?source=see_link\">",
"       Patient information: Crohn's disease in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/38/11875?source=see_link\">",
"       Patient information: Colostomy care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/59/40882?source=see_link\">",
"       Patient information: Ileostomy care (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/0/6148?source=see_link\">",
"       Patient information: Colon and rectal cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/39/10869?source=see_link\">",
"       Patient information: Ulcerative colitis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/40/24196?source=see_link\">",
"       Patient information: Crohn's disease (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/9/38034?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16724 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-2A6F391156-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38034=[""].join("\n");
var outline_f37_9_38034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10266582\">",
"      What is a colectomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10266597\">",
"      How do I prepare for a colectomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10266611\">",
"      What happens during a colectomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10266626\">",
"      What happens after surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10266641\">",
"      What problems can happen after a colectomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10266656\">",
"      How will I manage my colostomy or ileostomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10266671\">",
"      Will I have my colostomy for the rest of my life?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10266694\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16724\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/60/13250\">",
"       Diagram of the colon and rectum",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/7/6256\">",
"        Colostomy",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/27/19890?source=related_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/38/11875?source=related_link\">",
"      Patient information: Colostomy care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/59/40882?source=related_link\">",
"      Patient information: Ileostomy care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/17/42258?source=related_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_9_38035="EUS five layer pattern";
var content_f37_9_38035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic ultrasound (EUS) of normal esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    EUS examination of the normal esophagus showing the typical five-layer pattern: first hyperechoic layer (interface between lumen and mucosa), second hypoechoic layer (deep mucosa including muscularis mucosa), third hyperechoic layer (submucosa), fourth hypoechoic layer (muscularis propria), and fifth hyperechoic layer (adventitia interface).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Enrique Vazquez-Sequeiros, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38035=[""].join("\n");
var outline_f37_9_38035=null;
var title_f37_9_38036="Subcorneal pustular dermatosis on back";
var content_f37_9_38036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subcorneal pustular dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH4AXoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCEenpTqTFLX2x8wFIaWlIxQA2kNO7Gmnk0AI3akyTx0A/WnEE9sVWuby2tVzPOifjTbS1Y0m9iY9KK52+8U2kYxbo0p9e1YN74lvrgkRkQp/s1x1sxoUt5XOing6tTZHdSypEpaR1Qe5rl/E+oWUtuVSZGYehrmJ5p5yfOldgfU1EIsDGPyrzKuef8+4/ed0Mpv8bMObTXmnZlZQhORkda1oWkhVRFhMLglRjNWFjwORQtuWxjOa8OdZzd2esqVkRtLI6YdmKn15pnlnjAz9KuNBsGSwA9KWBSwZ4+3esXI1UCt5ZQ4dcH0NSLGxIAyPp2qbyyWyxyferEBMbA4FZOepoqY24gjRU8kszEZOe1ECeWQ55qRmDt6U5FBPFZuRtGFhZCXJLYye9L5UbHLLuYcdacQpJz161IhycAUc9jTlXYlgVU+WNRx07U9oEKNuZmLdye/wBKavHYZNSoy7iG47iq5w9nErxRbEwvOBTgmBkgnPTmp2CsRzz1460uCFyOg657VPMVyroQFflwTz2qNY8HnBHvVkgNtxgkdaa4HOTgUkxOJDtTzNwQBz39KiKLs6DOepqduTjqP1qNh14p8wuUrTFEAEhXB74qNlGMgYFWThuqkD36U10BHy9KVyeUouh7VEV5681e2jHaoWTrihSM3EqOp69+1PgdI5AZI93rinkEE8ZqMrzxzWikZyia1nNGbVooJABkkK3Wsa+lK8joeOaNpByDhqbdq0qIpGCOnvW1OzZhO6Ro+ErQPOZjzzXZEcAA4FZfh63SKyXaQT7GtU195gKfs6EUfJYyfPVbGMM9+fWmHpT2603FdmxxtDMGmsBxk1LimMBmmiWiNhjqcL603gA+makYBuDyKaepq0zPlIm5BpmD7/lUpHB54puD6mmTZHXDqaOBUcsscQ3SuqKe5NZF94ksrbKxsZX9Frz51IQV5Ox6sKcp/CjaHXiiR1RcsygD1NcVd+KrqUlbaNYl9eprEuLy7uXYzzs2a86rm1CGkdTtp5dVnvod7d67YWw+aYMR2WsW78Wrgi1gJx0LVyhTPOealgCmXayiRvQGvOqZzUlpTVjup5XCPxal641rUrrrL5a+iisyVZJGzK7M3qTWn5cqxkm28qPu7HiqsZWViEcNjrxjNeZWxlSp8TO6lhYR+FFdYTjOKiFo247nJHXFagjIX27CkKg9R9a4vaM6lSKghzxk0qxhPU1LGCD82MZx9KkREMoVzhT1NJSZfIVSmTnIp4LDuaszRoOEGcVA/CnAOabbC1txnBbJPNOC4BHY81UEe+6kzIQoxtA55rTSM7Fxjn1ND0CFpPQiCLjmlC9l5p7hlkCbc+pHSpdhXnHNZN2N1EjWPrkfSkCEDjg96sJ8vOaG27lGAHbp71Fy0hqoxUAd+tSqMDbnBpqA7yNx6VMhj6c5B6HvUtFDkjyDu4fp+FORR2PNPwDk5561GdvPsfzouVYVnJJIPP0xTYvMPLY9OKfISzZxhumAcU0HBypJYdKLisCo2CCc98Y6UuMj73A7VBNchHBkLk5xgfpU0Z804OTnsO1UxaMTC7eDk0wx5Jxz7CrHlxj7xHHSjym6gcnrii4mikqs5O+MqM4APemsjfMAh21fdSCOAB70wqCwGDzz9aLhYz5YNpyFH0zUMke1huXHpWjLGchlGCeDUfl8/PyBT5kTyGc8THJXH41XYmP7y/lWsUAzgcVG8WRyopqRMqZmcHgcfWkdSUwpxVx4gDgrkUgiAHTr6VfPYylTKlvLNajfDI29ecKeK1rTxDMFAnjD+/Q1SMfHHFMKZ4Nd1DMK1H4JHFWwVOr8UTpLfWLWbGTtfpg1fDK3KsD+NcSUwcc8UZkHR3U/WvZoZ/O1qkbnk1cmje8HY7ftmmtXNWOrzW/yzfvY/T0rag1K2n+6+GPZuK9rC5lRxK0dn2Z5OJwFWk9rosmmMOSSeKeDkAgg+mKawz9RXopnC4kbdeoxTKkYE9KTCf3aq6MmmctNeXF0xM0rv9TTAuBkCnW8YUVNtBr81qYiU/idz9Cp4eMdkQR+jfKKmC5BxzUcycc9BToJSoCgceprCU7m0YWJREpU7scinJEIx8oAHWjcew5Nael2Iv0ZUY+YD92pi2y2orcz7hpbgIspZkH8I6URwIuWAz6etaV/pNzYOqsCwbgECqKtlcDBI4pTcuppCK3Q09jnFMkJ4P4mpCPUZpduQc9qi5fKVJJMEBRnuRTY5+kbKS5/iPb2q4gPGzaMnn5c06SNWlLDG49eKtyjYzUJtkQGT0xUZlMJLoQD6npSyoTwWx+NLiOaJYmUAA4b3ojJIcot6EGnXUY1GE+Q8ilvmC8FjWpewPbSmORRk87Rg49qit4reBt0KfvAMbm/pUiszPuJzk9+9OU0OlT5dRioQMEkelPxlOCSR7daVlAOc80FjjGMCufqdFgIJBJAx0+tRDBILc8gfSmmRGcnPzY5GaW28wsfM27QOMdK0jBvUiU0nYtyqRJtSIDbwOf1NTNByZNuMDOM5xT4tm074ldv4ecGll+ZQMAKewqnKLVhqLTIpEZsFMDjtSLEAo4zjjk1OBt4QnI9+tIUySxJzzwO1YMsqviNgWf6inoRIzeWRtPYdasm3DIS/XHA60CPYSuBkjgjjFNCKhgGWJHanxghWCnk+lWDGEbJI39enWmmKETb1bYQPz/Cq1FYiTLdcj+tCM5yNuFz170/y2YE449D3pRDIT7AcAHrQhjQyZGep46U8IpXtimPG/ktsAEh4B64pbVJNmJWyyniixPUPKG4baikiO3DDn271eKgYKjjuDVdl5YEkjsTU6FFQpg4APPTimOpzggZqy6tuX5sYHWmsn97mjQLFMjtjtyab5eQTV0xgq20deageNhg5wOwpkWuQfZ2kViPuj0pjW5UDJIz0yOtXLd2ikzgH+9noa0WuNPkjASMoQOfrWsbW1MpRfQ58xlOv8qiAVumfxq7dMsj/JnA6VCispAbH4VJPIVzF7UwwnHzc+lXiuaaVyPlGSatTdyZQTRVWa4j+5K6ge9XodadFCzRbv8AaBqu0TdcZHtUUigcY5r0KGZV6HwyOGrgaNVe8jdtNRtrggK+1sdGq3x6r+dckIwaN8v9417NDiBqNqsbs8qrksW/cdiSDJUkjGasRpheOlIq4HSpUBKZUbT718m5H00YirEGHIyKGt0xkjgVPEpwQ2CcdaQDJ2j60uYvlRB5WVyhqP7RJbZZC6tnqlXSmAcMAaLUAtJG2zYwyxIyauLCUdNBbjUby7jiEe4oOc7uc1TjQsRIFALZJA6VdhSS2EqRvmOTgFgOlIvTIPC9qc5oiFKW7GgcYBGBTShPzDhak25X5R070ZzkZOaxubkDsI8kcDuaYj7vmBpl3C0gG1uB+RqO3gZSCW4PamlclrUjvUZyCuSPQdaLVCHJIbYOxq86LtDDO7Jz2qIqABg0/IVrakqkbvm6fyqULuIyQR2rPa6PlgsVYrwFHU1LDcF5CoQhsd6bg0io1E3ZF4jccE5HtUhQsi5zgdDihEOA4GCexqQOByBgdyf6VnszWxRlsQ5LK2xjnp3qxBagIWbJKjgjAAqcrvxt4P8AM06KBo2+foTjA71XM7aEOCvclRVUDKk4pZIz96PaD24qZCN5+XqecVIsWDuUE4HWkUQKgVU3DnuR3poKK67dwYHnjtVkqPLXqSeMYpojYyZ2tvHYdB9afKA8oQMsOc8GkSPhsgqAePU5q15LqACBuHIPep0QOpLn8ccmiwGd9nOGDFdh6c1GkCKMkbdp4PUYrQeNkcKR8vU8dKRIg8jFeFP6imIrLbsTnPBGRzyKe8C7u4HrVgIMBQATnOf6YoVWIIZePQnmgCk4zkkjPTioblJGVEhbyznlvatIRHbyqgZ6j0qN0ycgZJ70BYqbCImC/M3bPeoyoB3HrjpjpVlohtbg/U8GmpEwPLAj3qGhorMoI5HXp6VEVA+9ye9XTGA3Kgj0qJ13MRgcUWAq7T0UcVC67nPYirjKyAgHdnkn0qsw6Yb60xFd1JwBwTxj1quy7vlIxzzWhtJCMG2kHPAzmoLlQEO1STnnFWrWM9blXAXPIyOBmnRIxQsSC3ahV3Ek/wANOJ6HdzSATafT61JbMI5Ff5Tg9CM5pDHj5jnP14p3OQAuPai7Ww7Gs8umSKX2ywS46gZFYt9FCJcwneOxxipQjFcE5zUTxnaSexwatzbM/ZpFUoCeBg0zbVkD5cmmeUTzupJk8ggH4D3q1HjgkHpSW9uZm459vWrHksJMDoBUtaGiRExA3E9CO9SRY2jaOD39KguFZmywwo4+tPgfCBFHzdRmobLQrKSTkZH60AHIyMY4x61MvKtuGDTiBgFwQTzmhMuxGmS2DyPTtSNgMWCgAdcdAacSM8Cmv14FSwGuwK8HFMAAAPfuaXIck7cc4prg5A7ClqAwAYzjI7im5KsS44x19KlA+U5qvPvJXGSAKuJMiUKNpPeqsmTKDljnnr8tWouUAAzninSWodSGVWY9OeBWsJW3JnG60JbCC2Nsy+XE21PMYk5Ln+mKIbeKR3dVKkAAEdM1r6Rbm2sGvYL+KKbHlNDsycew71Q8rymblsn35NayloY0qbT1H/JtxgnsB71IqIU+ccjjHrTY7d5CuwdBkueKfZr5u5d58wHgVzOPU67odGoCkkcDualTcyHqcnIJGKnwdoYBCOQBjPSpbZFkBfay/wCzj+VCWgmyp8+9Spw2eewqxEjkFOd2BhvWpxbEkqcAZ5B56VOI/lCAptBz9BVkGSxlyAMsR83oQa07aIkBeS55O6po0jySBhj6DnH0p4ysfmYyeR8w96e4DBC6j5Ao54A5NTPCAqbCQVGcEYqUpvb58lx93jpT4lLDb/EfXj9aVguV2QhTuwN3HTrTUgjAIQ5HfPpVphlii5PbOe9Q+ayjYyscjjgdP/10WC5C8YBAjDqTTFGJM4OF6FvWrMbuzcLhvfORRKJW5JIB7GiwXKckbMSScseeKY8WwAE8AYzVkJ5YIOSxOail3dG4Vu/9KRSZVf5W2lSR6gZokTfER0HFPBzzt2oAeh60u1XKgFgAO460mMgZNnQblHoarvGXPJ6j6VfSMjAJ4HcDFQyfKX24OTwKQFDaUJyeenXrVK8docOELDPO0Z+lajxKQM8HruqDcEk2MpJA65xmmt9RSV1oV0OUHBAPJprIAMDBz3qxnHO05qKTCnOMk0gsUZo/mAiPJqq9sWlBLEYORWk6HOVA3HtmpNgVNzD2GfWqvoS4p6kCoSMZoC8FG5PY9KnZNvX7x9KjcHb1GaSY2NBKnAGUI/GmnJ6g/T1pUU4zuBUc8HmpHySTkbQKGwRVkUMMjt3PaoMN6ValUNCVLY5+lVCbkE4fj/eq42sZzbRdjUrIrKSPTFT7uTjAHf3qI7lcH+EHApxBBB2kDqTWV7mpHOjM4Hr69qVLcCQO55z2qykau+5yrDHWhyi8HINKwDJQqPyMLSNiTgMcD1HNQz3aBQuM7hyT2qaFsruXrjmk0McFGMsMc9qjKAvwenepVxt+YkNQybhtHPc0ICDaF6AHPPJ6VE4bPyEcnmpiCOnGKY8ZyHABHemBGxUnhifSmsQ27OBnjPpWlpP2czFJEG6TjJHQ0ySxZfNcAmONucITitlTbV0ZuSTszNjG2RdrkR+vWrdlGk0qxySBFZsFqks1s1mw6yzF0OwJ1Ddsj0rSitiLZn27ZFbccAckelUqbFz32JdQ0iXTXRJJ4ZN4yNp7e9UXg3AYxvxgc9OasXEiSTCSMShmXLGRs8+3pToI18zOcBRyw5/DFSzSO2pUgZ1cxgbs8E9q0oMFUjWPC9M46E9aIQcIOAoz8oHWrUcZ8ttuAp4G49D60mBGi/eTIDdDntUn+ri3AKq9MjvUixsoA4GDkyEZxVh4jKxVgQNpBJUYH0pqJLkZa3QMyxxlumSSMdO+a0o8HAUY/vAdz1p7WEOxcn5SeVI5Y49fSrnklIAGyCwAwOf/ANVaNRM1LuVgQvylQxPIJByPXBqaIYO47iOuCOvpV+1s3ml2oS20A/N274p4VdyNncoBzxyB7VNrj5ists4lDOWA6nPUgdqa0cZICfOh4NXvKCBizStv+Vd3tzVURs3LMD/GCDyDmjlQcxUljI+UIfl5GTUQhwC0nCJ24zk+tXbnLSMXLFiMMx4BxUTIzq43fL2xj56SQ0QDDKSVLY6VHIWLAICDn65qZSoOdwCrxwM4FNncIdoO3PbPGKGUQSl1XKAnjnNQkLLFktlzxnFWCFYAEPsPPsKjwNgYgAHg8jOPXFKwyrHCNwyOPQn+dOeMkHZn6ionKySEBxuBxtbjPvVpFDjCHLYxjOc0WKRSAYBuGY5/EUFcMSPu45I7GpjlTwwBBpOOeMnPJx/OpArSq2RsC4A4BNRTIQeV6dTU0zfMTgKo6mo51JUAkgn0/lUgVdxOfTsajkAXGMn+lWlQjjOVHWmyIGwScc4oApGJid7Hg88DpQ3Xk5PbPSp5WG7hScDg5rKmkO4Efw5JpqNyW7FxCygFyGH60sxQgcfL2B7VVSUsu7BP4c/hViIGRUXG4+uen/16drE3uMLgMqKct3z0pzRsCTx+dSxwBSSRlV496SUquDt6+tS2ikVHiMjHkr2xnin7McbDUr/cIUd+T6035/UflQMaG3HC9McVZGTlR24NVbbaVHB47mrCkAlj0+lKwrioCN3AGapiKV2MjZwp4FXlxg8Hd3qOVliiIc4bHFMZUe1ZnyV4PbvVtYtsIWNSMdj1qFJ2d8feHerqlioyMnGOtEhRIjnaMhW7ZqKbcjYzuXHTPSrE0YjQHBLGoLk5jcRIQeCCe9KxQxWDKSx5xVa4dwoVBkg4qW2jlMYL8c9BUwj+cFfvZwD6VaVhPUv6FbSJdQCeFibk4Q54Cjqa2Neu5ILWeC1LgqhZ8DBxnGT61k21zJazQKkgIiIUAJndzz9SasasLidzLZwyytJjzExtx7fhXRDbQ5qid7mfoy+RKhgA8xjtjXGWYnGSfT2rW8m3N4x852Yj5lY/Mpzg57VY03TpxIkL+VA08RAdzhl/z61E9xLHDZ2ciRKsSs25EDMS3GSfSqtczjdMNRshbMsbI6vtBOcZIP0qG3RWfZH1H8IGDn0qZoVAYm4klJCqGP6/lU8Plx7VQvkZOM85+tZS1OtPQWOJtmW+/wBzngVOkW7Ct0z94d6fCuARgLhe/rV1F/djuc9cYGfX6VFhXKoiBkV9uxcYB/nVtLYupKkFzjGTT0JBB2b2AHAHH1qZIiItzM7MclRjpznJNVYi43yjG5LYBOGVjyMnirMG1ZdnJkcnHy5xxT0t5HbIUKrj6jHripY9qpvMRQkggg8+/wBBVWJI4RlChfynBIU45xTzGVyw4KjJOPvA9amR1Q7zyhb5CozwR39acqplfmLMdwx0GcdaQFRkEQQ8uVIQc8+5BqJtq4EKgDJ3MVwfoP8AGrUyF9gyCp+U8d+9UrmXdh0G2JTjg9eeMCgdyrNtZMyAsgboeo/Go5HJYAqpxgZz2/xpsjOz7MKM4LA/561FPHhwu4f7WOTmkaWHjbL8iDDDrxiq00YkZQFJbOMFv1piPIWZtxx0PqT7UTJMWhWBX3SEBSeAe2fpTsxknlhIiMOXPyqMcMaRYY1t455Tt38RMwDZ+voM1PHaSRXyoUhnkgIkfbkg+xHpVnVRdXhkaDTEhtmYbcyDahx2z/KrUbGcqljn7xBCXhnhj35z5gGSvuCODRas2Hy8bEcBh3q59nuLQBJJDhG4MYztP8qhILTvKAoccMVG0/iP8KUloXF3AqCN3AJGajcNs6be/HTFSmQbSTlTjIAHJ9PzqEvkcggY5OKxZaZEsrKxRMA45A/wqPGcjaAF5yBjPFTgqctxvAxnPWombEZG3HHHNIZF83lYRR1zUe0gLz/+up0Uu4Q8yenWk8tiW4GQcfSpYFKZDlgeRjg96yWjBbHzByenoK23fMpjw25exHFNMSc8fNjimnYTVyhFEFXHQ/56Vaii2oFI4IJB96mEe7G8dMDpSyqN43PjB4GaHIdiNUIC5yPao2BlbMhwvQ4HSrCjgAEt7UFdwznGeKgClK6LkIfkFHmR0slr+8KxkZPc0n2V+zH8qrQnUYdpAVCdo7U4bvlUDjODUoiC5VBnPJNSx47ABzxn0oEtxsf7vLlflUdOuaiaMMwJBz19xVs9dg4x39aRQS5RByecnoaCiGCLyecckc1ZVeRlgc9gKfsY8nBx97+lNk3rjap55NA0hXHOGxjHJqo8eC5BOBwBVlpNxC4yT1xVadZGY7QVQfrTQCMiqNuCD3qNAjD5OxzU7qZAu6Q7scYFJFEoV1Iy4529KYiOJHluFWIbT99cHpitiHUpIrcLAqKx+Xc/zFvrUWjQICs7sSxwqx+pz0/AU+eKOORtoPOelax91EO0nZl69k+1R2sk8guZUwXcjGPRfpVJg5V48AK55A69eOfSp7cEKCfmY8YpRhpeclScE4xihzBRsNSMlgAeg5NWzArFFT5gOCD3NRFhtZhtIHAyPu/hWhFvfaiIu5znb0YAdwfWlcGOhV8gtyF447Y4q3MJJMsidAc5P6U2IOVJkcKn8WeDz2qdoSW2nAU8MX6GmiGNtYGVdsQIIJJIYnIxV3csbpGC/wAw3ZxyuOo+lUL6YWkW+M5fGPlHBOacZpkjWSWABUwvXPB4Gau5NjSZTCiFxlixwAx2kfh2pZMDMkTHeH3Pkfw9CKWCTzEQhw29gP8AdI7fSl8tkYBnztG35T8rA8ZpCCKUoqRHaWLeXuIxgdQBSsBcxMzHZKw3L/sYOMD3NMeJnmRi+WUZIC4ODwAfcc0skbBcgfuxKFVQcZ2jp9e9J2ArXDgO7MGKqcAqfvZ4IFVLthGcKvKpyewq5tHmGXZuCsSQB0/x5qnIzFuTluVYdTkDrUlooqpT95h8lTyRyR61Wn+VSELeZIRk9hmtG7DKBt+ZjGclenB5rMVWEuElGByNwxnihFoFOJCscIcqgDENjp1IHer32fE8bRukUS/OVY8txzj0qpZ/u8bY0bGGYMPmxng5+tXLmZ3vpFhlRmdco20Zjzxj8ea2RnUv0Iry/Rplu7eN44R+7wo2s/faWqrHG11cMpVWgfJB805Rh79DUsUTwQsHdI1jy6Iq5YsRjofbmo1UOF3EbN37v+HBxz+dPUlLQlX7U8MRsQZF+Yy704U9Kjt7SSebHVhnIPGDUxCpJGtnMADlsclkYckHt+FNku57qQXO4G3Q+XgHIPcmgUZWKEgMMzxy7W2ZHynJNRrIsjDy2Hy9R0IFa1zBC8KEEA56gc5qjd27RSRiNpZA6fvJAMgtntnpis3HU3jIqMnOdvzDjnvTHUEBegbjJ/lVrbuRVbcvYADPP9aPKWZGUoyleQCRjP19KzcS7lRo9hGOHHTFD7mLEtyT16UsQUEfM2cfMPekkTcpfGV6E1m1YZXki3sCDg57CmOTGSSDu6YPWpiqou8nLDoewqMHqrZXPzc0AKDnA5xjqaaYtzjcAT1zTxuwoAwRzntUUMrbnyB3A9D/AIUgFZRgqO3cHmncbMEEf0p3y/KuOnP4U0jDths+2MVIEIQKCVO7njPWpNx9aGJyxZV56Y7UvHpQUVVBPAGM+nep9o2DHHqaijV2PYAfyp5B2kkZx1B9K0MhOzHPApyGTzmJGB0FNjbe2OPl61ZQAkHJz0A9KCrkkhJK5xwOcUjj5e/IqUgbRkD3x3puxckBmXJJyaXUZTlZInTIwB2HUUuHYAAnD9TSXUQaTcGGGG3OO1SRyo25VbpjpQxDI8u+wAgfw57n1omik2jaMc9fWrMf3C+FIPQnqBSlw6gISe1NDEs/MgOUcZIGRjpnvVhV/eHjfnpn+Go+fM2MCAw59sVPHnbww3Djr/DTuKw+EH5T/CvGfalVlBAAGD2I5FQST+SxKsEOMqQMmrmn2Ek96qXkEzRMu5mQYIz0I96uKuS5JbjliVgd2doxxj/OKvfM5yACeOM9PXmoYmwdjo+E++pAGfar9spQ/wB35v7vPvgU7Etk0LbBnduUsEzjpVlBhmwCTuw4zu/H6ikKALgEFj/C/JIznPtU1qoZnEeVQuMnp+H6UEPUwteJa9ijEbuwOY2c5VvbHfNFzPcywsZHi8oqTsDrjd7AdDW5eW8F5EyHDP8AMUV+49vSk+xxveCeTy5PKiAQHkcY4zVLYXYq6WskVukTBYWdh82SQRWhKqrEGUEeWSBnvkinbQfLAY4VmVBjkE+ntQ0u2OUlQwPlkkEYYdKVxPVj7dlxEzsCFmb5Qec+3rTDA7QRLuTeVdwCO/r7dcYqQbfPjZ4w6xZ+UcZz0x+dJM581vLcMpUHYDgfKcHJpAitJGQERGOXyT/DtA6fhVNkQ+Y2ACCQm0/Xk+tWb2WIJMuXfDHCk9eM4qjt3M+c7jjI7ZwcUFoozljtVThz8hJGAB3xVSV1IPmHIT5VOc9/StCWJSqyOQ3UEDv04qC+hUqVCgBCxKjjg0FIdbxGK2MkkI3OqvEWPbkA47c9jVa1lUiSKUthj87KOS3XIHf05qOON2ZvLyrHhVXPI6citYQJvQ3j/ZwFBI2YUkcgHHcjjNaoiem5XiZGeTyRFOMAvHICqx49PeljsIZ0kVpxG7A7AQeAOhYdfWpH3TEXpSJLadgxiV8ng449adMqkz3Hm3Mtwkp/dk4Jj6btwHJx2qrmV2jJvIpTFABDlwWcnGEJHA+tWNA+0yqv2i3lMTvvBbKq3YgenNTztNJF5lxIsluTiBZGyQAOwHIJqZGvobMXEm/7bbFTDHL822P27d+lJsp2tcbc+SkjlE8sK2AM7x/n3qvI29GL4UOc5U8BvUCotOmZpJo7iRQxbdsZQNuf9r+lTMV8woBh+xyPpUM1jqV1dkAwWIByGVRwfemh0MgMkQYrjHHWpZFZPnU7g3ccZ9agmG4MidcgDacGspFkE8aNNKynGew6L7CmMuSgOfU+hqWfO0YGSO4H86jiSWX92m084znpWepRDIByoA/xqo4CncMkg8Z6CrjlyCjALIp28DOaic5j2AHgk9PWkMiRlflG4xjHvUflEkOuQCeT6H3qZVSF1UA+5x/Wpdu0qFzyQW9BQAxF3jO09Dn3NMKkMpYZ45PoanQEOVHrkc5xTWQHOATlsjnrQMhmTcSOgx1qgYZsnDrj61rlOMjOeeCep9qg2x/38e2ypsFymCMgDPzHnJ7092wuc9OMUxVHC47ZzU6r2C7+e9atGZAYzkAcA9c1diGQhyc4yaRYwQAThfU1IoOSHByOfpSGgVSORzk4/ClYZfOOPX0p6ZJztJYjIFIVZsDp3yewpNDKdyFaIrk7iRyB1q7Bp94uUijiKkZJfgDj/CkKEsMgY9QKJp3CEb2O1sgk9K0g0tyZJvYRkIQoDuBOM063iMcnzbiSO/emWReUN5m3jgYParkS5VjyfTJqWVci+XzNkgAI4LentRI28/L3GMjpgVC1tJJdYyQAQee471PcQAugAbaCAwzii1wGWpUWs1zI2WJ2p9a29ButSu5ljvL6FLa3DyMFQg+w96aYLcWrLGyLhfkKrgoSccn8TSaTaywWSIk6hBKDJ/ecZ5GT06CulJLQ5aiuaWomTMQZFQEBmOMYqS0dQSQrAs3LHnHr+NXJzDHdSSQMjug5Ehydp65NQBm2RuQUXefmZfusPX1zRJocdh6xMREhc7g2FZhgt6ZPpUqFPsoKsFkDfd3Htmqt00hEj/cRjuXAwfwFIW8wqzbTIr/e3YHPrjvWRVi7G7Dy9jhtwJPqPYe1OBBKxycNuIPljkA9CfUiqUKNvUOxijfhWHuMn3waAQQWyxUY4TgfQ0XCxaVvLkz5jAxtk7uRuI7UFEWTDJtUsisw5Vj6e3Wooukb4BCvhQDjj1OaktZcTsFIKFh8w6d+TQSWJQYHcyPny5CSQSQoxVaNhJKy5/gbaQvGevIpzuiKqvxIqE5/hbHAzUbGOPzGLHGVbAB7jGP50FJFRv3h4yTsPPUFj3I9eopcbxhmG0Y6DJz0/nTox853EqpkxuxjPX9KidgIphllCqQB29sfzpDRAUM5fOQg3HYeGJpl0CyIDwOh/wD10ElWQbmKZyzep6cGiUbY9xU7hkjJ96m5SKkUjwSb4jtPORkjcPQ1O+pNMVe5QSvLMpK4xn0H4VEwLYVstuOSW/n+tNFrgfvmJy2Se2OwrWLtoEoqW45op7Mea07sQSUiBG1VPJUEfqKv2u64uUvHlVNx2bY/lA4xyPf+dU5jJ9leNXYxZ83YRwGPXH1FV470RzW0MIUSS7gSV35Byc47EetaLUzlHQ3rS0t2u3ksZYPs7LhlkUkB8dQvc/40xomjRkmZpVwcbs7T26eg+vWmWOpJLcafE0SRMsbW4eJcE8Egn3561sau81pNBp8DqqxLli4BIbGQPxoMWjmV0+3Mnl5QMpxuDAZHXmoDFJG2FDr8/DsmOcZ5/CtG+06a3DubgtIrAeUi7twOB97p3NVzI8yP9qPJG0AnJI6D/wDXUyRvB9ik8jKfLKH5j1wQDVe4cb0jkiKt13Z5/CtZ4cBI3WUKo5GcbvxpsekJIqEnbnr1xg8AY6jmoUbmnMluYcztkNHndn65oiDphs7lyQc4BHtU15btZELJgI/C+npTJtu0EN3GCaiUWi07keP41B/HpSAA5zxu7VPtdI0eSNow5I8w8q1IYt7fMrbhyT6Vk00PQqmNXweXA/WpdrFCWA7Z4606UqkZQ4Emck00O5A3HJXg8cEmjUBkbDadww3TDdR9aZPhSygDdtz7fhVkJwGUZ7bfWmyCMoWzuAGc46U0gIFkARSFyvqOuKXc55CjH1oJRMAAFs52jsf8KrNBIWJ+fmizAhCfI+cEHGCBUqhssoOQPWkiBZeCcemKkVCy7V6H3qjJDkkHlj37ntVgAEAk8jg/41VSMKvHb171Zg3BRuOO+70oKQ445ONw/KpFxsztOemPSoGJwCchiMgip4H80YYn69vypFAFQkhsEYxxTRbAHAX5SOc8VKOSfl4FTqoKDK5XuaAIrSBdw27SmPwqwEOdgBUNxweaUIFXIJPbj17U5I+MkEygA59h1oFcjVNrZXp6H+GnQsZcsRsJyvzdcfSn4IddnIYdTwQKlZQxSViBnrmn0ERzK0S7V6vjt29Ku2dvG7MsY3jH8VQiAyScyOqgZBX+IZ9fSr9qmyVpNgVVyuB3z6D0rSJMmPgVJI/L8tlBJxjGWP19KjnBVDHMxbJwTv4XAxwasb1QjhCQvzKozz2JqBYXmwkrRgtkke/YD/CmQiWJ45Np2lolAG72Pp3qwV/e/MCuTuVFABI6dahugXbZn5TySBzwMHj0FMmkE0scbujIVHUkAfSmMmKosbyMS0qg7cn06E/gaoySuGZYwrM5HyLnt1p5ZY7t3iUnaAH2gjj6UsZZl8wgou7KE/xH/wCvSYEIYGIyfNEOmF4wCen6VZDgSjepJz5bntjrg+49aQQstsZCVVlzkAdG7Cl+zNFGPPdQkq7SpGAwHJIz70KNxNpC4aTKylQ643qAeTu+6D9KmkLf6tg5UEqGI+Yc559eKqoywEq/JZtxZT93gYx/Op23eRHJv+bbuc543Z5J/wA96TGMjXCv5YUrwAp67m5H44qKQZMkbH5ickdcEDp7Ur4W3GCA5YoCOwx1zVUyAKZFwPmOFHp60hiOCIQrn6epB6UwnfFubczep4xSPI7BXGGKnkFefwoLMmdp4UYJ9B3GKlFiIV+cg7WGGyf5U8EEAyZIb+DqfxqsoU7TGP3eAQO5P/6qsRSBFIRVDNydxHFO4AEaV2RchG6/0rO8qS1uN8bHzDGydMnBx+VacM6oZAuzoAWLdc9aaq+awDOGDcFuMgY61cZWJtcoQRB7yVZXCCNN6bDgMAfz6GtdImEW8h2JOBvbO/HTr04qvbwwhg2OgJTcOWHt6VoqzfZ9gbHfLnJwe+PxqnInlHRp5dq5DJ8wy4JIC89Rj09KiW2EYkmXaYccA85Hc/4VOsQwxZtqkY3H8j+VSTJG/wC74RGUjI4IA9felcDP2qVlETKpYZjO8/J6flTLhry3S5ki2loxtZj8zKT0IXP61ZnlxDLNYxR5DBNwjPPqSaiis1D/AGiQywXkIy7rlScnqQRzmrRE3qYNnG9zKYrp3jLAs+Uz3zn61LaWKXEs8e10A5hMoILDOBgVpXFvcxI96EaOKRcEsCeAcDB7fjWbaySCaO9EzoUcQYVDj1zn1otcSk1sMmSePzo5IjFEp/1Yyygexp8IIi54HYk53Vr6ntkMLlnYOCdw4LZ7Z7GsnyT93O5sfeArCpHU6ISutSlMhL8AHPIzUkUYWLccHJ9OoPfNWCmVA2EnGRmhVCysGL7T/CRWbKIVTd8zHoOB0pDBtYkEAEA9M5FWXjJAMR47+3FNY42krhhgnB7d/wAxQgIW095OYuFUgEdetZzB1YrsBwcZzW9A6weY0bFogfyXHYVEGnIysg29vkFdC5bE8zuc5nYRtGQBn61PESoJwMAk49KbjJUbT07dakQ8dAMH86xJQ/5mVSpGaljPyFuTgYHvUeTks7AZ/WiMMCoXAGOAvrQyiRxl8kbfcUqAKQACdozj1pygnC9VzyT60LhQWHBHQUh3J4APMUZGAeVH86nVTggBsMe57VVjRlf5SApA59quKWXKH3oE2KVPyjcAoweOeO9TxksD9dx46gVECGIGRu7Z71ZRfl/dqwdu+eg7n8qYrkMgJkJDAsevHGPapn2BEXf8j8lcdBmmhSyYAdWDY3AcYqHEnmpAG+Z3AJx15/zxTsF7l2KfayhVWRgflHUY9D7Yq40itZDYxC8lgcDJzwPzqOAK7QgSxooeSbzjyWHRRj35H4VZcgz20rx7jt27GGCPfHatVHQzbuR7lj8lVG1QQ0rheSx7e4qFkMatO7kyHA46rz0x2p8YEcv93Y+6NXHRh6g9uatmAmCR3IKEbUAGG3nnJHcVSRLdiCFdoMpKPsIPHcY5Jz1qLR0XUQ+xFjUFsqxwQPxx+VOe/iilURCIIFGWkJzx0AHTP1qcSveQNcyXMTTKGkkZ14J7fKOvpVNJE8/QgurU20bKHYyAAs69H+vpgVQQS/aN0JBHXB9e1WSxuLQqbl2dh5m3tg9M46Z96hliNskbSAncu5WU449aTWhpEtq7XHlSbo8qDyODkkdu9bBZZLuRlCCGJVAaQnJI9B71jROoYTEFCDuVgeVwOue3PeoJbmQzxJMDA3DEjJGOufqaSlYUo3J3Z1uSisXMbFypXAGTgj8KnuMKHkhOI3ONvrz1+gwKrKVglEbBt0uHjB65Jzk+2KsymOQRGPMcrHeyA47HK+xrNu5RUcMqTKGBcDPTHPHNUppFYYGd4XHSrZkYSFtoLDb8uMgn2PsBVSfAIZcY3EA+pJ5qGNAQVUMGOOgJ5OOmKikKmWRtuF6njqDViY4Py42kDp16elVEdfNdBuJQ42n+tItCltsrKBkZ+U/0/KoI1ld2DMwXG4+w704Aq7HBPz9fQVYs4lkZ5ArvHtKtGOWk5449CcCrgrhJ2RYjsvNRi21YxhSSwODjoBTF066FuTuRWLFuTn5QPvfTtW08MEFk7uXieMF8Mo5bP3V+grAjHn3/AJM8rO+PN+TKKG7KfU461s4owVVl2GOZpPKMke0ITwdu4AD5c+tXDGhUyIiqM4bJyRxxxVy9y9n5rW/3MMpJUAjv+NVI51Vd0qFmGNzHoxPOfp0pSjYqM+YsW6KUbEYAHRS2ee/FJeAqAQq7ADkA5/L9KieVUCu+Q2drCP8AjBB71GrNtITaEKk89h2zj1rNK42QTPKmx7cgMuHO4ZUDnt9Kvw3a6hZiZvJu7qRlMiklW2KMAgZwScjrULlhEqsNzRjcwA4yf51CLYBpGjQR9A6HgHPH41otCJq5Hd2sIEtykohtWUOnmk/KQcEbe+Tmq+n2wZoluMxwSM0hmKlQSehA68dzV62tCY5C/wC93gJl2+YcnBXsAOa0byNZLVZJHYvCgSOJ84Py53Z+vamJKzMO6iEMs0RlMihvlGcqfUg+vSoVGNrYB3YznqDVm55yW+/jeXz1J6mmbAcnHfjPfisZ6m8dCBkxtznpjNV5ss64JZV44qwXVgArDCHBB6CoXALExgiM8nHY1m0VcZGAsXJ59jk00NwG5Ppn+L0qTykSZwuSpXdn29KRwuAAMD265pbDE2o6blyNhGMcEE4yKPMi96V+FwQvPT1GKTn0X86q4rHPIxydhPoc+lT4GcDgVAmSuM59SOMVJlinJwwPfpiggfkBN3GM4OalRPmDHABHGKZGowWI4zjb704Eg7VO7B6jtQNDnfa4UEgnj8KmhXdywz8x5qNY/NK7yfQkf1qQhwpRc9eTikMniXaA3AUnB3VLvLkhMsw6n8eKqhhnaAWXsKlhbZJjP3iMk0AWoyEVsjORyQeh9Kk8wb8sMcD5e+KjQ5GAQWzkk9RT35cjZuAPc8EU0Sy1GoX5COCN2AevpxWfJHIkvnQhleMhkJOefQ1dBHmAZJK9z0HOKljDMrs5G1Pl3AdD64p3ES2d/D5UkdvYkT5Vt03AU47evem+a8zn94m9cRgMcFgT19sc1HLKomQ5C7EK7s5J4yM+3tVFXeW/QModtw4AIyO1axZNktjasJCNTS4iYZMhKlh1A74qS8lll3Dy41k5Krkn/J5pEeAEFQsMgzKXbjgD7g+tWbm2aOJJmVUilTfGC+dgB6ke9aXsYvcxri6ZZQxG9YlCYEYy/Hepj5koOyMQ4kxlTlQWHA/Dkmpby3tpLeOSaFoQHwJTnL+pA9vWmRhBZ/65nhQkRRD5SQR9/wCtU3dChB3uy7ptrG2BviUhWIkxhjs9vQn1qDxDE/nQrGxcsn3T7entT4I7aSB0SJoldgN5bLscc/QD+ZrN1CZ8hZDxGcIc8/Ss5PQ1inzBHJGyS4kCAAFVb7sjZwf/ANVDP9onPlOZeiM5HB46f59KilRFto5VlR97lXix8y4H3vxpYi0YVuijnHQZxwDWXMa26mmvBDYLgtzzztPGR+FOlGy33x4IRVbdjqc4596dBKrYC7Ds2qHx0AySB/KoC7SIpUoQV3DDdV3cjHemSV7hHW4fb1VycjnBxk/1qCUD5wBkYJXPJ/Krsjj5WaRgiqwwO53Yxn8TVRk5ZmwMYxjgA1EhoiuQzRKWxuU4+o/wqsWaIDcyjIwfcVPPlozECcpuBIHJA5qvIm+JeQAPm68n0H50ItEcsYkXBO35T16VqaZIHjiRFCyQqYzIi/eJOefpWdHkzBT90/f3DG3HvU1vLPDb34icK7xcKc+vOP51pDcU9UXtTja4a6hN2FhjQEJsJ7Anp19Saz7WKdtQhuo44bl2B3sXxuXHJA9McZpItQmt4oLSXdNFOm5ZNuZHbPr2ByRV63khtpmjgiCyzqu12blVJwQFHGODWyORl6yv4rlyskey1WIEMH3eXzyP0qPVIGggAtxiN1yqHlyT6enWsGaE4MW17UDOU3ZYjONxx+ntWtpmpRXFpHbxKTPlkDnkk9ySe3HFJu+5UW1sSRTYtWjkVmuI8owZT8p/+vU1hOsUkRjO2GXqQRnPpzwO9T2qWyIXlkZ5TllAPCvno/qOvSoTDbSTyqI9iyNuCKxBGBnj2qH7pte+xYt2k86STeyjbjbtzkHtiq42BlB3CMn7p5P40SzMqxGFn/e5PzHlgOAKljTZGrPukKncRnPOP/rUnILF2xhUOjBC5ibhiuAcjtUt0oCOIjtd1+TjlF78e1PsXjlVjBAzqF+YDvzzj3olLB5kCeWgGUUHnaPWldiZz53SSOGdZFBK7wvyv7isu5FzHcKqAeTn72OgPcA11MsRJZmQAHBxjlTWZq9u8chkbcI8bSFGenQjtQld6j5jDRFLmNpGEuflJbg+uas2wfBVmAIPI7flVhkG5ZpJAgVSVCDIIPofWqsgkVVuBsaLd5bDd8xOOce1Kokthwk2tRzI3m7JPlwew5NJPEVXBJ2qeSR2qWYMzF2JLHAyaa3KhXLEnv8A571iaIqrzICoyvJ46g1ZxH3DZ+lQhB9oBU47cdD70/n+6aYzmoyMEkEjHGKmQgEBgAaggU4XG7aR1qaMhmO0jryfSmZolDHYwDkDoPenQoBGzZO4gZ9jSR+h5I7VLEzKAE/4F7mgofChVQeR706RWVl2AmlUsGUMOvqeBTiGD7QeB1pXKGIfLORjJx34qXcFJIACZ5PrUZVcLwBgZ+pqGVyEJTknsKaVxMnW6PmKBkKCQM8g1dZtrxl2Gxj90HpWLyZox0Jy2T2z2xWkq74j8mGPO0DgevNXsS0aaSM1uzHBLfLkDkexp0bsiMJAuxCFb1NQRLNzGwLcADPbA6inq5l/dxjDNxuI7/3T70khEM8xRppI1R2Rtu0jtVe2US3A2SENJjccnr2xUksEtr/pJBCsCvTOPUVJAstnsubmArbTxFoVzyozgN7Vq1dE7M1kvCljGHQZCBHVsfezzk1ZeX/R2jVkSAkgEjsecfnVS+RVimRpRLLIxA2gc4x82O2e1PtHnnGMgjjaOm5vqe+O1UiGupLAZxKXuiTbSR4IJwcE+vbpmhY0a1miiKNAz/umLglT3J9sdqpW0lysuydpJDDKSh6hRnofp71oaj9mj1J5Yok+zSASXEynAdm4wfT6CjYiMrtlcKJLbznueU/doD6Dpx6GqRt3dFnB3Rq5TLMOWxycfTvWmSrweU5JUPwP7x6AjH8qgiDwxgSRr5ZJ2hOh9yOuTSkkzSLsZkmEGBgHAJ9OtP3OYWKMBvfOeDjHP8uKu3dr+5Mknc/N2w390+naqjIpDgbQRHyAOh71lYu9x1uyErtLBNwJz6en55NP0zTb6+t7m9T91axsI4+QNyc8j3qpuLKApTfksB9BgVYBmigSBZS1sGLGLGOcjjPpQtwd7aE1qQtuHPzlQUUggAgHJ+vfmqdy3l+WgZSmcbs/eB6U8AxykQsVj2EIF+bAJ6/TFQ3LNkORz5Y8tcenalJjRGP9YT83Qbj6j2qORlIQxjnkDHPFPmJSVQrcrgMvccdKhUDA5Pyk/QZpIqxPCjkEZXcwLsfx4B9KeMxyh/mYffdAOT2wPSpIGVIf74flsjkEe/0qw4AU8YJHX+v06VSE30G2zQW8NwnEcWPl3ffXJ5KH+earzaWY9Yu4nnQSPGjDa2SoYZVh+Hahoi0rW5OWkHyjPvz+FV5ZBa6gUurR8SrtW4UlZNuMDFbRZhONiW+Weyl80QxFUAUs78NkDpS6HLD9uaKONh9nUH5vvAnkgj0/xq5FbQ3FjDPIJnliIzHwQATyW9P51d+yxI8lxCEk8xtzYIz0HPNNshbWE80XiwGBCQAeeg5OefcVXnkmS9jktMEQjK9+e9Wo/nmkRV2kE7iowoz2AqFo5YmjaJox5bfLtXrz3PeokzaKGJFetGheJgNzPjGNueTg+lWbVkfyypXGCRn1qe+1TUby0jsZFiAA2B1OABVeGLK/IAzoABkYwBUSdyk3bU1dMi2/uVcxrhsHdwM/rU8sW+FSDxgLl+CQDyMd6LKMm2jcF1UP14GcDp7g5qSQtI+W2lSAU42kdR/+qkQytcESSLtIweueCB6j0qjd/voNrsyqcZyeRWhKd6uQCcAqVb5c/j6VUlAY5Vh0GTnjpxSuUjn7m2kL+W2wxufvEc/hTo4FGVZRlQNqnrWnIjEqhyODyOQPSqroVTJY5B/hOfwqXqWmV8dQW4Gdw7VnrKQ7ELwjcnPP1xWiRsRRu285qrLArsH7qefelcdhjnaqhx8xG4g85x6U8NwMAY96S5yVVVKrtwQRzj8aTLf89QKko5N2OcZbAzgCpbVlBPG0GqkTEqzdc8gVaTnr0+mOaszRaDMG6jd3qa3yHYHkdh6VUhYDBDHPTntVvK+W3GWpFonBBj4yOcY9aRJTkccnk/SoGlAUqzn2H9KRQHQNuPPIBpWGWGBwWYjc3r6GozCxAQt83UYOMVJCONwy46EVODHjcRjPQ4zTTAZaWwEmWJbHVhV4ud+BgOTgNmolySpXOMZ44zUiHOBkbmJx6EincVh4csu5s+YDnJOMd8Vo6HbNciGdirLuL7AfmY5OP6VkgsxweMc9OufUVWtbq6sZi9uwZeQik9CaqLsRJX2OqtNPa7uHSdmVc7AM9Oclj9elRXGnx21rNHNtJmGR5nJCq38HtWNY65fRTsZI2eR33lg3QnoDU01zLezeZcktLIwViDwo9BWntEZqDvqPh8tWbaPkj3DZnrxjNXYJGiETbg3RwyHkY9vWqVtKok+Y7HYjbj7rcjIP86vMscET/MNxyzEfxDsaqOpUkWLu5TUyWt7IC/mYhmRyAMcHcp689qyUuCLqJLrd5Ydd+PvDHp78dK0DJNdQb4Z2S5RflfBDEE4IGOh96rW9rGkTKqOzNyXY8j6f40zK1kT291HJOGMUkKR5y38TY6N9eeacp+0xFgV3KpYs3JOT0Uf1qFlOxGZt4cjc3Vj/APWp1oPNWZY8KCeC3G73pNmiRcKi4KR42KpAcglsjHP0I/rVO4jWNogjhpNm7DjPHfJrRjwqkO/lJhsMFyN+MDJ7/Ss254jTKlpCQhI9MdD+dS9hLRlJlYRcIOVG3nleec/SnkqY1ZpPmV2RVU43duv61NM5KSbCjEKcsOOPTPeq7Mh8vJD8kDjGF/vD1+tQWIJQGCcBUXacc5IBOPpVbcBE3OQuDjH3R0PFSvJKZkjIAG8lgMYGen14NVJHZXeQsCynOfqaljsQSy5cENkMvDnuKs6ZE1xLLCW8sKu4HqPxPrVC6bcGeOPcQFCRjoc1Ysrr7JcGQqDE4KyoD1H9CDTjuW7paHRz6ZJaRbmZWwMqgHI55JqGIhsZBAChsdPlx1rXncSaELmedWhiU7QxG4gHP4k1iaU0dxhYXO/OJEJ+6PXHftxWziuhzxnpqSTQLLkbcFkMkRJ9OopVljaG3QJl1UIUc/eY+nt7VZtwWbYo4BAUBegP16CopbV5D911ZWJWQYyD2P0oWmhTVxybfPkWNzsYbGb7oYen196jXP2YQPHHuhyd6rg8nox784+lWYEX7P5sRDun3+PlJH8+TThGGbzCSpY7Vzg/hQ2JImFwx8nBA4CqehGP6c96YE3qxTBU8A47+lWJmgeyaF3lV0OflXPmk9j6YAx75qlHJK8plkKohPO0nDe/sahu5aEZSkvOCcYI9qlhKlgQCSvVe9BUMoK8hMHc3BNSwqDM6lwMHPHJx7VDGadpvNvG2QTEcrz/ABc5B9RUCSB4wzsswBwrcnkHgj2qdWRvL8syZXjk9RjufrTHfhH+7H6Z6Z6qO+aZFiKVvPEgdmZlCn7p2qevFQy8Rhio+Yj5gvP0IqcyKod3DN5bcqBjOPaoZW+6pbdnqaljRBKnzKSWIHI56VQupBFkMMsew55q/MqtJIucbhzycVDPtBULj1Vu/wBKRSKKsx5IGOg9TUUqgoWYngc88VYc5OAMbhiqsoARdozjJIzUMtEU2CRg5z0B4qoWhBOSc/7tWJnwdqntkg+lQbPYfiKBnHQHMajlTjv61bDkIu7+9g+pqlGdzDJ2q3rUgPzHvjgGrMkX1UM+/ODn9KsKSu0KGwD+YqvGCSFUDA65qaMnewXIAApFIWQFpAQuOpJNTq3KovIxg49aY2SxGeM/T8KJSFyd2Dn5iO4pFEqyFMEEnB6ZqZZBIygdByDnGTWPLNKz9O+Dg9BWjCxVAR39O1DVgTuaCELgA89acpGPlwG9f9mq6uWXJznHOfSpEdccMGUds96QySM4O3zQSO/Q/QUr/LG6t8sakkkfzqJwpYdQO4z1pd6AMpByeSD0qrhYfG3AyCeozt4arIRmZipXJQAN2HPpVNJCX2BQUXknup9qmibbMu5yFJx1+79fWmAvnyTRpHJsURBCGRSDgelWg6AwmOQZcEFc5Ix2/OqgleJw0sDK4yRg/fGen0pLi7ieJUVFCZx15B+vrmtFIho2VRnIeRXXaNvHc9RVi4jkhjMhBUYznjAJHpVe3doLOMyRnewzkt17Z/GszUNVZogYFVrreQi/wKM4yT3+lbLY55S1Lis3mxmTcUfIT61JfRPazQrOp2Sn5QOee3NVFmIhhzKpkXIUqu3cf909Oat61fzStAJ5SyRKpjfH3cdQB6VPqaJ3asLPIEyEV2VRgezYySB3xnFNiAVssWSQEYkYjvyT+VZkV5EB5oLlmyWHTHHX657CrVuyNAHWUtb4wy9drHqQvYdgfekhEhCg7wFKOy8ryFAB/L3qmwYqFXKhTtIXjGeCv8qllJSVkdJEjc4Poh/u4HpUMzrI2YNrKiqwYjr3PHfOKhoaKjlnK5fA2YxjnA4/oKiD7gA3ccDsO3NWJgwYkAqnq3JHqPbmqi4fq2SCBkDGD2qDQdKFZ3HJ9CSBioHB3HByOD9D6VOqh1wdoIXJB6E1FIoUqwIJySMcUIZPdS313PZW1iJGhMajCkfLKO59Qa19PsbuxmhubuSXeszLOHXJKHnp3PPXpismzna1lWWPjy+nGd2eors7fWrbVhHFNmO5CbSGxkEH1PH0reL0OacGndGPf3Vql5DHB5pDhlkfHLnHHPYDirV1e/O0lowOBt2L05AJ/HNZ1zJJBdR3EquEimzubG4V2NrDp2pIHEqRQo+9kCAhicckjk8flRdFSfLYw4TNIiyhh5GcKMYYn3x/Kr0YZQAuGizycjg+1UkWCK5v1WTEZnyv0x6VYgm2hjGcyY5DLww/DvUNlbq4XKskmGJ2cAhOWX6+9Rb9mFA3FeAzdx71LLGSpcKCnOSThhkY/GqczKqq+G/ugk84Pc1I0TCRN21nYswGFPT8KkUSKV4+fJPAqvbyMDuGG2nKnP61ZxztLsxfGSp/UelQUi2rhWyfvBMLjPPqcVK+05kCl2HXB7+3p+NV7dgFIJCyKuAx5VjTw+1B+7yD95uhz7CnckRtwbJkLdVJK8HNQuqCT5skkc45x6fSpOMYIGWAGajuHWORRvKjGOByaQyJm2MeQBtx1qtkncT1/kamDCWMsoHT7x9arso2Agkk9OODSKRDKcwunO7tjvVcE42k4AHU08yI+GU8kHIqKQjB65I70mUiCWQlcKoOOjYqPB/u/wDj9JMWKZUcjk+1RiQY+8KQzjUU4OSQcZ4qxEzNk8ZxxzULNnYBjp60PIADnG5ehqzIvQn5jtPHbIqzuPIOcnnA7VThlBXJIywGfapNzdwQQScevpQykWJJQVB5zxkUcOeGzkY4FQBj8pyDgd+9ODsyEqCe30FIq5PBAncDIPXNW4wgxuBbPfpVJMgZIyAcgCrKNkgYfPelqFi5tzJgMBgHj04pNwyVAwM46d6hQEAbiCFzzj+dPd9w3E9ccDqaLDFZyJMHOwH5uM5Oe1IQSGIJKc4Lf4UivlztJDDqDggmkDhWHAKfx5/mKLASiYR5JLDIxgilDEqWAUuDjjopprMPMUlclhjimWpUMxxhTkgOM/n+NUgLSMeNxZlJIO3uaJVzJhAGXGdzcHPrUVu6AsrMXwpOc9G7GrcTokUUk43w7QCM4ByenrkCriiXoSpJNfpbhWEb7WhyzEKOw/8ArVnSwT3N75d7CIpIDwBENjY4znua1YIiyyyKdxckIvc+lNu0vnure3nup4I9qq6eWCWXqMMK3RyVEmzNQwSywrbgNtf/AEl9p5x2BPf1qxukuWIK7VLZw53HHUD2NWblvs8KW9qiAsSybx90Dufc+lVwuQFb5SeS2fvH3pSZrBWRZTaobiNsqo5PPXIH51IqrIC4QkueuMZAxyQPfjmoD+7Yuz5JBXDDsP5VYe2nMcxEjtLIGBwfuqD0b3ORgVBTK85MUjLvaSSVt5B4UyE4/QUgG5X2bWlGWB3Y3Dptz7U65MKkrHIwbnG8ZKAADp6knrTJ8yGUFw/ybQem0Adv5UmJFGdmyWUsjqOTnIPJ/wAaYHO8tu28blYDrwcZpSTIsrzIVLDPHHPQH8MdKhLAyxyOAUYAEr7+1Q0UOkDKowh3HBI6DPr9KSbGwlGBjJ3rxkc9qGl2Ngg4AC89Qc//AKqkdQTgkjIyRjmi5VysHVifMXGGGCOB71pTRKse8KEeMYHHLD6e1VNIk/s3VYpJGt2jGHUXCbkb2Naobz3k2ssqM5ICL8qD274ANWhNtaEkBKwE7VlikUH5uSR3z/jT0gSMg2bzIpP8B2n6H/Gq1un2ZlRSxjwcrngZ9P51et3V5GDsxjxzjnmkxNXJoIPJU4BJOSCe+e+e9TRGSJ1cndht25euR6CooQ0a7BLkgAhmGcDNOlkzNGVwrkcr1BY/56UgLgu45n3BFSTO055z9PeopiEOBtDEAjf1x2qEeZ8jKvycnpgqPUUGaOXClNsgOCOuT3I/wpXBIZH8s+VVNpP3Qe/tVuNycFlHsOhP+FUkYebk4C8dO4qeN8bdqkqeOTmpGXPMQsEbBMZGGP6VE8km07mbYG5PTPuPalgZWgkUkyYYbV28qOx9xTXOeQwLD+9x27U7CHyuJRIV2GMngeoqKSRSSCpwByc1XEgwGycc5GKWVwyEvgknG3HapKsOYKq4GS2OADUMu9trY3FeWxwFHqKgdmDEKSM5yPamNKe2CCcYB/PNS2VYY77n5+U5+960wkbSCRuJ4FJcEupG0se3/wBaptYEGnxWCCJyzoJmlY5Dk9segoWo2ylqMMkEEXnLtEqb4yG5YetUQ7YHC1q+IbaJI7S4hjMC3MJcwklgnOMjPOD1FYoV8DCE02gTurnMhh5hz168UmwvcDaAfXNQwviP6cVreHYUupLtFOJgqtEffPNaRV3YwbtqJHH5YxtDEcH2NPDbQBkgHr3zT9RYpdOrnexyS3Sq6H95j5ge1TJWZcdiRnYspChU9PWpITj5hyDnOOxqIYbAGc+hFTxqAAVyQQRz2PvRYonQghQoJPXrjFTY2spxxjOc1BEjTXMUanDNgZFbYsViFmZD+7uVbJ/ukU1FsbkkZxYqrLn3xj71RSuJAQMqO+OoPekuSqE7CfTJ4J+tVnOIWwWYkZwB1NJjLpdhIpRxjbuGKjiuCgPmEnB+Y5xxUKu2wBiNijAAJ4p/yF2Vg27jCHj3oAtSTnrGQSp3cdc461Iu14fm+YEZIxnr2OO9VsFvmbLE/KMHGB2NMWRo4WKH+LgDg+5poTNjTNNP2YSyIW4G0Ee/fH0NackToVWONFjdicdQAOg/Oi2lM1nBNZuhG4F42O35h1xVq51FlkEYBCFw0kzJlYxkZP55roSS0OZ1HfUzLedrdY9pYkH5S64UDuPcntXS3UcYtzI37rCZLZGRnjGex/lXDNrf2i9mWHdMBIWJYfKQDxwOD9BXRHU7i1+1QTrB5xCGNGYEcjPI+lN6EN8+qM2dg0sohkXylBAJPU8fnT0iV90fybxypYZwAM5OKpJdFtx3s7BduVAyefT15qyjsxiSUYZgMY428d8dahu5uW7WJYmEqwwSgEqxlPGT1IHr2FWo7iJIV+0TO7kHAI3AKvAJI45zj8Kzd4PzMcQr8qnsSOQfzJx9KstDKYwqCKRAgwiHlgx6gHrk46UR1JG3Ia8aC3kKq5QNJiPa2eTtDdsjFUJpQjO44ZcKVGcIOTjnrmrcoVUWB1MZEZZwWIOfU+/Haor6B/siag/lFZZeQWw3XAyO3GcUOI7ox5pmkRhA0hbG7LN0/L61FDcKscWWcKigN7tnk+1JNiO5zHKjLjaw6kjOTn1+tOUKJdudwc4YdADWZZKzr5znqm3O8DBORxmpWBJCnOSeG9jVe3csi7Fy5BXn0z0NSCMjCqOQOobuO30qUA9m3ABwGaJeW9q09NLOsjxK+0ALIyjIHsfwrHmciN8bQOnHcGt/SLeKLSEYlRJIu/ceQSG4De+K0jG4pSstSW7iKMUcONmWGVxn8KjRjsDBflJGc9h9K0b6FHhjWZ9suPmwdzEY4YDuKyICCjsfvg4Kg9R60mrCi7l5HYADcyqW+VmGevYD0qRMBgso2gZwwHT2xVNThlyxVRgMPSpWlYqx3biRxkcnHH4Uhk9yQzb1IkzjBzggDoPwqKV1WQGRyVJ+/joT3psYYsHz8390ACq9xJgPux5ZOMd/y9KlgWFC7TucjGcHPX6fWhpsKpC/ODg/l1Iqn5oZNuQR0G2o55ASG3Dg9uOMdKEVY1Y7lI4yx3grjac4AP8Agaja7R40BUbjk5YdP/r1s6VptjdWEDNcxRMU3HLHHJ6H0NYOuXccmrPFbSrJFD95wMBmPUj2rSSSW5nB80rErzgnIUqRx8xzn3ppmLKQoXHrVZnBCnBBPBz6U7zVL52849awubWHSTEMgAJzyMioXYq5YcKemfWmOzHb82QD65A+lNLgjJbIU855zUsYplw8jABVzwTwcV0VmZrWzgSfVLaISKJUglh83aD39s1ysqllAVOemMZzWvLfae8FqbuyvmnhjCeYjBd2PbFVAmauP1VDNeIWvku5GGXfaVCD0we1c6SmT8ko9q6FJ9JuijRvNalEIdLg8vnofes+YaL5r/8AE3I+Y8Ctm4mKk1oecnPmBcjb3HerFvLLbTLJbPscjBwM8VAqjg5+buKkHUE9D6Vncdi7vdiXLbnPOfWgsWzuBGenNMRgoIHUDpRO72kcR2HLblRmHGQRn6iqirjc7F2yiTYxnk8lScIzc7j6Vt2tghQxuBkIdxH8/eufv9StdSjaS5WOP7PhYo0ABP1H9a1fDOrwQ3UQv0L2rt5anILRA/d574rVWRl7RjLGZIb6GWQsI1cjcf4cjGf1rrNQazg0yCZ7mNnigESAYO5sYyPc1k+J7MozSoYny5WNohwVxksa5zYFGYgFz/Opbtsar37SJlYPNgLhVxk9KRgflCFGJ6KcjP1qPOWwpXbwOeTmp41BJIOe3P8ADWZoEYO8EjJA6dqkIy5bPJO4A9akAIUhTtPBKk4zUD4G0JjbnIHUUFErqEBwOoHflT61qaJYpdW80wQuyH5RtyBzg5/PNYcsjyKyscZ4JHOOePwqzo2r32mu6WZWQPjKk9D6471UNzOpe2he1uNrSaKaCB1kLhgDwGCng47d6W3u1+0xC6uJJ7ZjmWNW2s65zjHt6mqN5qn29JrYSNJG7ALcSgFxnqPanPbStMqIyO54GGGQAM/hxXRGPU5no7E00K/aXuLe2nt0ZsbI3BUA8gZ/yagsLaeUlpIfKiLk4PJUdhnNSWLxNIDcO4im+VmBOMgcZXt9auia1tI3ENs/lKm1PM+8xPfPt605bCjqyOT9yCECsituKgcehye4FTQNkb3XDAArk57cZ9ge1V4syDc+CJTt3HpxyfoKk81V3FHHmMNpYHOeMn6Vg9zpLSshS3jySpOCw+6/HBx7dasx3NtZxyKQ63KhVgH3t57FR/DkEcVlK/ll5HZPMj2hVIwOfb6elU4UvrlxFZB4ip81pgpBKg9RVwInsLfaixuHDFhKmYvmGGDdxn29aXULt50gCSSuqBYo/Mx8uASf1PWrBt7WJILqK3M8zghlSUKWP0P5msq4jcXpKjagUtgj2HNWzOLbeo2TfG5wignoxPJI9KlQhwQZOMhgc8HH+FVWKrId/ODzk4OCc5FLCBu2qQzHgNnGR1xWEtzdamkgJQHbjHODxk055dnznrzwvp3qtE4ZcAk4OTu7D0NSSBsYVjgAcKcgiosMnVUmjVZN68fL7+5+ta3hS9hwLa7j3GM/dzgkCsqEs0Uikhh90Y6gf/WqGSNS4dsxyg4DKcZ+hqyJR5tGbN9KWupdshIQbF3t0Ve3601JdhUgHd/F+NULVtigFiWB3EOeT659auKU2kuSyEckDpmgpJJFhZPKTYz7sHkZ7/WhpCFyAWQHGVGetVpS2QSymHocjOPSneZjblGcHpkYOPqKljRJ5rLKRzhhwRzxSM+EU4OM1Xkl5D9F/u5oCyRIZgFMecYzwp9KkofLmLG3Dbv4utQFwco2G7HIxg+tI77zjpxkL1FQqxVvlUk8nnkUMdhwkuIY2jhkPlt1GTx9PSlgURLkABT+H50nmbjluD0OOppwzhhnKjgilcaRbifjZJlQfzpud2VCrg9vWq/K4QndjvTQ5GQQfXrUXGWdwbKq27jGKaPlJCg4PaoUJGCOSckkccUGQIdxcrxwR39KQ7Fm11C4tJfPtJTE20ruwCcGrEniTVtqkXjHPU7Rn+VZcjgkP+fHWohHNJKiJG8hkbCBQfm+lNNrYXKnuh+rXc+plHvJWmZBgFgBgVmeUf7g/MVrXyW9vCLeS3uob1Fw5lbA3f7uOmO9Z4ZQMc0Nsa20Oe5D47nmnA7mwMDHrUCsoIC5FWtPgN7diJshVBdyvUKO9aJXOVyshUZVkDSAgHjg4zVVD507QvI5CN8m7+EnsKvX9jGZvLdnXy2+Qev4VTtEwwJAZTyRnBPvntXRCNjCcncVY0TzFkjR024ztPSrujRQJY3YlxvRSYm25PJxtFVykiSqrthuVJb1HatvRreK5eCOVMyGbCrj5iemM9Md6uSISHtfSppf2SUFUKY35+8P4V/D9TVvw7ZPcb0MM877WYlFGN2PlBJ/pS6/Fp8F9erBKTBHsGUbO6To20+grLvNR1OWNFe4bCOoUg4wB0yBUWubKXKi5dWNxC0Mfl7Xdc84wST0+tWrWzkkdvLgfzQmQM8qo747n2rOgvjLdQDUGBRGMo8wkgg/wZHSuj1PXLVS9vp0YVrhljdCMmID+EN6H+lDiNVG1oZ14zxQLIJWVlYZXAzjrz+dQyQyS2bSAOYwxDHgY9yK2tU0qG0+1LcvnZHtd2cMCe2MfyrnJ7o/ZIbHbMoj+ZgxBDE89vapmjWE7laTCrhF27xtH+NNlJAw20Ooz8vBHtTx84Vn3M4HTGOPSmLIoaOSWJujAg9SMdazRo9RqCaI5WOKUr0jft07VtR3J1WB71vLjlRc7VXbwOOhqloFtFekpNcwWrD53mkHIUHjB9farv2rNopXZJKsoj8t85uUJ6kf3T3rZdznkrsoPNDGk0r7plXaEVFJIJ/ycVJC01xCDIBHGvAiB5VR0ye5+lXvs4to2W4dTlyWePmNO+0Hvj0pry7oixIYg5b1YU5BCNmDKcE7V2Y4xxt9akYYJZsbMfeA4x2/GoUcbmYMFZT90nlQSMUEMglCtgAkFW7k1ibFlnQRxtIPNZCNiAdcep9AKjttWaFY0G1kdj+73/6sA/oM0yQs0hAbafQd/wABURkhhDu8ecAlFUDcQBnB7DmtYuxMldHQag1vNbpbrFC1/IcNNuwEB759cdq5i48uBfs6ISc5klc7ieTjPp9KW/vZLuVJtohIGQiHAB9z6ionhd4lYco38BH3j1JPqabZmo2KLKzyKpbdIMbcn72Ov6VLgF1b5lHsB8pz1qGYtbyYxtPORx0PGKWMbQgDY3EEOOtZstFxZGSRi+Pn/i75FSlhjcGBRumO5HWqhkwQpKqDwff6/jUqOny7twBGCOTipKuTxsI2IDFQeFPWp2PnQkJzgZJxVRc7Bkduo6VYtMFOP4iNzdwaYEts7ssSTY3R5AbnP0+lWoyynZwhGcZ5GKqsjo6uvKsTkjjHvUyuXlBYHcR0PtSAt5AZQjBSegPbPf3qvLJsyocA4xhs805md1IVenAYjJqNwzMo2KSPlJB6+9JjQMQRnnLdiOtMk3KQwOw/7XQ/hSq+0EIqkDOAPWoXJC/xN9am5ViTJbk/KvXK8ColJRmKHg9O9KWLoSpy2OM8VE2PvE4b0zSKLMbgnCjA9u9OZgmSBkn0qvE2RjOO647VOYDcLuVlWT7xUtjNFrhewivyeScj8DQjA58xs45PHf0qBCWGAxznpjp9KdkkkbiOefWs2USM2cschT2HaoCRkggYbgUOx/vH2PrTF5ILjH92gZPIrKny+n5V0i6nawWMN6l3EXisvs9tbD76Stwzf1zXOiUNCyIVHHQ8ZNdJDamLTJrWG2iEEmm/aDOEBeRywBwfbkYFbU4N6oyqSXUw/EEyP/Z0K3IupbeDy5Zl5DtnIAJ64HFZu/3i/WtXxVELY6a/lCCaeDdIoXaMg4Bx2JHNYu5vf/vmpcG2VFq2hygJDDarEH34Faek37adfpcqpZQpWQDup4IrPUk8DgjofagPwQefrVJnM9dzYuruK81AXGGSHd90HBxVCC/iNo8P2TZMJCRJyS/PRvao7UGRvLRSSTWg2IHlTYJHUbQr8DdjOSfpW0HoYySK0IWeHzi52sxjeMHLZA6gdea6TRXk04NqFzbNDB5bxWpYH95KVwDg+mTXNWgMdxPtLIojLxyJxg/Sulg1e5uLGxh1W8820hHmIhXLxknHJ78VWrZMbGf5MguJ1iB+QqQoGdozkkU7VbyRmjKgCORCGK4xJznd9eMVqaDJah5o0fIV8hgeSD0IrF1KSOIBUVSRIXjf/Zz0/nRsaW6DLeSJmh85PPjLcICQRwe9TzO32qyWRQmOWdRywI+8fWqSuMibeV8t/l6YJ/CuhtbxZzLcvbQ2xRVjTYhZfr7U2xRVtS3riJawLFbylrAAyrk48wjjP/1qxtLgS6uS87FI1XdtBwSeaTV9R+1iJI0IWMY35yWJ5z7c1T1K8im06CO1UxNHgTt/EzH09R71CfMzX4Y3Nu5sRHa77Z3cxOBKVGQu7pmql7DJAdkgBdScHPGOxqjpl5MtzKIiFEpG8Z4GOn45p9xcyXdy010xkklOTxjmlK1iqUnIjiVjkcEk8HP3a0dPUm64C5CHL5ztPuaqYCKMqOO4NaenuzaZeQB0G4Z8zO0Z4wDj2zUw31LlexCiXckKWUEjfYzJ5pQ/dZj/ABZp1x5mxApwEB2v/eHf+taes6ibuy0+3VGgtLRNijALO3fsMD0rHkZ5ZWd5MkLgkAdPStG0QixGWCqFVdp7nkHHemlyHyygrggkHg/SjeFiJbA3DPI6+gpjsu3aE+8ei89O/wCdZlEjkiNjnIPGwHOSRxUU0g+ZH+7lcnHT0A9jUe85BLgc/ez1454prkFgFwvGMr90fT1oGhhlC4MgY7mA46nnitjWSsFlE0W5dygbS4PzYO48dulYhRCCoLc9BnnpTNm58BSu4d/Si9iGrkPJdWDLhTwGHUe5/GoLuWe1jEkA2qH7jP4Y9KmkXG8qGBGMr2P096jlQttL5crx1wee1BLZc8wSr8q8EjOe2e49aR5vLB2kjIBPHQ5rMFw0aYcbUBO7068VatmLHBBbIyPf6VXLYFK6NCzkjkbaHYhsFtvY1Y8w2s+5QSHyrY4x71Rt0CA/MoRiCe1aG9nwhAIK43Edal7lR2LcbAkYJUrgk9jQIwVLLlstjrgj1FRxEAkHO3HBHSp2YAlih24BIHX60ihCcMSq59RnG33puUDFhg56A8f5NBCl/vBoxjDev1pm5lyyqHX14yfpSY0KxXAAJwePxqB2HXHA6H/GnbhhSuCOhDU2Q9SoyD1XPSpKE3boyd44BI4pkRYk+ZgoO55pHOG5KgAc+9RsxVsLnaPTrSKJJZkDAZPHfNammNZSWzpcSGOfqUI4fHQ5rEkAkViOOAD9KcUDg7lwRzxQpcomrj3m82ZyFwu445qXzFA44Y9DUBQeWH/iHJz3pSwJXDL8wxgc1DKRMOVIZsn19KYH3A+x6HtSKcIRyMcimE5xg4z37k0iixaSRtIFlB2nluM4xXRQXg0W1tfO8RS2SzqZvI+z79invjtXJAAt+86N129TXWf2bF4h0+1mutL1Cby0ESz2pCiVF6Ag9+2RXVS2sc1daDdY0S31Blkj1WS9u3hNwry5BeLuy9iQByDXENqlqjFflbBxu3kZ967S+llsr1UXSLi2QW32azDNxGjZDk+prlJdIvPNfYLbbk4zGM4rVo5otmAuecjg/rTCrFsjoKdFnGc8dcnvTsDHmDA965jVhbzeQskirucghSDypPGaIriRsq7llGCQO7ep96kglEdlPb+SHZ2DK5HKgdqYbVrbdJIkkJkQyKCDggd63RlJk9qqyTRpITJG7DgHB+mas6fC9vdvDGpCu5BV+o571V0uKCSWKaW52sDvRV5yR2/OtKW/uLi4muXhVWc7pSv5Aj8aoVNXZSkfyJT5JddjA4PcirjNb3MM91uWPZICbXHUEfMVqlISd3O7Pr3qs25JFU8ZFYqZ0uKZq/araM4gtABuyTISxYfSrN1qBuZWcr8oGCOnGOOlZSvtHXLHqaVDj5jwOhzSc2yowSHG5UTRSiJXaMjcrcB+f1qGZ4p76ZkhEMbtvCluBx0Ge1SEDfwvI4zQsS/xKDzwDRGdgnTuiK2OI9seSowSPT0+tW12KcEkDqRmo7aAoz7c/NjjtVmPac8Yx7f0pTlzMcI8qHpIQ/y4x6daeN6yEhmTHBI4NIAuwhmIkP3cLwf8KkjO3luT0HfNSjRkqeYzkyPvLE/M1JO4jXIXcBgNignazD5cHnGcfjSjaCpYlwTjB4xmqTM7FhHZoy5TIA3BSc4HQYpshyy8AHO356bISu5QSjDrnrz0IprvuyDu28nr/KmIEJTIPyqOduOvqKibBOOByNoHQVJI2B8gz04PaoMMST6fdX0JpjKd68oYLGCxYdh057mrTH5VwxJ6ZX1P9Ke3zL8vGD35z+FNdRuweqjI2kf596blchRs7lKY5BYHnJOO/wCNRyuMEucRnpu706Z2jYshTaw+Yen/ANakVlZWQqdpH1A9/pUiY2SJZEJIfHXHYU+3QRqCCF75PXHtUgddhAU9MgH0Hc0qHftYZK4IBP61V7onRFmMlmUhD5in5MY647/hU1pLPGHFzxHk5bHzL249ao28wjbkYVcg/LkZ9avWknlsm9Q44IB/P8aSsVYvRk+cq4YHbnBHX609XGMDlcZIJ4HPaq7OpXdGxBPzcng++acGGAWjYd+M4+lDLWpNuMcm2UMQxxuXGT9KdIyAkhG2np6fhUDMMbRw3r3p4Py8grt/hB4xUsaInBDHjK9x6UwsNuUOT+oqWdtpAXJIHcYqq7HBxnJ6n/CpKH4JAKtyenqaQEbgRgk9aYGyoAP3eh6fhQegLDAAwMUh3DAc7hxzyD3pyEBeeaZEMZYnBxkmnOx2nAyaTGIXbdnBxnljzSjI3KMLk8DPSmuwKFV6mmIx3MGwuehx1pDHtkHGQeOmec+lPVGHODgD8veoziRi+ME/xU+GXZMGcbcdcnNSgCbbsJOVY/5zXTxaiHezRb5Egu7A2gXzCvkSgdSO2Tj5qyLqznmsri42ZgiXJbsfTBqzKunWlpZFNHj1ATQq7XDu53N/Eox0x0xWqvFmcrSRB4kvbyA6XE94st3Db7bgxOHUtn5QSOp21mf2xcf3V/75o1N4JZENvp6WC4O5ELEOfXnpVHeP7v8AOm6ruCp6GbMVywQDGMfjTJV2Ar1x2qWyuI7my+1TRBXErZb++T7Uum2n227lUDhEMmPp2rVx1scindakcexICfMIkc7Qncj1H0q5qd9dX/2T7TcnNsnlRZj+XbjoR71d1C2gsrZJLba1wiBhkDo39RWaymeCRjMcovLYxz2q0ZO7K1hHCglTJcgFgmMdf8KtQXRjWbfH5xZQisTjaPUVYs7DybIvccswBc9+ec1Qn+UDZg+tRNtbHTRWhbsLV7hZJVAEca5JY9/SoJHz9/nHT2psbSiGRFd1jflgDwacj/MuSCM4AxWLfY2SJIypTfnA75pH+/hTuUHPPQ00g4xgc96NwIIHK98cUkVcf8wPGQ7Dt2qQ7lwGOTgUttHuTKElT0xz+tTmIbAAQMjnPah3KuRxE5IzyPyp4UHkksQOSe9MjVR9xhj6VIH55GGHT396kCQKWQgrg+nU1NGdp2jr79KrBlRcHg9PxpyE5HCsD/Dn+VUBZ2ETBkZV3cZI4bHrQ452Ec5z6CnZxGTGeR39+uKUsh5fBye3b60/QhhGqDJkPfBx0+tKoOcDAAHGR19KhkOZcJyODyeDzUqyMoz95vbr7YqkIaNvl7iCvcH37mj5QeeSOuPTtTictgEZHGaaW2rsOQW5IHQD0zTERyK2OWCgHjH0qIkLHvyQM4OR34GKU5A4IJA4A7e5qK4YcfOSvT8PWgGVLhJA8jKDuj4J46+vvxVZXAYbSeB1PpU0i73Pljc+cBucDj86hl8sNIxIx/DgcUEE8bfOMsMqORnP0pkRlinYy4eJjt9CD2/CmW7lVPBaTnoeB05qWV/NX+BcNxz949j7UybFnkcPhcfMCR/X6VYtY3aSNYSAzggbGwc9jzVZXCqEYgN8xxjOCB0rLuPNhkfyxuR2H3zu2L6mqirik2lodTayK0aum7aTgAf+PDHapVfePuheQeO3ufWuVtLqdJAizsZG+ZGHO/HBHP4V0RkDY3LvLAE7f1pSVh058xZfJIZcdefb6UxHKnCZwTjNLwhByQcYBAyTUe4EnemT6j+XHeoZsiQyEgjg+1Qbt5Dbc44YikYhRg9ehp8W1AMZx1xUlDHwNxPUcA0sTNjkcDjjtSugdSFOR1/DvUQO0FQBtI7UgJBleXA3H9T7Uk2V27evqRQobZ8wJA6HPShiWIxzgdjigaEONoBUeoOOppgbeuWOcHsO1KFGcge3XpUiosYJj45+UYqWUNLDkBfmPBUU1u/BOQMe1PVGRiwLBfQdqYcYyQOOhqQJGkleAxCaQRk/d3cZ+ldc39snT9P/ALIvYLS2EChoROiEN3Jz1zXLadJBbXW+7s/tMQUgx7yvPY5Faf8AaGjHroC5PTNy1XF+ZEl2RS8RDUftMJ1a6W5k2HawkWQBc9Dt6Viea3ZX/OtbUpLS4kjawsls1AKunmF9x9eap7I+5Oal7lLYwI7lVsvJRFCk5zjHHt6VZ0bUzpt/56RCRWTay+tZj7egOe4p6rg1s5u5yKK2Jy8k9w8g3ZdicD+VWdNnjt5iLhQFY/eI5U+4rR8N20FzaXCNcLDdRurIpONynqazNT/4/JgSGYHlh0NVfl1QJKWjJJb57jYHJLlcN6GoQcg4/T1qKPOMrz2p65jcknk1lJ31NlZaIVGJYDaQTUqjnJ4YVGX4O0mn54+apGhzNtHB7Yz6VCRsYtxgetPYgrg9D2odcqT3xTRR3Fp4dubW2jkCI0TKhweM7lz+GK5y+lUSyKAAy8NjnBqwnijUG08We1VG3aZMnkVlIdzdSXxgVcppqyM6ad/eJEJMeWGPelj5YEHOOwo3FiFPP9aeOckEgdsd6zNhygnaSe+R6VOGBU4Cljyc8EVAihSclsHoM1KMK67QGJOefSqQmOOC3Ofoowfxo+dW524659vSjG8nJ2qBkj0pdpU73bcuMYA4z6VSJY2PfuA2svpk81bjVnTZkfXNMJCqQOehBPWomlyDg/ie4qhE6NGG+QAH7wB7duaJ18tCdnPRS3TPeoIxxt+XNMmuJ5o0ja4cwRsxVCOmetAhgIJySCoGSuffFQyqDjbn0Yd6eRscquCRjjFQzy4QFBjavUDt6UAyFmZSZEdfNX5Sy9ef/wBeKqopwDkMo+6D656Vbfdsxkbhkj6Z7VVd04wrbyc5JxnighjMhXIDY4+bdwM1PBMihg5JVjzx90eoqGZswqrk7kwACc59RTVwBuyTGPvbhxj+tHUm5bG4fvBwG+Zm7GnbirHKqxUYx13D1BpLaRZYpFZdkyOysD1IPIYeo7VO0ZES+WDtIyCP7wqmgvciS3LoqLIHj3BwpGfm9j29xVy0lmy0crDAfI4waitMSuViGDyQrN1I9/Wr1xCInCM6Fgu4kc4z6+9N6oqNlsI5IPykKyjHXpTyxJJY5YcYHT86gjwG287P89KsYVULICQfWs2aIFCuwcvs9u1G/BOMBSeai8z5fnXGOhxxUgG/JQZyMHFSUKcux2sc+ntURK4yvUnGD1qXABUFQrdAf896bIMksRx06daQDd2w4YsCegNOLBxzgMKibBIVTvzxz2p6jCr8wyO3c0DRJgsODnd3B9PemIzFt0h78d8Ui7cEbiD6Cgk9fmI+6enFSxkjMd2OAAeOOf8A9dRyYC5PPt6e9OQEgbhn+tK+ckDv696kZY062FzMFe6hgDAnzJs7eO3Her0ukWaBS2u6cB6lm/wrIPRSMhl65HSuxgS0jjjsRpVnOG0/7UksybjLJjJH06jiqikyJto5TUoIrKRBHeW12pG4mEnA9jmqmIzznr71teJBHJHplzBbRWsM9vuEMabdpDYbPrntWHs/2qUlqVF3Ry6D5f1qaPnviolOCc4HvUin5R6GrOYcy5YYOD60/wC6M5yaRcEYA6d6UFd2T27UMY4E44p2MckjHp6UzPzAelPIJ9s9aVylqHAOWIyOeKdHhlPv69qYSegGAOPrTui/L19PSkUSpyR09s06UDGSenUdqrw5UEEnntUjZxkHIFAxsbbiRzzwM9KtREAnkZJ5xVTOzBxgeoqdTxycccUDRYJ+YbfXHtUiNuzjHPSq4ReD1zx9KlQFWKkglecigolXBGV3En07U/crDIx74qMEBRkHA7j1pIwzYGAOTg9zTSE2WVbB2gncemaeWDheScHbnrk1Cgy3zE+2RnmrVuzAhQw89m2iILz9c9AK1jG5m5WQ5mVEjKAKuMjJye45qqzD75PyDp0zWs93brEsdzFKnmLuRivEn09qxJJA2Sm0ZzhfQVUo2RMZXHZ2ptUbyecg1G8oCqy4cE85PNMGQvynHUnmg8EdSO5A61ncsdJLlMKvzMMhvTHFVZAQpVVJZR9c8VO5Cg/LnnPqPpUDbhwMjPXnkCmmJjZHEaMrKSRnjPrVSTEbqVwxb5R61NK2MDJyOvr61XnIK/Lgc/ifWmZyFyy/MHwPuk9x9aX95G4ONquMY7URSv5gbarDHU9KSUnd5bhQ2c7hz2ovZk2JbW+isJSJmBSZSjbQc4z61uNbxIiNiSPzIhLFnkOMcbTn+dc7KgktJElKqDjO0c49frT4VwkKM5OxQqE+nWtU00Qr3Lc22ZHU5U7flfoQfapbWSVWAnZTLgISRncPU+9JJIZU2sRkEBcngH/CmJyFVSynH1zUXsapa3NeT908aSxybz8pGOvuO2Ke8Yji3KSy5wFOQQaZqGsyT6UiSW/+kRkKXQcuoPPHsKjtNQWaJLJAJW3bEmJwCT6e/rVOIoz1sxMnGQ3yf3O5NODJuBXscmrOo2r2lx9nvPkuV5xjcvPQiqahjgjBxwT03D3rFqxuncnZhty5DFuB6U4k9+gHB71BhuMHcuTx6U9DhMEEg9akYxmVV57dD605hiSNh3+b86Y22LOR8rHPXvUcMm2clcknt7e1HQpFnZnG0A45x7UsROfmwCemF4NV2b5MgY5xxTi7cAAls8HtipAlfAO4jr0WgKOGPH8IoVTkE89/rQvGARyeMdsVIx8gHUnpxWxfyHTIdJjS8nNzEguMZAWIN0C/h17Vk21vJO0yCSJQkZfMh25x2HvXTWCzyadbC6Oh3aImYhdS4eMH+Ekc8ehqokSZleK28+5tb1Z5pYruHfH5uMx4OCvHGM+lYW5f9qtvxCbg3kZu5rWT93tjW0IMcajooHasXn/nnSluOOxykY5O4mpgR07VX3fMM9KlHP3as5yZeeOlK2N2OlNA+UZznrxzTj06496BjkXvzUhZjxjHvUIyAOT+VOGd3BFSUiQEEH5uPWlIByCOSKYpA6fjTmbGMcn0oGNMYBU8j+tSISSAQevP0oXjd1x79qTaR3yD1oGNaRchSevNTL94hME9yf6VD5eF96fGQy4YUxlncRjkjt0qSM4YKSDzjmowCACqkdxnvQPvYcDjke9CQ7lhugyCFpA2TyOg/Sm7gSPvelOLhTgbs+9MCSEZKjopPX098VJeTug3hnkwNgkYYA9RiqrPkcYA71E8sk/liVv3UY24HAPv9a2hKxnJXLV7eXN8kMl3cmR4jhfcYxgAcADpUCMd2SBjHApqED5Y12Kvb0qYMN4LnOOuKmb7BFWHFA5GflA4xSHHzKCcD5s47UjnhSeM5zTXUMGPzEZA9h/jUoYfewFYnJ/KqzKdzcE+3tU0hPTefp61XnwrnBJPfPAIpiYxiSdoGXHH056VAWwGGOp6+tDkjP1KnB65pEAPVto/QUzJhtXgZBBzjIp6sewIIwOmfxp8Y3YDDI6YA5p55O4Z6HHOePSkUQpsUjJBU8fMcYPrUip+5Jik3Jzx/XNO8oY3YHPIJ6g09ScNllXI+YEZB9xTQrCW+9WG7JBHU9KnlUMNxIyOBUUa7GZTgDqO/wCVSx8ZYkAD+92/+tQy4kkd26201rcMEhkX0ByR09xzV7RtPaGRbk22+0jQuZGkz2/LrzWcwV1wpUOeuD29qbhvI8pXZUzwAx21SmKULu5q6hb3Nrc/6TIJfO/eI+cjaemD2pobhlPDKBjHH61SWSYBVdi0a9ATwParKFZACMsp4PsfSom76msVZFpjkKOQx6+hH9KaxKHcTjPI+lLGrK3J59uce1RM+JNjAFT68VBQkuJhtcZ9c/0qHyjEmC+FYHHtVgDBPGV6Yz0pWUcoORn8qVxlcFvLb5ApbvUkak4wM/jRsXOM9eoz1pisOVAJx1A4+lSMsDHAzgA4p5xj5iM/yqEkbgPTkg9qcGy4AJDe461IDnCkhhyB78it6+l0vTLexil0a3uZpbdZXld2AbPpz+dc+HBDDGADjJrq7C4bTtMtV1LUYIlZfMht3tBO0anoefug+lXEifQW6tNMu44obfThaSXNi13E6M2UKg5DZ4IOODXGhWIBw1b2s3F/aTzM98txFqESn7Qq48yME4UD+EA8EVgf8DaiTVwinbc5OCNpZFReSxxWpc6dLZKhlBG4Z4qro88VveI1wcRkEbv7p7GtjxJq0dzNCIpRKqIBuA4rXRI5IvUy8c8Emo5Mk9MUgLH5jwP509BnmoNRSWIHSl/hUdc96QjGScYHekUg8g/TFSUOCdt3A5x60YG33PQUmfXA9KQ5P3fyx1ppDuTqDjJIHYCnwjcB1IHHsPxrcs9DlhBNwhBCo5yOgaqFyr2ZnQIAh+UEjOCO4q3CyuxJp7FaZUiO1CGwOoGRn2NMtPmuEQSKgY4Lt0FMLksGA3e4p0DLDmbIDKcAZ5570RV2U3ZF1hHHnJygPHBw3vSQndubauRxmqf2+dbnzmCuqHd13Ej0xV4RvJFkKu7luOMDrWjhpoZqonsP3FsDA+opj9T8+4dj0/8A11EG4PB44G3r+NTRlSFLAnsVUf1rJJvQ0voQsvILLgc8UzDMzL29TxitFtoGZF/d4zx1P51SUpI+7GATwDVvQm9xqLsYYOAucn1qZfug/dB6AdcUxcsw4GBnJNSgEk9CCOff6UtxiAYUruG3pgnrQFI4B688HNOQEd8dh6UwqQi4Pzgd+5piGMuPlYgDAPB6DvVWUYJI+9krxzxVsptXe5BRuVJPWqcg5JxhB0x3pNCbKhYY+VS2CM84yaRAD97+EdjnApzRCNGEQYgsTk9Tx2pgJ56KMc4H5E00jJssRghcqR7EHOKnwOi4IPcZzUCsyHs2T8x64qdfuADJA7HtQWiVdwYlsjjgDvUbJlRjAbGNvqPWpR9xWAHTggU4Ab1J475xn+VIbQxgzgbiCFG3OOSKi83hP48ZHI6CpyBvAYHLD5eeM0yWA4fO5WP8XUAimIUDJVic54KleMf0pxOEIAOOpqGIMFO8jeucc/rT4yxUc7gpzwM4+tSy07jz8p+V2Ixyp9asoSFHLDFV2OW+YAgtkjpgUq7lACt8w4VuxpXLRpRSDcFOMHqx4qS5g3feUEDjPXms6ObH8W4D+EDpRJqJWR98W5R17HPqRVRV0Fy1tKqdvBHHOM1KGySucHODx1qqLlJANyhWPpzUwIKkDr1xWc42ZadxTGOTkMD+dNwFOQCe+OlOdiTt3bPlyP8ACokZm+8ST6+1QMcX2kEruOecUoCkEnk57etIQDjdxjjC03cAGI69MUAPyAGBHNbf27S7+3gGpfa4riBFiLwKHEqj7pIPQgVl2Vsb65EKzW8LBd2+d9inHv8A0rS/4RuXAKalpGPX7Tj+lNJkya6sg1+5EqWSw28kFikJW281ss67vmY/U1jbR/cWtzxLGIoNKtvOt5pIbZld4X3qDvJ6/jWDul/uZoluEdjlnA2D1PWlRfkwPWmA4TrU1vyMflVnKtyUAhevFKoOBzig5wFHPFSAKQOxpXLQ4jcBxj3oVcAAYpVJCkkgj9aXccED+L2pF2I0jMhZeFwCSTVnbHavAyyo+Arn0yO1R7cAA0wqDwOx6dqtOwWPTbjxjpr2clwwUTzRqPKUZ6ADH6V5+7XGpXp2qWlmcsFB6ZqlsYYPf2q1pt7Jp96lzGisU6qfSjmvuTGPKnYsXNk9qCsp2nO1hjlT6Gs+UsqsAMjtmtPVtWudVnWaWCNVA4AHB9z71nhdyhjjI444ptq+hSTa1Fsmgt4TsjPnk5LMPWugsUjEBZnAcYCgc8Vzu3cOc5q4lyyRhQvTj5uauNS25Hs7bFjUduVdV+c9xU2jX1raErdhnJOcKOox0rKcs+cnn2p0S8Y+6D1IFQ5a3RTjdWNHVdT+3+WkcCQQR5HA+Zvqao4IIAA9amChRgrxjjPanryqgJu4wfShu40rKw1BtAPJPXj+WanQY28Abc5461GM9MdOgFSI6kt1FFwBiEYYyRjJ4/SoXkYOxJOQcjiiaVIDvmLH6darpcNKh3qVXPy46mqEyGYzSSFzGeTwCO1RynGE3r77f5VYI3kDJ+mMYqAqACVODjGKCCu7bPL4Jy3Y4qJZG2vsDYU4JI5OakKDIyCcdvSmlDhwvLHAOTmghospMlxGWVApzggcYHpU1tceWCjKHyMc9vfNZ0EYCD5W3g888VobNsZLAEdMUFJlknzPujHcgc04bsgKuOetUIZWhuTu5ToAeDV9W3YwpRj0z2+tPoF9RdingHpyAOtEbdQxZcDBJ5x74qTGQAoDA88dKZyhDMxTBxkikWkKYwpY4GFHHfH0qvnDYMZbdyGB4IqwrPkI25g/8IPOaSZCFVkUk55I4AqWMbj5RtKk52ntj0pC2AEYZXrk9RULAgMCOCakEjKNhJI/hB7Uikx+NpLLx6560gXzJAyj950B9aaztj515HY9cVJa3DW1wksRyVOdhoTsyiOOIh2Ej4XqT3q2kmwADOw9xz+tJLL9pleQgDcclcUjFRGpGQMY2+nvUt3KSsTl1OOeh6+lMjRwSW+gAPUVErM+cFSpHapFUoVCjLAYGKgY4qQ2SBg9fY0hxzgYI4p2QDhhvI5zQ5RiDjgc470AMZt3yuOKUIhXGBgd6taZLZx3qHUITcWp4dFJVgPUEdcelaepzaLaXkkK6Ok0anKyJePh1PIPt9KaWlxOVnaxgDjGBxznHrS7k9/yFS6lc2s8kbWdmLNAuGTzS+735ql+A/OkM5dVLKOOOmatRcZHpx9amtlwUQc546dTVg2MjyN5SAMiln56D1rplT7HBCd3ZlVGwO4NSL83XrU1zZPbJbtIy5lG9cNnAzjn0NSeSmFydsnTB71nyaGyZEoI+71p8UgiZmMauSMAN296kW5MVq1uIQGZ8l88j2quxJJ54qXoaboUBm5JpAeeOtKD26e1CY/h5qWCDOOTkn0owSQc/hTj1OO1OUkjPShMY0ktg+/QU77vXk57UinBK8fjSoAV4xn6Uhhu2nDEeuD3pyMACAM47+lNTCkFsHJxn0pz5GFXGT39BVAOO0AFT83fNSplcE5ye2KW3iIIxyO+6nOu0lmO4k96oQ7gglgWY8e/4ipYSThcf7IwOlQxAEEbSO5PerATMY+9jsDQDEDhCQSCV6Z/pSj5lOAMYzk04Ig6qSMYI9KjXPOFIjHQnuKskjuVD8Yyx5PeoWjwFwxOOlTsMsRzz0A701hxgHBHYdqYisScg4zjkD0qFm+fnIz29anlIUbTwcVXYEc5Ax3pMGV3G52GDhu4OaQZYfLyQeeKfKQw+RsMO/oKRSwxtJJx9cigyBcqd6Eb1welW0mTGPmOfmAPaoEAPTHHYccVINqsuX254U0x2HNEsvMgJHXmrKAkDaWwB+YpIhtcuCPl/EGmi4iEqr/EccjpigZOQPKBUnY3GaccqoKspPfIpVjMZ2FgOOp4z/jTthzwAcclev1xRYZG5jWNWJK44HoTTldW+fGV7Dsfeq77J3zEwJxyKW0jMcREhwB8wbGcH/Ciw07lvyreQbRIIyepI+U+31rNkUphZFOB6jp+NW8uHyiBwy7tvfI60kAlvLW4bZlIk3gZPTOCR6gU2rg3YqrJkAMQPccmkEiiTjBx1I64qFhhcqd2P1qPkYbJ91rKxakakRz1JIx1H9aXzMD94cqOhAz+dULa58uQFxuXPQHBH41cWWO6JaIY54HTAoUdB85HLfKjiMrjPOcVeimVvnABHbFZhhWQ5JIPPBp6f6OODg9OtPluCk0zSZgWHPTt1qMBRIWU8DjNP0tGvJdiMiY4Yu2AKmu7Z4wAAGRyVR15DY+lDpMpTTDTbM6heparPBDJJ9x5SQpP93j1rQl0COOR4pNY0uN0bayMzgg+h+Wsu1tLi8uY7S1jMk7n5UHHTnOe31rXv9GuL24ea81jSmuCAGBnGSQMDJAxn3qeXyFJ67mRqVklnKiJd212CuS8BJC+xyBzVXf/ALtTapp9xp9x5F2gRtodWVsqynoVI4Iqhx6/pUMaM6wedogRwFUhX9BUF1d+W8bQszSkYbPf3q7pweGzYq2SCTgemKxmJldnkRdxbgr3rvPKu+htWN3JdOFdWOeWJHJ9qv3UMTzlUOHkx5YPQn69qwLS4+wzK6s7RdTEDjJrWyLiJJHCKHG/y938qTSsbU5O+o63tzcNJyF8sYbJ4BquzAZHX8KiJIBO4qD1wetIGD5U9vTvXJJo607jyx28jGelOVxyoPPsKbgY55ApM46kke1TuBI7sFwFzT1yRnI6fnTEyxyCcj1pd/y8GkykyQDnp260q9MqeO5qPOQQR1HT2oLYAAPA7U7BccwByAcVJarvlHBIJwPrUSuQPlGD3NKCAMYP1HeqWjDcvzLLG+EWNsDIbOFx7/So4iWOTgk/54qtH13EZHcetTRsRyPrmrbTEk1uXAueeoBxjFTLheQOQcZPpUKM5AMQGTxzUm3AwW69T3pWGx8QLhjg/KOuabPIoIVCCpHbpTDH5mVySOnFKqbM4HygY3DtVIljW+VQM9epqNkIQEcKOAKsoi8+Y27HUZ5FRvlshflz3DcmmIolCTnGTnnJpkgIZjxgYxmrL4WPcoKqOcnnNVSN4CsQccjNAmyrKXABjAJyTuI/zxSbmC5cj2A6U5xJu3BAI16++PSpCAw3rheckev+FDIsKBnBdRu7n+tKY1bKsCRnPHamgMDyxp0ZOw4BOTzQMsoR5ZH8I646/lUbW24K8agYOSD1z61KuCw+XJzmp4hl2A25PI57elCBhEzbAhJx1G7kEVYwrjOMMRwe+aBDsIQkeWw4pwba4TClRwM9TTbuUkVGkhj4faHXgnOCfxFI2DyCMdR35p93ZR3DrJkq277w/qKkjiWJCrjd23Doab1Erp6mbI7RXRlYFo5OSQOhHH51paWJLi8R4ZkjVPmeVm2gD37GovLI+ZV+VuoJ604qvlldo2k/w8Gi42rlTUJo59QmkjjVULHC5xn3x6H0qi+Vc7QMd605IkZW2Ek4/i6/jVW4UEkBdpB4IrIdtLFFsYA6e/enRuy/KrEgnJFB2qwLjnP4Gms2DkLj2oJvYuRybepHtUmDMMINx6Yqgko5GKkSZoW3oSFPrTjo7lNpolucyO0RQxwlQcKMn/OabY3Dadd2s481kiYOQrYJ5/KrEkqzxAxyOkjD52xkAfSnQlYZfMMSTFVI2sdoOe/Fb30MeVnQWuo2lvrN3eBZ/wCz54mjkDsFlUOOdo9B2pEstBGSmuHYeSHtW3j2xnFR+FI1udWeVo45roQSPbRSEFHlA+UYPX6etSQagdclbTfEapbaiDiC6MYjMb/3JAP4T09qzmkaxbWhU1++t7pbGCxWX7LZxeUkkww0mWyWx2GegrKIbP3h+db3i+3ms7XQ7a4j8qeO0KsvvvPfv9a57etYSWprFqxnadeWcNqqvJIszEh1x8pXtVOWJYpCqn5G5U5rOYAkbePpVlDhcYrsloebEngtZCXPBVjlyW5q1JKGRI0HyINqnviqKnr1qzCV28GsJTN4pEvUEd/SnxZPOCAP1qMHt+tPEnIByay3NkyYHAJxik3AsGzx3qMsD07Um7HHBFA+YmIB59OnPegSHdjoaidiMAHpzUbOSQe5oC5aLjgMc+9NLjkg4qs7+XjHJ/lSphyGPOPyp2FzFpJCwJJAAqWMZ5JwD61GicANxnpip1GSFB5FDLRLFwp4BA96tIirwpAB7VDFEBkscMOMetWEGQAVyF68cGgoehwrDGMY5FSuNzMp259aYi/KM8YOPanAMVKKeSaoTFjG4jb94dh3pc/Mditvz949qEQxsGU5+vH6U5SvIwARywJyB71SJCTYSAclhzj+tQz54VNrYBOO9WSVKZjCg5znP6//AFqqSAbmGcnH3ulMghc/KAhBABP0qqn+ryo8wHktjt/SrMykxeXgAAc5PFQsFCDB+XG0c4yPWgCvMuYsYUKWxz3pFjCAEBgrkZFOlY4Y4AUjo3ODUG1gVKscHtnr7+1Ah5I+YyMABknJxipEljiw8rExt3U5zVLULcz20iggtwQT3I9ajtIpfsbxXEeFDB4wecev4VXLoRzO5r7t4JQ7uQR6EUun3SXflgEqQ3JPQ062SNLdY8gEchlP44NQW8RS5UYVYgdxwOpoSHdm1GylwgUKnYn9RR5PyY2sD0woyAaZ8hT9316kf/XqVHwgAfa/Aye3elY0H7Nozy204xjmmK6lmBI3A/lVl7cxzDzSV35OVOA3vUEqhQpAxu9OPzptWBEAJG0tkIeoI6fjT7iJhCrp3PBBFV5BIGcylVHQAZ+b61FcMXiCqnlyZyHU8flQrdQYjSbiwfHmdMj+tRysCvzDknnIxmmBGGC5Bc9SO/vSbl4V8nHIxWctCk2RzQrjDYwOxqlJEyn+8fT0rSz8pHaoWXLApjHcmknYTjcyixGQTk579qUMAxJJ9wTU80avkbcZ71XNsGRisi7h/C3cfWqWpk04kiyNklOPpViGcKMFwD1+boayVlKnjjHY9alScHrRrESkmbZuVQBssWH3ST9z3yKtnTNVuYWumsbyVXy7SmNjuHrzyap+HDGlzdXTIkrWds9xGrjKlwQFz6gFs49q15iF8bJazy6hM5dYTMJSJXkYD94uP4cnIHTAo33K5rGLPcy3AjWWV3ES7V3MTsHoM9KZ5p9RWl4nO57S5YoZ7hZFmdRgSNHIU8zH+1jP1rEyPQ/nUtamiloc1BIS+Sfxq7G5Y8nJoorsmjzYMmViPepFkwoCgD1zRRXJPc6oD1kAyQSKUMeCDRRWZqPBH97mkDBuSRRRQA4Nk8jIpAw6UUU0AwwiR924gfWrUabVULgjFFFJvYaLUKHcMN9M1aA2kZPXkiiig1RaQKvHfHfripBgccjHU0UUATq25RgdDg46H3NORQFBJAyc5FFFaEibsk5YBV9T6f1p8gU5KtlnHYdPaiirAacoCCpCg56ZPaoGdQx4Bz0Hr9aKKCCCQ5UtwQvHp+dQp8x2EE57noKKKQEbxExnPz/Xt6VHwFK5UIOc46fSiimIhUbiVzu7j3FOQeWSBtz2GciiikBajxyEyFz6ZxUqKWBTjPbnvRRQA8/L8y885OB0/CobxDKEkWQqUONp/wAe9FFXEUjSsfOmhCXRbIOEkLZ4x/nmrDqySEADB7nndRRRLcuOxHOoWJAgJUdD2WoZULkBlwR6DGaKKgZE4UKzLjaPTqarsuOXBHHrRRSkMrSMxGScnOeaic8ZByevFFFSwIpZMIdw5xVRFMnzHgiiigl7kU0SseRk+3WqrQspJViceoooq4toxmh+natNpd8lwqBioKvG/KSIRhlPsRxXSweJrAW4SLUtbhgCbRZqI2ZF/uLMfmC9unSiitWla5zqTMXU9TbULhXWNIIIkEUECHKxoOi57nuT3NVPMb0/Wiis+VHQj//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple flaccid pustules and crusted plaques are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38036=[""].join("\n");
var outline_f37_9_38036=null;
var title_f37_9_38037="Acidophilic body";
var content_f37_9_38037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acidophilic bodies (apoptotic hepatocytes)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This specimen shows two acidophilic bodies (dying liver cells) that should not be confused with Mallory bodies. One is in the vacuole of a Kupffer cell and the other contains a shrunken pyknotic nucleus. Note that the whole hepatocyte is shrunken. This patient had acute hepatitis B.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38037=[""].join("\n");
var outline_f37_9_38037=null;
var title_f37_9_38038="Knee (tibiofemoral) dislocation and reduction";
var content_f37_9_38038=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Knee (tibiofemoral) dislocation and reduction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/9/38038/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/9/38038/contributors\">",
"     Michael C Bachman, MD, MBA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/9/38038/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/9/38038/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/9/38038/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/9/38038/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/9/38038/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/9/38038/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dislocations of the tibiofemoral joint of the knee are true surgical emergencies. Without rapid identification and repair, associated vascular injuries may jeopardize the leg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Immediate reduction followed by careful neurovascular assessment is necessary.",
"   </p>",
"   <p>",
"    This topic will review the mechanisms and management of acute tibiofemoral dislocations. Patellar dislocations and procedural sedation for the performance of joint reduction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24581?source=see_link\">",
"     \"Patellar dislocations in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomy of the knee is discussed separately; elements of special relevance to tibiofemoral dislocation are reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6618?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of the active adult patient with knee pain\", section on 'Basic knee anatomy and biomechanics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The four major ligaments responsible for maintaining the stability of the knee are the anterior cruciate, posterior cruciate, medial collateral, and lateral collateral ligaments (",
"    <a class=\"graphic graphic_picture graphicRef50421 \" href=\"mobipreview.htm?5/17/5395\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69611 \" href=\"mobipreview.htm?34/27/35251\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70435 \" href=\"mobipreview.htm?42/54/43873\">",
"     figure 2",
"    </a>",
"    ). Tibiofemoral dislocations cause injuries to multiple ligaments. Usually both cruciate ligaments and one or both of the collateral ligaments are injured.",
"   </p>",
"   <p>",
"    The popliteal artery is the continuation of the femoral artery. It originates at the tendinous hiatus of the adductor magnus muscle, which firmly anchors it to the femoral shaft (",
"    <a class=\"graphic graphic_figure graphicRef77245 \" href=\"mobipreview.htm?41/16/42247\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57848 \" href=\"mobipreview.htm?5/42/5799\">",
"     image 1",
"    </a>",
"    ). Within the popliteal space, the artery gives off five branches which arise above and below the knee joint creating a collateral system about the knee. Distally, the popliteal artery is held firmly against the bone by the tendinous arch of the soleus muscle. Thus, the popliteal artery is tethered across the popliteal space like a bowstring, making it susceptible to injury during knee dislocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/3\">",
"     3",
"    </a>",
"    ]. Up to 40 percent of patients with knee dislocations sustain an associated vascular injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peroneal nerve winds around the fibular neck. It provides sensation to the dorsum of the foot and controls ankle dorsiflexion. The peroneal nerve is injured in up to 23 percent of patients with knee dislocations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM AND PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tibiofemoral dislocations, although infrequent, are potentially limb-threatening injuries. They are caused most often by high energy trauma (eg, motor vehicle collision) and involve injuries to multiple knee ligaments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. An algorithm for the management of tibiofemoral joint dislocation is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef72754 \" href=\"mobipreview.htm?24/46/25327\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Many tibiofemoral dislocations are clinically obvious given the history of acute trauma and the abnormal position of the knee. Often a significant hemarthrosis and ecchymosis are present. Pain and swelling often limit the physical examination at the initial presentation, but a clinical assessment of the direction of dislocation can be made.",
"   </p>",
"   <p>",
"    It is important to note that a significant number of dislocations spontaneously reduce prior to medical evaluation, in which case the diagnosis can be difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. Limb-threatening vascular injuries following knee dislocation have been misdiagnosed as compartment syndrome or missed altogether for this reason [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, it is important to inquire about the mechanism and the position of the leg immediately following the injury, and whether it changed subsequently. Assess distal and popliteal pulses, motor function, and sensation of the lower extremity. To the degree possible given patient discomfort, evaluate the structural integrity of each knee ligament. The knee examination is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6618?source=see_link&amp;anchor=H30#H30\">",
"     \"Evaluation of the active adult patient with knee pain\", section on 'Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of tibiofemoral dislocation should be assumed whenever gross instability of the knee is detected, regardless of the absence of obvious deformity, particularly following trauma of any kind [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/3\">",
"     3",
"    </a>",
"    ]. Hyperextension of the knee (&gt;30 degrees) when the leg is lifted by the heel suggests gross instability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tibiofemoral dislocations are defined by displacement of the tibia with respect to the femoral condyles. There are five main types, of which posterior and anterior dislocations are the most common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/2-4,14\">",
"     2-4,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posterior &ndash; Result from a direct blow to the proximal tibia that displaces it posterior to the distal femur.",
"     </li>",
"     <li>",
"      Anterior &ndash; Result from a hyperextension injury to the knee that tears the posterior structures and drives the distal femur posterior to the proximal tibia.",
"     </li>",
"     <li>",
"      Medial &ndash; Result from valgus forces to the proximal tibia.",
"     </li>",
"     <li>",
"      Lateral &ndash; Result from varus forces to the proximal tibia.",
"     </li>",
"     <li>",
"      Rotatory &ndash; Result from indirect rotational forces, usually caused by the body rotating in the opposite direction of a planted foot. Rotatory dislocations are subdivided into anteromedial, anterolateral, posteromedial, and posterolateral. Posterolateral dislocations are irreducible by closed reduction. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Contraindications and precautions'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dislocations are also classified as open or closed, based upon the presence or absence of lacerations at the knee joint, and as reducible or irreducible. Irreducible injuries are rare, and opinions vary as to the best treatment.",
"   </p>",
"   <p>",
"    Most knee dislocations are the result of high-energy injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/6,8,15\">",
"     6,8,15",
"    </a>",
"    ]. The most common reported mechanisms are motor vehicle accidents, falls, industrial accidents, and sports-related injuries. Both contact and high velocity (eg, downhill skiing) sports may result in such injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Contraindications and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterolateral dislocations are irreducible by closed reduction. Reduction is prevented because the medial femoral condyle is buttonholed through the medial capsule and the medial collateral ligament is invaginated into the joint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/16\">",
"     16",
"    </a>",
"    ]. The presence of an anteromedial skin furrow indicates a posterolateral dislocation. If the furrow deepens when gentle longitudinal traction is applied, an open reduction should be performed promptly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Analgesia and sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Provide appropriate analgesia. Generally this means procedural sedation, which is discussed separately. There are no reports of intraarticular injection for analgesia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Method of reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Closed reduction of the dislocated knee should be performed immediately and must not be delayed if there is any sign of vascular impairment. Only patients with good peripheral pulses may undergo prereduction imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Generally two clinicians are required to reduce the knee. The procedure is performed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One clinician stabilizes the distal femur; the other grasps the tibia.",
"     </li>",
"     <li>",
"      Apply longitudinal traction to the tibia (often longitudinal traction is all that is required with severe ligamentous disruption).",
"     </li>",
"     <li>",
"      If traction alone is unsuccessful, reverse the direction of the dislocation. As examples, for an anterior dislocation, lift the distal femur anteriorly and push the tibia posteriorly; for a posterior dislocation, do the opposite. For medial rotatory dislocations, rotate the tibia laterally.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For isolated anterior or posterior dislocations, the knee should reduce easily with a satisfactory clunk. Special care should be taken to avoid applying any pressure at the popliteal fossa during reduction to avoid further injury to the popliteal artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/19\">",
"     19",
"    </a>",
"    ]. Emergent orthopedic consultation is necessary if the knee cannot be reduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     POSTREDUCTION MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Initial care and evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately after the tibiofemoral joint is reduced, look closely for signs of vascular injury. An algorithm for the management of tibiofemoral joint dislocation is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef72754 \" href=\"mobipreview.htm?24/46/25327\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Meticulous evaluation of the extremity's circulatory status includes palpating the distal and popliteal pulses, measuring an ankle-brachial index (ABI), and performing a screening duplex ultrasound, if available. Obtain emergent bedside consultation by a vascular surgeon if the limb manifests",
"    <strong>",
"     ANY",
"    </strong>",
"    sign of vascular compromise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/20\">",
"     20",
"    </a>",
"    ]. Such signs may include diminished or absent pulses, pale or dusky skin, paresthesias, and paralysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13368?source=see_link\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ABI is a ratio of measurements of upper and lower extremity perfusion that is calculated using the systolic blood pressure in the brachial, posterior tibial, and dorsalis pedis arteries. In one prospective series of 38 patients with acute knee dislocation, no patient with an ABI of 0.9 or above sustained an arterial injury while every patient with an ABI below 0.9 did [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/21\">",
"     21",
"    </a>",
"    ]. The performance and interpretation of the ABI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=see_link&amp;anchor=H58544655#H58544655\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Ankle-brachial index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the examination is complete, immobilize the knee in 15 to 20 degrees of flexion using a knee immobilizer.",
"   </p>",
"   <p>",
"    The vascular examination following a tibiofemoral dislocation is of limited accuracy and fraught with potential pitfalls. For these reasons and because many emergency clinicians will not have experience with these uncommon but potentially limb-threatening injuries, it is best to follow a management protocol, such as the one provided (",
"    <a class=\"graphic graphic_algorithm graphicRef72754 \" href=\"mobipreview.htm?24/46/25327\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/11,22\">",
"     11,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pulse examination has limited accuracy in the setting of traumatic knee dislocation. According to a metaanalysis of seven studies including 284 dislocations, the finding of abnormal pedal pulses has a sensitivity of 0.79 (95% CI 0.64-0.83), specificity of 0.91 (95% CI 0.78-0.96), positive predictive value of 0.75 (95% CI 0.61-0.83), and a negative predictive value of 0.93 (95% CI 0.85-0.96) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other elements of the physical examination are likewise limited. The degree of initial deformity cannot be used as an indication of the likelihood of injury to the popliteal vasculature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/22\">",
"     22",
"    </a>",
"    ]. The presence of warm skin over the dorsum of the foot and toes has been reported in the presence of complete popliteal arterial occlusion and cannot be considered evidence of an intact blood supply. Perhaps most importantly, the presence of full dorsalis pedis and posterior tibial pulses following reduction does",
"    <strong>",
"     NOT",
"    </strong>",
"    invariably mean that the popliteal vessels are free of injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/23\">",
"     23",
"    </a>",
"    ]. Contusions of the popliteal artery or severe injury to the intimal and medial layers without loss of continuity is a common consequence of traction injury and can lead to thrombus formation within hours to several days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obtain anteroposterior and lateral radiographs to confirm reduction (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79060 \" href=\"mobipreview.htm?18/55/19327\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61394 \" href=\"mobipreview.htm?14/6/14447\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Approaches to imaging of the lower extremity vasculature following knee dislocation vary. We suggest a selective approach based upon the clinical evaluation (",
"    <a class=\"graphic graphic_algorithm graphicRef72754 \" href=\"mobipreview.htm?24/46/25327\">",
"     algorithm 1",
"    </a>",
"    ). However, at some trauma centers, imaging of the lower extremity arteries is performed on all patients with tibiofemoral dislocation due to the limitations of the physical examination.",
"   </p>",
"   <p>",
"    In either case, consult vascular surgery emergently should any arterial injury be identified. For patients without apparent vascular injury at the time of the initial evaluation, close surveillance, including daily vascular checks, must be performed for several days. Further study is needed to determine the appropriate role for noninvasive Doppler studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with multiple trauma who are hemodynamically stable are generally evaluated with computed tomography (CT). Preliminary studies suggest CT with angiography provides accurate assessment of extremity vascular trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Its role in the assessment of vascular injury following knee dislocation is likely to expand.",
"   </p>",
"   <p>",
"    After a thorough vascular assessment, magnetic resonance imaging (MRI) may be obtained to determine the extent of injury following knee dislocation. MRI allows for the identification of ligamentous injury as well as injuries to the joint capsule, meniscus, and articular cartilage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/15\">",
"     15",
"    </a>",
"    ]. Bone marrow edema, occult fractures, and bruising may also be found. Identifying the full spectrum of injury assists surgical planning. If multiple ligamentous injuries were not anticipated but are identified on MRI, we recommend immediate imaging of the popliteal artery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Popliteal artery injury is the most dangerous potential complication following tibiofemoral dislocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/20,29,30\">",
"     20,29,30",
"    </a>",
"    ]. Delay in diagnosis and repair increases the period of warm ischemia and the corresponding risk for irreparable injury requiring above-knee amputation. After eight hours of ischemia, the great majority of injuries will require amputation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/22\">",
"     22",
"    </a>",
"    ]. Of note, popliteal artery lesions or thrombosis may not become clinically apparent for up to several weeks following the acute knee injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other potential short-term complications include peroneal nerve injury, compartment syndrome of the leg, and deep vein thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/29,32,33\">",
"     29,32,33",
"    </a>",
"    ]. Complications may also include pseudoaneurysm, instability, arthrosis, stiffness, and chronic pain. Associated fractures may occur, including injuries of the tibial plateau, tibial shaft, and the proximal fibula. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42233?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of lower extremity peripheral nerve syndromes\", section on 'Peroneal nerve'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;After postreduction radiographs are performed, the patient is admitted to the hospital overnight for close monitoring of the limb's vascular function. Serial reassessment of the neurovascular status is of the utmost importance, and exams should be performed every three to four hours for a minimum of 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following discharge, anteroposterior and lateral radiographs should be repeated within the first week to confirm reduction. Close orthopedic follow-up is necessary to assess ligamentous injury and determine the need for surgical reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38038/abstract/35\">",
"     35",
"    </a>",
"    ]. The patient should be provided with clear written instructions to return immediately to the emergency department for any sign of vascular compromise, and these signs should be carefully explained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tibiofemoral dislocations, although infrequent, are potentially limb-threatening injuries. They are caused most often by high energy trauma and involve injuries to multiple knee ligaments. An algorithm for the management of tibiofemoral joint dislocation is provided (",
"      <a class=\"graphic graphic_algorithm graphicRef72754 \" href=\"mobipreview.htm?24/46/25327\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Many tibiofemoral dislocations are clinically obvious given the history of acute trauma and the abnormal position of the knee. Often a significant hemarthrosis and ecchymosis are present. Pain and swelling often limit the physical examination, but assessment of the direction of the dislocation can be made. Of note, a significant number of dislocations spontaneously reduce prior to medical evaluation, in which case the diagnosis can be difficult. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism and presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The method for reduction of tibiofemoral dislocations is described in the text. Of note, posterolateral dislocations are irreducible by closed reduction because the medial femoral condyle is buttonholed through the medial capsule and the medial collateral ligament is invaginated into the joint. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Popliteal artery injury is the most dangerous potential complication following tibiofemoral dislocation. Delay in diagnosis and repair increases the risk for irreparable injury requiring above-knee amputation. A meticulous evaluation of the extremity's circulatory status is mandatory and should include: palpating the distal and popliteal pulses, measuring an ankle-brachial index (ABI), and performing a screening duplex ultrasound, if available. Obtain emergent bedside consultation by a vascular surgeon if the limb manifests",
"      <strong>",
"       ANY",
"      </strong>",
"      sign of vascular compromise. Such signs may include diminished or absent pulses, pale or dusky skin, paresthesias, and paralysis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initial care and evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/1\">",
"      Seroyer ST, Musahl V, Harner CD. Management of the acute knee dislocation: the Pittsburgh experience. Injury 2008; 39:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/2\">",
"      Rihn JA, Groff YJ, Harner CD, Cha PS. The acutely dislocated knee: evaluation and management. J Am Acad Orthop Surg 2004; 12:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/3\">",
"      Reckling FW, Peltier LF. Acute knee dislocations and their complications. J Trauma 1969; 9:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/4\">",
"      Shields L, Mital M, Cave EF. Complete dislocation of the knee: experience at the Massachusetts General Hospital. J Trauma 1969; 9:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/5\">",
"      Wood MB. Peroneal nerve repair. Surgical results. Clin Orthop Relat Res 1991; :206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/6\">",
"      Kapur S, Wissman RD, Robertson M, et al. Acute knee dislocation: review of an elusive entity. Curr Probl Diagn Radiol 2009; 38:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/7\">",
"      Henrichs A. A review of knee dislocations. J Athl Train 2004; 39:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/8\">",
"      Hollis JD, Daley BJ. 10-year review of knee dislocations: is arteriography always necessary? J Trauma 2005; 59:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/9\">",
"      Robertson A, Nutton RW, Keating JF. Dislocation of the knee. J Bone Joint Surg Br 2006; 88:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/10\">",
"      Wascher DC, Dvirnak PC, DeCoster TA. Knee dislocation: initial assessment and implications for treatment. J Orthop Trauma 1997; 11:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/11\">",
"      Nicandri GT, Dunbar RP, Wahl CJ. Are evidence-based protocols which identify vascular injury associated with knee dislocation underutilized? Knee Surg Sports Traumatol Arthrosc 2010; 18:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/12\">",
"      Steele HL, Singh A. Vascular injury after occult knee dislocation presenting as compartment syndrome. J Emerg Med 2012; 42:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/13\">",
"      Varnell RM, Coldwell DM, Sangeorzan BJ, Johansen KH. Arterial injury complicating knee disruption. Third place winner: Conrad Jobst award. Am Surg 1989; 55:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/14\">",
"      KENNEDY JC. COMPLETE DISLOCATION OF THE KNEE JOINT. J Bone Joint Surg Am 1963; 45:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/15\">",
"      Borden PS, Johnson DL. Initial assessment of the acute and chronic multiple ligament-injured knee. Sports Med Arthrosc 2001; 9:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/16\">",
"      Quinlan AG. Irreducible posterolateral dislocation of the knee with button-holing of the medial femoral condyle. J Bone Joint Surg Am 1966; 48:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/17\">",
"      Hill JA, Rana NA. Complications of posterolateral dislocation of the knee: case report and literature review. Clin Orthop Relat Res 1981; :212.",
"     </a>",
"    </li>",
"    <li>",
"     Scuderi GR, Scott WN, Insall JN.. Injuries of the knee. In: Rockwood and Green's Fractures in Adults, 4th, Rockwood CA, Green DP, Bucholz RW, et al.  (Eds), Lippincott-Raven, Philadelphia 1996. Vol 2.",
"    </li>",
"    <li>",
"     Simon RR, Koenigsknecht SJ. Emergency orthopedics: The Extremities, 3rd, Appleton &amp; Lange, Norwalk 1995. p.385.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/20\">",
"      Kaufman SL, Martin LG. Arterial injuries associated with complete dislocation of the knee. Radiology 1992; 184:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/21\">",
"      Mills WJ, Barei DP, McNair P. The value of the ankle-brachial index for diagnosing arterial injury after knee dislocation: a prospective study. J Trauma 2004; 56:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/22\">",
"      Barnes CJ, Pietrobon R, Higgins LD. Does the pulse examination in patients with traumatic knee dislocation predict a surgical arterial injury? A meta-analysis. J Trauma 2002; 53:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/23\">",
"      McDonough EB Jr, Wojtys EM. Multiligamentous injuries of the knee and associated vascular injuries. Am J Sports Med 2009; 37:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/24\">",
"      Lynch K, Johansen K. Can Doppler pressure measurement replace \"exclusion\" arteriography in the diagnosis of occult extremity arterial trauma? Ann Surg 1991; 214:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/25\">",
"      Peng PD, Spain DA, Tataria M, et al. CT angiography effectively evaluates extremity vascular trauma. Am Surg 2008; 74:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/26\">",
"      Miller-Thomas MM, West OC, Cohen AM. Diagnosing traumatic arterial injury in the extremities with CT angiography: pearls and pitfalls. Radiographics 2005; 25 Suppl 1:S133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/27\">",
"      Inaba K, Potzman J, Munera F, et al. Multi-slice CT angiography for arterial evaluation in the injured lower extremity. J Trauma 2006; 60:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/28\">",
"      Redmond JM, Levy BA, Dajani KA, et al. Detecting vascular injury in lower-extremity orthopedic trauma: the role of CT angiography. Orthopedics 2008; 31:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/29\">",
"      Jones RE, Smith EC, Bone GE. Vascular and orthopedic complications of knee dislocation. Surg Gynecol Obstet 1979; 149:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/30\">",
"      Frykberg ER. Popliteal vascular injuries. Surg Clin North Am 2002; 82:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/31\">",
"      Gable DR, Allen JW, Richardson JD. Blunt popliteal artery injury: is physical examination alone enough for evaluation? J Trauma 1997; 43:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/32\">",
"      Chhabra, A, Kline, AJ, Harner, C. Management of the multiple ligament injured knee. Current Opinion in Orthopedics 2005; 16:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/33\">",
"      Niall DM, Nutton RW, Keating JF. Palsy of the common peroneal nerve after traumatic dislocation of the knee. J Bone Joint Surg Br 2005; 87:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/34\">",
"      Nicandri GT, Chamberlain AM, Wahl CJ. Practical management of knee dislocations: a selective angiography protocol to detect limb-threatening vascular injuries. Clin J Sport Med 2009; 19:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38038/abstract/35\">",
"      Levy BA, Dajani KA, Whelan DB, et al. Decision making in the multiligament-injured knee: an evidence-based systematic review. Arthroscopy 2009; 25:430.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 261 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38038=[""].join("\n");
var outline_f37_9_38038=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM AND PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Contraindications and precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Analgesia and sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Method of reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      POSTREDUCTION MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Initial care and evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/261\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/261|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?24/46/25327\" title=\"algorithm 1\">",
"      Management of knee dislocation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/261|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/42/5799\" title=\"diagnostic image 1\">",
"      Popliteal artery A gram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/55/19327\" title=\"diagnostic image 2\">",
"      Knee dislocatn ant1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/6/14447\" title=\"diagnostic image 3\">",
"      Knee dislocatn ant2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/261|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/27/35251\" title=\"figure 1\">",
"      Anterior anatomy of knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/54/43873\" title=\"figure 2\">",
"      Lateral knee anatomy adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/16/42247\" title=\"figure 3\">",
"      Anatomy of the popliteal fossa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/261|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/17/5395\" title=\"picture 1\">",
"      Surface anatomy anterior knee",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42233?source=related_link\">",
"      Overview of lower extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24581?source=related_link\">",
"      Patellar dislocations in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_9_38039="Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults";
var content_f37_9_38039=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/9/38039/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/9/38039/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/9/38039/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/9/38039/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/9/38039/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/9/38039/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/9/38039/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic regurgitation (AR, also called aortic insufficiency) is due to inadequate closure of the aortic valve leaflets. It can be induced either by damage to and dysfunction of the aortic valve leaflets or by distortion or dilatation of the aortic root and ascending aorta.",
"   </p>",
"   <p>",
"    This topic will review the causes, epidemiology, pathophysiology and major clinical features of chronic AR. Issues related to course and therapy and to acute AR are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/35/20022?source=see_link\">",
"     \"Acute aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic regurgitation is caused by disease of the valve leaflets or enlargement of the aortic root. In the developing world, the most common cause of AR is rheumatic heart disease. However, in developed countries, AR is most often due to aortic root dilation or a congenital bicuspid aortic valve (",
"    <a class=\"graphic graphic_table graphicRef50707 \" href=\"mobipreview.htm?10/19/10556\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38039/abstract/1\">",
"     1",
"    </a>",
"    ]. The causes of isolated AR were illustrated in a review of 220 patients referred to a single center in the United States for aortic valve replacement between 1993 and 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38039/abstract/2\">",
"     2",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Valvular disease accounted for 43 percent and nonvalvular disease for 57 percent.",
"     </li>",
"     <li>",
"      Among patients with a valvular disease, the two most common causes were congenital malformation (mostly bicuspid aortic valve) in 62 percent and infective endocarditis in 20 percent.",
"     </li>",
"     <li>",
"      Among patients with nonvalvular disease, the two major causes were \"cause unclear\" in 74 percent and Marfan syndrome or forme fruste in 12 percent. In the \"cause unclear\" group, 91 percent had systemic hypertension, suggesting that altered elasticity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      geometry of the aortic root may have been the cause of valve incompetence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The widespread use of color Doppler echocardiography, a sensitive technique for detecting valvular regurgitation, has increased recognition of AR, even in healthy subjects. A study from the Framingham Heart Study found that, in a population-based cohort, AR of more than or equal to trace severity on color Doppler echocardiography was present in 13 percent of men and 8.5 percent of women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38039/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of AR varied with age and disease severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38039/abstract/3\">",
"     3",
"    </a>",
"    ]. More than trace AR was unusual before age 50 and then increased progressively.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For mild AR, the prevalence was 3.7, 12.1, and 12.2 percent in men at ages 50 to 59, 60 to 69, and 70 to 83, respectively. The comparable values in women were 1.9, 6.0, and 14.6 percent.",
"     </li>",
"     <li>",
"      For moderate to severe AR, the prevalence was 0.5, 0.6, and 2.2 percent in men at ages 50 to 59, 60 to 69, and 70 to 83, respectively. The comparable values in women were 0.2, 0.8, and 2.3 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;All forms of AR produce a similar hemodynamic abnormality. The inability of the aortic valve leaflets to remain closed or coapted during diastole results in a portion of the left ventricular stroke volume leaking back from the aorta into the left ventricle. The added volume of regurgitant blood produces an increase in left ventricular end-diastolic volume and an elevation in wall stress. The heart responds with compensatory myocardial hypertrophy (",
"    <a class=\"graphic graphic_figure graphicRef58408 \" href=\"mobipreview.htm?40/2/41003\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The combination of hypertrophy and chamber enlargement raises the total stroke volume. The net effect is that forward stroke volume and hence cardiac output are initially maintained despite the regurgitant lesion. Although left ventricular volume is increased, end-diastolic pressure remains normal due to an increase in ventricular compliance. Thus, the heart initially adapts well to chronic AR, functioning as a very efficient and compliant high output pump.",
"   </p>",
"   <p>",
"    An additional factor that plays a role in left ventricular performance is vascular adaptation. One study found that in some patients, total arterial elastance, determined by measuring left ventricular pressure and left ventricular volumes during different loading conditions, decreases to maximize left ventricular work and maintain performance while in other patients elastance increases, enhancing afterload excess and leading to a reduction in left ventricular work and pump performance; this is most apparent in those with impaired left ventricular contractility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38039/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15762271\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AR may remain asymptomatic for decades, even if there is progressive ventricular dilatation. If, however, there is a large regurgitant volume, the patient may complain of symptoms related to the increased mass of the enlarged left ventricle. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A sense of pounding and an uncomfortable awareness of the heartbeat. These symptoms are especially pronounced when lying down or lying on the left side which brings the left ventricular apex closer to the chest wall, augmenting the sensation during systolic contraction.",
"     </li>",
"     <li>",
"      Atypical chest pain induced by a mechanical interaction between the heart and the chest wall. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=see_link\">",
"       \"Differential diagnosis of chest pain in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Palpitations due to tachycardia or premature beats. The latter cause a compensatory pause and postextrasystolic potentiation with a further sense of variable cardiac motion by the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms of left-sided heart failure (dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, and eventual pulmonary edema) occur in the presence of left ventricular dysfunction.",
"   </p>",
"   <p>",
"    Angina pectoris is uncommon with isolated AR, since the coronary arteries are typically large. The presence of angina suggests either underlying coronary artery disease or, if there is marked left ventricular hypertrophy, subendocardial ischemia. Angina can also occur at night when the heart rate slows and arterial diastolic pressure falls to very low levels, thereby impairing subendocardial blood flow. Some patients also develop abdominal discomfort at this time due to splanchnic ischemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15144?source=see_link\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination in patients with chronic AR is often dramatic and frequently establishes the diagnosis without the need for laboratory testing. Both examination of the peripheral pulses and auscultation of the heart are important. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33013?source=see_link\">",
"     \"Examination of the arterial pulse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15762210\">",
"    <span class=\"h3\">",
"     Palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased stroke volume results in abrupt distension of the peripheral arteries and an elevation in systolic pressure. Regurgitation back into the left ventricle then leads to a rapid fall in pressure with quick collapse of the arteries and a low diastolic pressure which may approach zero in severe disease.",
"   </p>",
"   <p>",
"    The net effect is a wide pulse pressure, which is manifested on examination as a \"water hammer\" or Corrigan pulse. This finding may be best appreciated by palpation of the radial or brachial arteries (exaggerated by raising the arm) or the carotid pulses. Other findings are associated with a hyperdynamic pulse:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      deMusset's sign &mdash; A head bob occurring with each heart beat.",
"     </li>",
"     <li>",
"      Traube's sign &mdash; A pistol shot pulse (systolic and diastolic sounds) heard over the femoral arteries.",
"     </li>",
"     <li>",
"      Duroziez's sign &mdash; A systolic and diastolic bruit heard when the femoral artery is partially compressed.",
"     </li>",
"     <li>",
"      Quincke's pulses &mdash; Capillary pulsations in the fingertips or lips.",
"     </li>",
"     <li>",
"      Mueller's sign &mdash; Systolic pulsations of the uvula.",
"     </li>",
"     <li>",
"      Becker's sign &mdash; Visible pulsations of the retinal arteries and pupils.",
"     </li>",
"     <li>",
"      Hill's sign &mdash; Popliteal cuff systolic pressure exceeding brachial pressure by more than 60 mmHg.",
"     </li>",
"     <li>",
"      Mayne's sign &mdash; More than a 15 mmHg decrease in diastolic blood pressure with arm elevation from the value obtained with the arm in the standard position.",
"     </li>",
"     <li>",
"      Rosenbach's sign &mdash; Systolic pulsations of the liver.",
"     </li>",
"     <li>",
"      Gerhard's sign &mdash; Systolic pulsations of the spleen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although all of these clinical signs have been described as ancillary findings useful in the diagnosis of AR, there are few published studies that have assessed the predictive value of any of these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38039/abstract/5\">",
"     5",
"    </a>",
"    ]. Exaggerated or bounding pulses and these physical signs are not specific for AR, since they can be seen in any condition associated with a marked increase in stroke volume and a hyperdynamic circulation. Included in this group are sympathetic hyperactivity, anemia, fever, pregnancy, thyrotoxicosis, large arteriovenous fistula, patent ductus arteriosus, and severe bradycardia. Severe mitral regurgitation also can cause rapid rising arterial pulses, but the pulse pressure is not increased.",
"   </p>",
"   <p>",
"    The combination of left ventricular enlargement and forceful systolic function results in the apical impulse being displaced laterally and inferiorly and being diffuse and hyperdynamic. A prominent pulsation (and occasionally a thrill) may be felt at the sternal notch due to concurrent dilatation of the ascending aorta. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9909?source=see_link\">",
"     \"Examination of the precordial pulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cardiac auscultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic AR is associated with changes in the heart sounds and a distinctive murmur. The heart sounds typically have the following characteristics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      S1 may be soft, often reflecting a long PR interval",
"     </li>",
"     <li>",
"      S2 is variable; it may be soft, absent, or single",
"     </li>",
"     <li>",
"      A2 is often soft or absent while P2 may be normal, but obscured by the diastolic murmur",
"     </li>",
"     <li>",
"      A systolic ejection sound may be due to abrupt aortic distension caused by the large stroke volume",
"     </li>",
"     <li>",
"      A third heart sound (S3 gallop) is heard when left ventricular function is severely depressed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Discovery of a diastolic murmur is essential for the diagnosis of AR. In a review of the literature, the presence of an early diastolic murmur, as heard by a cardiologist, was the most useful finding for establishing the presence of AR (positive likelihood ratio 8.8 [ie, the odds of AR are increased 8.8 fold]) and its absence the most useful finding for eliminating the presence of AR (negative likelihood ratio 0.2 to 0.3 [ie, the odds of disease are reduced by a factor of 0.2 to 0.3]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38039/abstract/6\">",
"     6",
"    </a>",
"    ]. Among patients with end-stage renal disease, a transient murmur of AR may be induced by the effects of volume overload; the murmur disappears after dialysis, when the excess fluid has been removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38039/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diastolic murmur of AR begins immediately after A2 (",
"    <a class=\"graphic graphic_movie graphicRef77962 \" href=\"mobipreview.htm?0/12/195\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef76340 \" href=\"mobipreview.htm?39/27/40368\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef56371 \" href=\"mobipreview.htm?41/61/42960\">",
"     movie 3",
"    </a>",
"    ). It is high pitched, often blowing in quality, and may be sustained in intensity or decrescendo. It may be soft and barely audible, often appreciated only when the patient is sitting up, leaning forward, and holding his or her breath in expiration.",
"   </p>",
"   <p>",
"    The intensity of the murmur does not correlate well with the severity of AR. However, the timing and duration of the murmur may be helpful.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In mild AR, the murmur occurs only in early diastole and is blowing.",
"     </li>",
"     <li>",
"      As the regurgitation becomes more severe, the murmur extends through more of diastole, may become holodiastolic and is often rougher in quality. Patients with a longer diastolic murmur, a displaced left ventricular impulse, a wide pulse pressure, and the peripheral findings of a wide pulse pressure cited in the previous section are considered to have severe AR.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the physical findings are not sufficiently reliable and echocardiography is typically used to assess severity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In very severe regurgitation with ventricular decompensation, the murmur may become soft or even absent. This change in character reflects the near equivalence of aortic diastolic and left ventricular end-diastolic pressures which markedly diminishes regurgitant flow. A similar situation can occur when AR is acute and the left ventricular end-diastolic pressure is very high.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The intensity of the murmur can also be affected by certain maneuvers. As examples, the murmur increases with squatting and decreases with the Valsalva maneuver. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41876?source=see_link\">",
"     \"Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The site at which the murmur is best heard varies with the cause. The murmur is heard best along the left sternal border, at the third and fourth intercostal space, when AR is due to valvular disease. In contrast, abnormalities of the aortic root produce murmurs that are best heard at the right sternal border and apex.",
"   </p>",
"   <p>",
"    A systolic murmur can be heard in many patients. It typically resembles the ejection type of murmur heard in aortic stenosis, ie, a crescendo-decrescendo harsh murmur beginning after S1. This murmur does not necessarily reflect concurrent aortic stenosis, since the increased ejection rate and large stroke volume across the aortic valve can lead to a \"functional\" stenosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=see_link\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second type of diastolic murmur (the Austin Flint murmur) may also be appreciated. This murmur is a mid to late diastolic rumble, heard at the apex. It is the result of antegrade turbulent diastolic blood flow from the left atrium competing with the retrograde regurgitant flow from the aorta. The murmur may be confused with that of mitral stenosis. Distinguishing features from mitral stenosis include the absence of both a loud S1 and an opening snap of the mitral valve. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of tests can help to document the presence and assess the severity of chronic AR. The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on the management of valvular heart disease included recommendations for the use of echocardiography in patients with symptomatic and asymptomatic murmurs (",
"    <a class=\"graphic graphic_table graphicRef50108 graphicRef58419 \" href=\"mobipreview.htm?39/46/40684\">",
"     table 2A-B",
"    </a>",
"    ) and for testing for the diagnosis and initial evaluation of patients with AR (",
"    <a class=\"graphic graphic_table graphicRef75256 \" href=\"mobipreview.htm?6/52/6989\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38039/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) reflects the adaptive changes that occur in the left ventricle as a result of the volume overload. Left ventricular hypertrophy typically leads to an increase in the amplitude of the QRS complexes with concurrent ST and T wave changes, indicative of underlying chronic ischemia. There is often evidence of left atrial hypertrophy and the axis may be leftward.",
"   </p>",
"   <p>",
"    Among asymptomatic or only mildly symptomatic patients with pure AR, the presence or absence of repolarization abnormalities on the resting or exercise ECG (ST segment depression) correlates with left ventricular size and function. In one study, for example, the absence of these ECG abnormalities predicted a left ventricular systolic dimension that was &lt;55 mm, and an ejection fraction &gt;45 percent at rest and &gt;40 percent with exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38039/abstract/8\">",
"     8",
"    </a>",
"    ]. By comparison, up to 83 percent of patients with rest or exercise ST segment abnormalities had an enlarged left ventricle (&gt;55 mm) or reduced ventricular function &lt;45 percent.",
"   </p>",
"   <p>",
"    Conduction abnormalities are usually not seen, but can occur late in the course of AR when significant left ventricular dysfunction (myopathic ventricle) occurs. Isolated atrial and ventricular premature beats are common, but sustained supraventricular or ventricular tachyarrhythmias are unusual in the absence of significant left ventricular dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine chest radiograph shows cardiomegaly due to the dilatation of the left ventricle, which enlarges in an inferior and leftward direction. Gated studies may show substantial differences in cardiac size if end-diastolic and end-systolic phases are shown. There is usually no calcification of the aortic valve and aortic root unless there is associated aortic stenosis. The ascending aorta (and often the aortic arch or knob) are typically markedly dilated.",
"   </p>",
"   <p>",
"    Left atrial enlargement does not occur unless there is significant left ventricular dysfunction. Thus, its presence in patients with mild to moderate AR suggests associated mitral valve disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is part of the standard evaluation of patients with AR (",
"    <a class=\"graphic graphic_table graphicRef75256 \" href=\"mobipreview.htm?6/52/6989\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1082?source=see_link\">",
"     \"Echocardiographic evaluation of the aortic valve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35445?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of aortic valve disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Characteristic echocardiographic findings include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The valve leaflets may be normal or abnormal, depending upon the etiology of the AR. Abnormalities that may be seen include thickening, vegetations, calcification, and prolapsed or flail leaflets (",
"      <a class=\"graphic graphic_movie graphicRef57999 \" href=\"mobipreview.htm?21/29/21971\">",
"       movie 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The aortic root is often dilated and there may be evidence of an aneurysm (dissecting or saccular).",
"     </li>",
"     <li>",
"      There is often high frequency, diastolic fluttering of the anterior leaflet of the mitral valve which is due to the diastolic regurgitant jet of blood from the aorta.",
"     </li>",
"     <li>",
"      Doppler echocardiography (transthoracic or transesophageal) is the most sensitive noninvasive technique for detecting the regurgitant jet AR (",
"      <a class=\"graphic graphic_movie graphicRef79578 \" href=\"mobipreview.htm?9/54/10081\">",
"       movie 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef70063 \" href=\"mobipreview.htm?25/7/25716\">",
"       movie 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef76115 \" href=\"mobipreview.htm?7/27/7604\">",
"       movie 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef54254 \" href=\"mobipreview.htm?8/2/8227\">",
"       movie 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef53257 \" href=\"mobipreview.htm?37/25/38288\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The left ventricular end-systolic and end-diastolic volumes are increased in chronic AR (",
"      <a class=\"graphic graphic_movie graphicRef57999 \" href=\"mobipreview.htm?21/29/21971\">",
"       movie 4",
"      </a>",
"      ). Wall motion appears to be increased in parallel with the enhanced stroke volume. When left ventricular decompensation occurs, systolic shortening is reduced and end-systolic volume increases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these findings, echocardiography can determine the stage of the disease according to left ventricular function (",
"    <a class=\"graphic graphic_table graphicRef69635 \" href=\"mobipreview.htm?7/8/7308\">",
"     table 4",
"    </a>",
"    ), which in turn may determine the need for corrective surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Severity of AR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography can determine the severity of the aortic regurgitation. Severe chronic AR is considered to be present if one or more of the following findings are present on echocardiography (or magnetic resonance imaging) (",
"    <a class=\"graphic graphic_table graphicRef53536 \" href=\"mobipreview.htm?22/19/22844\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38039/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A regurgitant fraction &ge;50 percent",
"     </li>",
"     <li>",
"      A vena contracta width &gt;6 mm",
"     </li>",
"     <li>",
"      A regurgitant volume &ge;60 mL (which should be considered relative to body size)",
"     </li>",
"     <li>",
"      Central jet width &ge;65 percent of left ventricular outflow tract, (which is not so reproducible and is therefore less often used)",
"     </li>",
"     <li>",
"      An effective regurgitant orifice area &ge;0.30 cm",
"      <sup>",
"       2",
"      </sup>",
"      , (which is difficult to measure)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Severe chronic AR is typically associated with the clinical features described above, including a longer diastolic murmur, a displaced left ventricular impulse, a wide pulse pressure, and the peripheral findings of a wide pulse pressure. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Serial monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of serial clinical and echocardiographic monitoring in patients with asymptomatic AR varies with the severity of the disease, the LVEF, left ventricular dimensions, and whether previous studies have revealed progressive disease. The recommended schedule is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/29/25050?source=see_link&amp;anchor=H7#H7\">",
"     \"Course and management of chronic aortic regurgitation in adults\", section on 'Serial monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Bicuspid valves and aortic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;When AR is due to a bicuspid aortic valve, there is the additional concern about dilatation of the aortic root",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ascending aorta, which are present in the majority of patients and can lead to aneurysm formation or dissection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the proximal 3 to 4 cm of the aortic root is easily visualized with echocardiography, the midportion of the ascending aorta may not be; as a result, evaluation with magnetic resonance imaging (MRI) or computed tomography (CT) is often needed. Yearly testing is recommended in patients with an aortic root or ascending aortic diameter greater than 40 mm (",
"    <a class=\"graphic graphic_table graphicRef82459 \" href=\"mobipreview.htm?23/34/24107\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38039/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196380\">",
"    <span class=\"h2\">",
"     Other noninvasive tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of other noninvasive tests such as cardiovascular magnetic resonance imaging (CMR) or radionuclide imaging are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of contrast angiography of the left ventricle in the assessment of chronic AR is increasingly limited because of the use of echocardiography. Nevertheless, angiography can permit assessment of the following parameters, which allows determination of the stage of disease according to left ventricular function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determination of the size and systolic function (ejection fraction) of the left ventricle",
"     </li>",
"     <li>",
"      Aortic root dimension and associated disorders (eg, dissection, sinus of Valsalva aneurysm)",
"     </li>",
"     <li>",
"      Aortic valve movement and the number of leaflets",
"     </li>",
"     <li>",
"      A semiquantitative assessment of the severity of AR",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommended cardiac catheterization in only one setting: when noninvasive tests are inconclusive or provide discrepant results from clinical findings (",
"    <a class=\"graphic graphic_table graphicRef75256 \" href=\"mobipreview.htm?6/52/6989\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38039/abstract/7\">",
"     7",
"    </a>",
"    ]. Cardiac catheterization should be performed with aortic root angiography and measurement of left ventricular pressure to assess the severity of the regurgitation, aortic root size, and left ventricular function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/41/3737?source=see_link\">",
"     \"Hemodynamics of valvular disorders as measured by cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue, the indications for coronary angiography before valve surgery, is discussed separately (",
"    <a class=\"graphic graphic_table graphicRef66360 \" href=\"mobipreview.htm?29/4/29772\">",
"     table 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38039/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/29/25050?source=see_link&amp;anchor=H10594952#H10594952\">",
"     \"Course and management of chronic aortic regurgitation in adults\", section on 'Role of preoperative coronary angiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/35/32306?source=see_link\">",
"       \"Patient information: Aortic regurgitation in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15762070\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aortic regurgitation (AR) is caused by disease of the valve leaflets or enlargement of the aortic root. In the developing world, the most common cause of AR is rheumatic heart disease. In developed countries AR is most often due to aortic root dilation or a congenital bicuspid aortic valve (",
"      <a class=\"graphic graphic_table graphicRef50707 \" href=\"mobipreview.htm?10/19/10556\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with AR may remain asymptomatic for decades, even if there is progressive ventricular dilatation. Some patients with a large regurgitant volume may complain of symptoms related to the increased mass of the enlarged left ventricle including an uncomfortable awareness of the heart beat and atypical chest pain. Symptoms of left-sided heart failure occur in the presence of left ventricular dysfunction. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with chronic severe AR have a wide pulse pressure which is manifested by a &ldquo;water hammer&rdquo; or Corrigan pulse. The apical impulse is displaced laterally and inferiorly and is diffuse and hyperdynamic. (See",
"      <a class=\"local\" href=\"#H15762210\">",
"       'Palpation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration, but not the intensity, of the murmur of AR correlates well with the severity of AR. As AR becomes more severe, the murmur extends through more of diastole and is often rougher in quality. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cardiac auscultation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echocardiography is helpful in determining the severity of aortic regurgitation as well as left ventricular size and systolic function. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Echocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When AR is due to a bicuspid aortic valve, there is the additional concern about dilatation of the aortic root",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ascending aorta, which are present in the majority of patients and can lead to aneurysm formation or dissection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=see_link\">",
"       \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with AR, cardiac catheterization is indicated only when noninvasive tests are inconclusive or provide discrepant results (",
"      <a class=\"graphic graphic_table graphicRef75256 \" href=\"mobipreview.htm?6/52/6989\">",
"       table 3",
"      </a>",
"      ) or for coronary angiography prior to valve surgery in patients at risk for coronary disease. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cardiac catheterization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38039/abstract/1\">",
"      Enriquez-Sarano M, Tajik AJ. Clinical practice. Aortic regurgitation. N Engl J Med 2004; 351:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38039/abstract/2\">",
"      Roberts WC, Ko JM, Moore TR, Jones WH 3rd. Causes of pure aortic regurgitation in patients having isolated aortic valve replacement at a single US tertiary hospital (1993 to 2005). Circulation 2006; 114:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38039/abstract/3\">",
"      Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999; 83:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38039/abstract/4\">",
"      Devlin WH, Petrusha J, Briesmiester K, et al. Impact of vascular adaptation to chronic aortic regurgitation on left ventricular performance. Circulation 1999; 99:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38039/abstract/5\">",
"      Babu AN, Kymes SM, Carpenter Fryer SM. Eponyms and the diagnosis of aortic regurgitation: what says the evidence? Ann Intern Med 2003; 138:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38039/abstract/6\">",
"      Choudhry NK, Etchells EE. The rational clinical examination. Does this patient have aortic regurgitation? JAMA 1999; 281:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38039/abstract/7\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38039/abstract/8\">",
"      Chen J, Okin PM, Roman MJ, et al. Combined rest and exercise electrocardiographic repolarization findings in relation to structural and functional abnormalities in asymptomatic aortic regurgitation. Am Heart J 1996; 132:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38039/abstract/9\">",
"      Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38039/abstract/10\">",
"      Bekeredjian R, Grayburn PA. Valvular heart disease: aortic regurgitation. Circulation 2005; 112:125.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8159 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.236-1521AB7FD8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38039=[""].join("\n");
var outline_f37_9_38039=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15762070\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15762271\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15762210\">",
"      - Palpation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cardiac auscultation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Severity of AR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Serial monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Bicuspid valves and aortic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H196380\">",
"      Other noninvasive tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15762070\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8159\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8159|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/2/41003\" title=\"figure 1\">",
"      The law of Laplace",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/25/38288\" title=\"figure 2\">",
"      Aortic regurgitation CW Doppler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8159|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?0/12/195\" title=\"movie 1\">",
"      Aortic regurgitation as heard at the lower left sternal border",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?39/27/40368\" title=\"movie 2\">",
"      AR as heard at the second right intercostal space",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?41/61/42960\" title=\"movie 3\">",
"      Aortic regurgitation as heard at the apex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?21/29/21971\" title=\"movie 4\">",
"      Aortic regurgitation long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?9/54/10081\" title=\"movie 5\">",
"      Aortic regurgitation five chamber color Doppler echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?25/7/25716\" title=\"movie 6\">",
"      Apical 5 chamber echo with color Doppler AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?7/27/7604\" title=\"movie 7\">",
"      Parasternal long axis color Doppler echo AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?8/2/8227\" title=\"movie 8\">",
"      TEE aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8159|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/19/10556\" title=\"table 1\">",
"      Causes of aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/4/36939\" title=\"table 2A\">",
"      Echo asymptomatic murmurs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/35/17979\" title=\"table 2B\">",
"      Echo symptomatic murmurs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/52/6989\" title=\"table 3\">",
"      ACC AHA diagnosis evaluation AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/8/7308\" title=\"table 4\">",
"      Stages of aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/19/22844\" title=\"table 5\">",
"      Severity of AR in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/34/24107\" title=\"table 6\">",
"      Bicuspid AV dilated asc aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/4/29772\" title=\"table 7\">",
"      Coronary angio valve disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/35/20022?source=related_link\">",
"      Acute aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/29/25050?source=related_link\">",
"      Course and management of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=related_link\">",
"      Differential diagnosis of chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1082?source=related_link\">",
"      Echocardiographic evaluation of the aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9909?source=related_link\">",
"      Examination of the precordial pulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15144?source=related_link\">",
"      Pathophysiology and clinical presentation of ischemic chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/35/32306?source=related_link\">",
"      Patient information: Aortic regurgitation in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41876?source=related_link\">",
"      Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35445?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of aortic valve disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_9_38040="Osteogenesis imperfecta: Clinical features and diagnosis";
var content_f37_9_38040=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Osteogenesis imperfecta: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/9/38040/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/9/38040/contributors\">",
"     John F Beary, III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/9/38040/contributors\">",
"     Arkadi A Chines, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/9/38040/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/9/38040/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/9/38040/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/9/38040/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/9/38040/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteogenesis imperfecta (OI) is an inherited connective tissue disorder with many phenotypic presentations. It is often called \"brittle bone disease.\" Severely affected patients suffer multiple fractures with minimal or no trauma, and infants with the worst form of OI die in the perinatal period. Mild forms of OI may manifest with only premature osteoporosis or severe postmenopausal bone mineral loss.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical features, diagnosis, and differential diagnosis of osteogenesis imperfecta are presented here. The management and prognosis of osteogenesis imperfecta are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26185?source=see_link\">",
"     \"Osteogenesis imperfecta: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated incidence of OI is approximately 1 per 20,000 births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/1\">",
"     1",
"    </a>",
"    ]. This qualifies it as an orphan disease, which is defined in the United States as a disease affecting 200,000 patients or less.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of OI is established in most cases. In patients with identified molecular defects, OI is most commonly caused by mutations in genes encoding the alpha-1 and alpha-2 chains of type I collagen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/2\">",
"     2",
"    </a>",
"    ] or proteins involved in posttranslational modification of type I collagen. Type I collagen fibers are polymers of tropocollagen molecules, each of which is a triple helix that contains portions of one alpha 2 and two alpha 1 polypeptide chains. The composition of tropocollagen is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef77562 \" href=\"mobipreview.htm?21/2/21550\">",
"     figure 1",
"    </a>",
"    ). Type I collagen is an important structural protein for bone, tendon, ligament, skin, and sclerae. Defective bone quality explains many clinical aspects of osteogenesis imperfecta. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42519?source=see_link&amp;anchor=H4#H4\">",
"     \"Bone physiology and biochemical markers of bone turnover\", section on 'Bone formation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with OI have an autosomal dominant mutation in",
"    <em>",
"     COL1A1",
"    </em>",
"    (located at 17q21.31-q22) or",
"    <em>",
"     COL1A2",
"    </em>",
"    (located at 7q22.1) that affects the structure of one of the two alpha chains of type I collagen. The severity of the clinical presentation depends upon the effect of the mutation (",
"    <a class=\"graphic graphic_table graphicRef78737 \" href=\"mobipreview.htm?20/3/20541\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73256 \" href=\"mobipreview.htm?4/26/4525\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. As an example, mutations in",
"    <em>",
"     COL1A1",
"    </em>",
"    or",
"    <em>",
"     COL1A2",
"    </em>",
"    that lead to decreased amounts of normal collagen cause the mild phenotype seen in type I OI. In contrast, mutations that disrupt the formation of the normal type I collagen triple helix cause the lethal phenotype seen in type IIA OI. Other",
"    <em>",
"     COL1A1",
"    </em>",
"    and",
"    <em>",
"     COL1A2",
"    </em>",
"    mutations that result in structural protein defects cause moderate (type IV) and severe, but not lethal (type III), forms of OI.",
"   </p>",
"   <p>",
"    <em>",
"     COL1A1",
"    </em>",
"    and",
"    <em>",
"     COL1A2",
"    </em>",
"    genes are normal in approximately 10 percent of cases. Many of these patients have autosomal recessive genetic defects.",
"   </p>",
"   <p>",
"    A recurrent mutation (c.-14C&gt;T) in the 5&rsquo; untranslated region (UTR) of the interferon-induced transmembrane protein 5 (",
"    <em>",
"     IFITM5",
"    </em>",
"    ) gene located at 11p15.5 is the cause of OI type V in several families and also in simplex cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Expression of this protein, which is thought to be involved in bone formation and osteoblast maturation, is highly restricted to skeletal tissue.",
"   </p>",
"   <p>",
"    Mutations in the FK506-binding protein 10 (",
"    <em>",
"     FKBP10",
"    </em>",
"    or",
"    <em>",
"     FKBP65",
"    </em>",
"    ) gene, located at 17q21, were identified in a cohort of five consanguineous Turkish families and in a Mexican-American family with recessively inherited, moderately severe OI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/10\">",
"     10",
"    </a>",
"    ].",
"    <em>",
"     FKBP10",
"    </em>",
"    encodes a molecular chaperone that interacts with type I collagen and tropoelastin and is involved in the folding of type I procollagen. Mutations in",
"    <em>",
"     FKBP10",
"    </em>",
"    affect type I procollagen secretion. The OI phenotype associated with",
"    <em>",
"     FKBP10",
"    </em>",
"    mutations (designated OI type VI) most closely resembles OI type III, because of its severity and progressive nature. However, histologic findings of distorted lamellar structure and elevated alkaline phosphatase in some of the affected children are consistent with OI type VI. Mutations in",
"    <em>",
"     FKBP10",
"    </em>",
"    can cause a related disorder, Bruck syndrome. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Other skeletal syndromes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Mutations in any of the three components of the 3-prolyl-hydroxylation complex that modifies type I collagen posttranslation can cause",
"    <span class=\"nowrap\">",
"     lethal/severe,",
"    </span>",
"    recessive forms of OI with normal collagen folding. These components include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cartilage-associated protein (",
"      <em>",
"       CRTAP",
"      </em>",
"      , gene located at 3p22) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. CRTAP deficiency was detected in 3 of 10 children with recessively inherited lethal or severe OI who had type I collagen with normal primary structure, but excess posttranslational modification of the alpha chain helical regions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/13\">",
"       13",
"      </a>",
"      ]. Mutations in",
"      <em>",
"       CRTAP",
"      </em>",
"      cause type IIB OI (a perinatal lethal form) and type VII OI (a severe, nonlethal form) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/13-15\">",
"       13-15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prolyl-3-hydroxylase-1 (P3H1; encoded by leprecan-like 1,",
"      <em>",
"       LEPRE1",
"      </em>",
"      located at 1q34) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Mutations in",
"      <em>",
"       LEPRE1",
"      </em>",
"      cause type VIII OI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/12,17-19\">",
"       12,17-19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Peptidyl-prolyl isomerase B (also called cyclophilin B;",
"      <em>",
"       PPIB",
"      </em>",
"      gene located at15q21-q22). Mutations in",
"      <em>",
"       PPIB",
"      </em>",
"      cause type IX OI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/20-22\">",
"       20-22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mutations causing severe, recessive OI resembling type III OI have also been identified in other genes encoding proteins involved in bone formation and homeostasis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <em>",
"       SERPINH1",
"      </em>",
"      (located at 11q13.5) that encodes a collagen chaperone-like protein (serpin peptidase inhibitor, clade, H, member 1; also called collagen-binding protein 2, CBP2; and heat-shock protein 47, HSP47) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <em>",
"       SERPINF1",
"      </em>",
"      (located at 17p13.3) that encodes a multifunctional glycoprotein that is a strong inhibitor of angiogenesis (serpin peptidase inhibitor, clade F, member 1; also called pigment epithelium-derived factor, PEDF) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <em>",
"        SP7/OSX",
"       </em>",
"      </span>",
"      (located at 12q13.13) that encodes specificity protein 7 or osterix, a zinc finger transcription factor that is an essential regulator of bone cell differentiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DISEASE CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;OI is classified into nine major subtypes based on genetic, radiographic, and clinical characteristics (",
"    <a class=\"graphic graphic_table graphicRef78737 \" href=\"mobipreview.htm?20/3/20541\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73256 \" href=\"mobipreview.htm?4/26/4525\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/3,14,26,27\">",
"     3,14,26,27",
"    </a>",
"    ]. A more useful clinical classification, based upon the typical problems that manifest in infants, children, and adults with mild, moderate to severe, and lethal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/28\">",
"     28",
"    </a>",
"    ], is presented below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations vary substantially within families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/29\">",
"     29",
"    </a>",
"    ]. One member may be significantly affected clinically, whereas another member with the same mutation may have normal function. This emphasizes that identifying a mutation in a particular gene does not necessarily result in a clear clinical diagnosis and suggests that it may take defects in other connective tissue components to fully express the genetic syndrome of clinically observable OI. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinical manifestations of OI include (",
"    <a class=\"graphic graphic_table graphicRef78737 \" href=\"mobipreview.htm?20/3/20541\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73256 \" href=\"mobipreview.htm?4/26/4525\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excess or atypical fractures (brittle bones) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Short stature",
"     </li>",
"     <li>",
"      Scoliosis",
"     </li>",
"     <li>",
"      Basilar skull deformities, which may cause nerve compression or other neurologic symptoms",
"     </li>",
"     <li>",
"      Blue sclerae (",
"      <a class=\"graphic graphic_picture graphicRef51775 \" href=\"mobipreview.htm?0/63/1014\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hearing loss (usually detected in later childhood to early adulthood)",
"     </li>",
"     <li>",
"      Opalescent teeth that wear quickly (dentinogenesis imperfecta) (",
"      <a class=\"graphic graphic_picture graphicRef68896 \" href=\"mobipreview.htm?35/46/36576\">",
"       picture 2",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/440?source=see_link&amp;anchor=H22#H22\">",
"       \"Developmental defects of the teeth\", section on 'Dentinogenesis imperfecta'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased laxity of the ligaments and skin",
"     </li>",
"     <li>",
"      Wormian bones (small, irregular bones along the cranial sutures) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Easy bruisability",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mild (type I)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone fragility is the least severe in type I OI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/30\">",
"     30",
"    </a>",
"    ]. The fracture rate is variable. Individuals with type I OI may have few or no fractures before puberty or numerous fractures throughout their lives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/29,35\">",
"     29,35",
"    </a>",
"    ]. Deformity is minimal and stature is usually normal. Individuals with type I OI occasionally present in the perinatal period with intrauterine femoral bowing or fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/29,36\">",
"     29,36",
"    </a>",
"    ], but they usually do not begin to have fractures until they begin toddling or walking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/37\">",
"     37",
"    </a>",
"    ]. The most frequently involved bones are the long bones of the arms and legs, ribs, and the small bones of the hands and feet. The frequency of fractures declines after puberty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults with OI type I may present with premature or accelerated osteoporosis following menopause. In addition, adults may present with premature hearing loss. One study of 133 adults with type I OI found that 58 percent had hearing loss, predominantly mixed conductive and sensorineural, that began in the second to fourth decade of life and was generally progressive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/38\">",
"     38",
"    </a>",
"    ]. Only 17 percent of these adults had subjective hearing impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Moderate to severe (types III-IX)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone fragility is moderate to severe in patients with OI types III, IV, V, VI, VII VIII, and IX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/30\">",
"     30",
"    </a>",
"    ]. Those with OI type III are most severely affected. However, children with OI type VII and VIII may also develop a severe lethal type of OI resembling OI type II as described below.",
"   </p>",
"   <p>",
"    Children with OI of these types have an increased number and frequency of fractures, mild to moderate bone deformities, kyphoscoliosis, and variable short stature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/17,30\">",
"     17,30",
"    </a>",
"    ]. Some children are immobile and require motorized wheelchairs. In addition, children may develop ossicular dislocation, stapes fixation, or fracture of the ossicles, resulting in conductive hearing loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29927?source=see_link\">",
"     \"Treatment of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adults with moderate OI develop hearing loss and osteoporosis, similar to adults with mild OI. However, the onset may be earlier and the expression more intense. Mothers are prone to accelerated bone loss following pregnancy and breastfeeding. Aging and physical inactivity also accelerate OI-related osteoporosis. Hypermobility of the joints of the hands, wrists, and feet can cause pain and decreased function requiring orthopedic intervention. Cardiovascular abnormalities are more common in patients with OI, particularly type III, compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The practical aspect of identifying moderate to severe OI is that bisphosphonate therapy is helpful in these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26185?source=see_link&amp;anchor=H13635515#H13635515\">",
"     \"Osteogenesis imperfecta: Management and prognosis\", section on 'Bisphosphonate therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lethal perinatal form (type II)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with lethal perinatal OI (type II) usually die in utero or in early infancy. Severe fractures and pulmonary failure are typical problems that accelerate death in this group. Genetic counseling is indicated for affected families. Treatment of OI type II is supportive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although biochemical parameters of bone and mineral metabolism are usually normal in OI, some abnormalities may be noted, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated levels of serum alkaline phosphatase have been reported in type VI OI, reflecting impaired bone mineralization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypercalciuria is common in OI children, and its magnitude appears to reflect the severity of the skeletal disease. One study found increased urinary excretion of calcium in 36 percent of children with OI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/40\">",
"       40",
"      </a>",
"      ]. The children with hypercalciuria were of shorter stature and had a greater lifelong fracture rate compared with OI children with normal urinary calcium excretion. However, their renal function was not compromised [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Markers of bone formation (C-terminal propeptide of type I procollagen) may be lower, and markers of bone resorption (C-telopeptide of type I collagen) can be higher in OI, particularly in severely affected subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5114631\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone histology may show disorganized (woven) bone, especially in more severely affected children. A bone biopsy study in 70 children with types I, III, and IV OI demonstrated normal mineralization with significant reductions in cortical width, cancellous bone volume, trabecular number, and trabecular width [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/43\">",
"     43",
"    </a>",
"    ]. This study also found significantly increased bone remodeling (turnover) in all types of OI studied (ie, about a 70 percent increase compared to age-matched controls). The latter observation provides a rationale for the use of bisphosphonates in children with OI. Bone remodeling, however, is normal in type VI OI, which is characterized by defective mineralization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/26\">",
"     26",
"    </a>",
"    ], and thus bisphosphonates should not be prescribed to these children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26185?source=see_link\">",
"     \"Osteogenesis imperfecta: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical diagnosis of OI is based on the signs and symptoms described above. The diagnosis is usually straightforward in individuals with bone fragility and a positive family history or several extraskeletal manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/30\">",
"     30",
"    </a>",
"    ]. However, in the absence of these features, diagnosis may be difficult. Extraskeletal manifestations can be subclinical (eg, hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/38,44-46\">",
"     38,44-46",
"    </a>",
"    ]), nonspecific (eg, dark or bluish sclerae are commonly present in infants, limiting the usefulness of this sign in this age group), or more obvious at certain ages (eg, dentinogenesis imperfecta may be more noticeable in the primary than the permanent dentition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/47\">",
"     47",
"    </a>",
"    ]). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is no definitive, readily available lab test for OI. However, research labs have made advances in molecular genetic testing that will eventually be more accessible. The types of tests available for the various genetic defects and laboratories that perform them can be found on the GeneTests website (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/\">",
"     file://www.ncbi.nlm.nih.gov/sites/GeneTests/",
"    </a>",
"    ). The structure and quantity of type I collagen can be determined in vitro from fibroblast culture using a small skin biopsy. Abnormalities either in quantity or quality of type I collagen are present in about 90 percent of OI cases. Sequence analysis of cDNA (which requires skin biopsy for fibroblast culture) or genomic DNA testing of white blood cells for mutations in",
"    <em>",
"     COL1A1",
"    </em>",
"    and",
"    <em>",
"     COL1A2",
"    </em>",
"    can detect 90 percent or more of all collagen type I mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/30,48,49\">",
"     30,48,49",
"    </a>",
"    ]. Negative studies do not exclude the diagnosis, because of the OI types that are not associated with type I collagen mutations (types II B and types V through IX) and the false negative rate of about 10 percent.",
"   </p>",
"   <p>",
"    Prenatal diagnosis of OI is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42585?source=see_link\">",
"     \"Prenatal diagnosis of the lethal skeletal dysplasias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of OI includes inflicted injury (child abuse) and a variety of skeletal conditions associated with bone fragility, including rickets and osteomalacia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Child abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with inflicted trauma have multiple fractures in various stages of healing, similar to children with moderate to severe types of OI. They also may have metaphyseal, rib, and skull fractures. OI is a well-recognized cause of fractures that occur with minimal or no witnessed trauma, but it is a rare disorder and consequently is seldom the cause of such fractures. The differentiation between OI and child abuse is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11641?source=see_link&amp;anchor=H13#H13\">",
"     \"Differential diagnosis of the orthopedic manifestations of child abuse\", section on 'Osteogenesis imperfecta'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Rickets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rickets can cause slow growth, bone deformities, elevation of alkaline phosphatase, defective bone mineralization, and in some forms, abnormal tooth formation. However, scleral abnormalities and hearing loss typically do not occur. Radiographic findings in rickets are characteristic and include an increased width of the epiphyseal plate, irregular hazy margins of the distal metaphysis, and marginal metaphyseal overgrowth that results in a ball-in-cup-like appearance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin D-resistant rickets in children, or osteomalacia in adults, may be associated with hypophosphatemia (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15767?source=see_link\">",
"     \"Causes of hypophosphatemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21209?source=see_link\">",
"     \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Osteomalacia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomalacia in adults can cause bone pain, insufficiency fractures, and alkaline phosphatase elevation, but neither hearing loss nor blue sclerae. The most common radiologic finding in osteomalacia is reduced bone density; other abnormalities include Looser's zones or pseudofractures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52768 \" href=\"mobipreview.htm?7/43/7862\">",
"     image 1",
"    </a>",
"    ), narrow lines of radiolucency at the cortical margins of bones, and the loss of distinctiveness of trabeculae in vertebral bodies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27494?source=see_link\">",
"     \"Epidemiology and etiology of osteomalacia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11416?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of osteomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other skeletal syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other skeletal syndromes with moderate to severe bone fragility",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deformity include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bruck syndrome &mdash; Bruck syndrome (MIM #312750 and %259450), previously called OI with congenital joint contractures, is an autosomal recessive disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/30\">",
"       30",
"      </a>",
"      ]. Clinical features that distinguish it from OI include congenital contractures of the knees, ankles, and feet; webbing (pterygia) of the elbow and knee; and clubfoot (talipes equinovarus) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Osteoporosis-pseudoglioma syndrome &mdash; Osteoporosis-pseudoglioma syndrome (MIM #259770) is an autosomal recessive disorder that was previously called the ocular form of OI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/30,51-53\">",
"       30,51-53",
"      </a>",
"      ]. It is caused by deletion of the gene for low-density-lipoprotein (LDL) receptor-related protein 5 (LRP-5). Other characteristic findings include microcephaly; pseudoglioma (inflammatory changes of the vitreous body, secondary to iridochoroiditis, that mimic retinal glioma); blindness (with onset in infancy); vitreoretinal abnormalities; cataract; absent anterior chamber; iris atrophy; intraocular calcification; and hypotonia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/54,55\">",
"       54,55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Panostotic fibrous dysplasia &mdash; Panostotic fibrous dysplasia, the extreme form of polyostotic fibrous dysplasia (McCune-Albright syndrome, MIM #174800), is caused by a somatic mutation in the guanine nucleotide stimulatory protein (",
"      <em>",
"       GNAS1",
"      </em>",
"      ) gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/30,56\">",
"       30,56",
"      </a>",
"      ]. It is characterized by cystic or ground glass lesions in",
"      <strong>",
"       all",
"      </strong>",
"      bones. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=see_link&amp;anchor=H22#H22\">",
"       \"Overview of benign bone tumors in children and adolescents\", section on 'Fibrous dysplasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Juvenile Paget disease &mdash; Juvenile Paget disease (MIM #239000), also known as idiopathic hyperphosphatasia, is an autosomal recessive disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/30,57\">",
"       30,57",
"      </a>",
"      ]. Patients with idiopathic hyperphosphatasia have increased serum alkaline phosphatase, which distinguishes it from OI, in which alkaline phosphatase is usually normal. However, elevated levels of serum alkaline phosphatase have been reported in some patients with type VI OI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43989?source=see_link\">",
"       \"Transient hyperphosphatasemia of infancy and early childhood\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7978?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Paget disease of bone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypophosphatasia &mdash; Hypophosphatasia (MIM #241500) is a rare, autosomal disease caused by a deficiency of tissue nonspecific alkaline phosphatase and characterized by abnormal mineralization of bone and dental tissues [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/30,58\">",
"       30,58",
"      </a>",
"      ]. Patients with hypophosphatasia have decreased serum concentrations of alkaline phosphatase, which distinguishes it from OI. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/60/8137?source=see_link&amp;anchor=H11#H11\">",
"       \"Systemic conditions associated with periodontal disease in children\", section on 'Hypophosphatasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cole-Carpenter syndrome &mdash; The inheritance pattern of Cole-Carpenter syndrome (MIM 112240) is unknown. It is characterized by osteoporosis, short stature, craniosynostosis, hydrocephalus, and proptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Idiopathic juvenile osteoporosis &mdash; Idiopathic juvenile osteoporosis is a nonhereditary form of transient, isolated childhood osteoporosis that occurs in prepubertal, previously healthy children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38040/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteogenesis imperfecta (OI) is a rare inherited connective tissue disorder with many phenotypic presentations. Severely affected patients suffer multiple fractures with minimal or no trauma, and infants with the worst form of OI die in the perinatal period. Mild forms of OI may be manifested by only premature osteoporosis or severe postmenopausal bone mineral loss. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      OI is most commonly caused by autosomal dominant mutations in genes encoding the alpha-1 and alpha-2 chains of type I collagen (",
"      <em>",
"       COL1A1",
"      </em>",
"      and",
"      <em>",
"       COL1A2",
"      </em>",
"      ). The autosomal recessive forms are caused by mutations in genes encoding proteins involved in posttranslational modification of type I collagen (",
"      <em>",
"       FKBP10",
"      </em>",
"      ,",
"      <em>",
"       CRTAP",
"      </em>",
"      ,",
"      <em>",
"       LEPRE1",
"      </em>",
"      ,",
"      <em>",
"       PPIB",
"      </em>",
"      ) or other mechanisms of bone formation and homeostasis (",
"      <em>",
"       SERPINH1",
"      </em>",
"      ,",
"      <em>",
"       SERPINF1",
"      </em>",
"      ,",
"      <span class=\"nowrap\">",
"       <em>",
"        SP7/OSX",
"       </em>",
"       ,",
"      </span>",
"      <em>",
"       IFITM5",
"      </em>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef78737 \" href=\"mobipreview.htm?20/3/20541\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      OI is classified into nine major subtypes based on genetic, radiographic, and clinical characteristics. It can also be classified by clinical severity. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Disease classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis should be considered in patients who have bone fragility and any of the following clinical manifestations (",
"      <a class=\"graphic graphic_table graphicRef78737 \" href=\"mobipreview.htm?20/3/20541\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef73256 \" href=\"mobipreview.htm?4/26/4525\">",
"       table 2",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Short stature",
"     </li>",
"     <li>",
"      Scoliosis",
"     </li>",
"     <li>",
"      Basilar skull deformities",
"     </li>",
"     <li>",
"      Blue sclerae (",
"      <a class=\"graphic graphic_picture graphicRef51775 \" href=\"mobipreview.htm?0/63/1014\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hearing loss",
"     </li>",
"     <li>",
"      Opalescent teeth that wear quickly (dentinogenesis imperfecta) (",
"      <a class=\"graphic graphic_picture graphicRef68896 \" href=\"mobipreview.htm?35/46/36576\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased laxity of the ligaments and skin",
"     </li>",
"     <li>",
"      Wormian bones (small, irregular bones along the cranial sutures)",
"     </li>",
"     <li>",
"      Easy bruisability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis includes child abuse, rickets, osteomalacia, and other rare skeletal syndromes. The diagnosis usually can be made clinically in patients with a positive history",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      several extraskeletal manifestations. However, the diagnosis can be difficult in the absence of these features. Skin biopsy for analysis of type I collagen genes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      testing of genomic DNA for mutations in",
"      <em>",
"       COL1A1",
"      </em>",
"      and",
"      <em>",
"       COL1A2",
"      </em>",
"      may be helpful. However, normal results of these tests do not exclude the diagnosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/1\">",
"      Marini JC. Osteogenesis imperfecta: comprehensive management. Adv Pediatr 1988; 35:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/2\">",
"      Prockop DJ, Kivirikko KI. Heritable diseases of collagen. N Engl J Med 1984; 311:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/3\">",
"      Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; 16:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/4\">",
"      Cohn DH, Byers PH, Steinmann B, Gelinas RE. Lethal osteogenesis imperfecta resulting from a single nucleotide change in one human pro alpha 1(I) collagen allele. Proc Natl Acad Sci U S A 1986; 83:6045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/5\">",
"      Byers PH, Starman BJ, Cohn DH, Horwitz AL. A novel mutation causes a perinatal lethal form of osteogenesis imperfecta. An insertion in one alpha 1(I) collagen allele (COL1A1). J Biol Chem 1988; 263:7855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/6\">",
"      Cohn DH, Apone S, Eyre DR, et al. Substitution of cysteine for glycine within the carboxyl-terminal telopeptide of the alpha 1 chain of type I collagen produces mild osteogenesis imperfecta. J Biol Chem 1988; 263:14605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/7\">",
"      Gajko-Galicka A. Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans. Acta Biochim Pol 2002; 49:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/8\">",
"      Cho TJ, Lee KE, Lee SK, et al. A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet 2012; 91:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/9\">",
"      Semler O, Garbes L, Keupp K, et al. A mutation in the 5'-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. Am J Hum Genet 2012; 91:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/10\">",
"      Alanay Y, Avaygan H, Camacho N, et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2010; 86:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/11\">",
"      Tonachini L, Morello R, Monticone M, et al. cDNA cloning, characterization and chromosome mapping of the gene encoding human cartilage associated protein (CRTAP). Cytogenet Cell Genet 1999; 87:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/12\">",
"      Baldridge D, Schwarze U, Morello R, et al. CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Hum Mutat 2008; 29:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/13\">",
"      Barnes AM, Chang W, Morello R, et al. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med 2006; 355:2757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/14\">",
"      Ward LM, Rauch F, Travers R, et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 2002; 31:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/15\">",
"      Labuda M, Morissette J, Ward LM, et al. Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone 2002; 31:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/16\">",
"      Vranka JA, Sakai LY, B&auml;chinger HP. Prolyl 3-hydroxylase 1, enzyme characterization and identification of a novel family of enzymes. J Biol Chem 2004; 279:23615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/17\">",
"      Cabral WA, Chang W, Barnes AM, et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet 2007; 39:359.",
"     </a>",
"    </li>",
"    <li>",
"     Osteogenesis imperfecta, type VIII. In: Online Mendelian Inheritance in Man. Johns Hopkins University Press, Baltimore. www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=610915 (Accessed on April 10, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/19\">",
"      van Dijk FS, Nikkels PG, den Hollander NS, et al. Lethal/severe osteogenesis imperfecta in a large family: a novel homozygous LEPRE1 mutation and bone histological findings. Pediatr Dev Pathol 2011; 14:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/20\">",
"      van Dijk FS, Nesbitt IM, Zwikstra EH, et al. PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet 2009; 85:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/21\">",
"      Barnes AM, Carter EM, Cabral WA, et al. Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. N Engl J Med 2010; 362:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/22\">",
"      Pyott SM, Schwarze U, Christiansen HE, et al. Mutations in PPIB (cyclophilin B) delay type I procollagen chain association and result in perinatal lethal to moderate osteogenesis imperfecta phenotypes. Hum Mol Genet 2011; 20:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/23\">",
"      Christiansen HE, Schwarze U, Pyott SM, et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet 2010; 86:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/24\">",
"      Becker J, Semler O, Gilissen C, et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2011; 88:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/25\">",
"      Lapunzina P, Aglan M, Temtamy S, et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am J Hum Genet 2010; 87:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/26\">",
"      Glorieux FH, Ward LM, Rauch F, et al. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002; 17:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/27\">",
"      Glorieux FH, Rauch F, Plotkin H, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 2000; 15:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/28\">",
"      Antoniazzi F, Mottes M, Fraschini P, et al. Osteogenesis imperfecta: practical treatment guidelines. Paediatr Drugs 2000; 2:465.",
"     </a>",
"    </li>",
"    <li>",
"     Byers PH. Disorders of collagen biosynthesis and structure. In: The metabolic and molecular bases of inherited disease, 8th ed, Scriver C, Beaudet AL, Valle D, Sly W (Eds), McGraw-Hill, New York 2001. p.5241.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/30\">",
"      Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004; 363:1377.",
"     </a>",
"    </li>",
"    <li>",
"     Osteogenesis imperfecta. In: Preventive management of children with congenital anomalies and syndromes, Wilson GN, Cooley WC (Eds), Cambridge University Press, Cambridge, UK 2000. p.256.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/32\">",
"      Cremin B, Goodman H, Spranger J, Beighton P. Wormian bones in osteogenesis imperfecta and other disorders. Skeletal Radiol 1982; 8:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/33\">",
"      Greeley CS, Donaruma-Kwoh M, Vettimattam M, et al. Fractures at diagnosis in infants and children with osteogenesis imperfecta. J Pediatr Orthop 2013; 33:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/34\">",
"      Semler O, Cheung MS, Glorieux FH, Rauch F. Wormian bones in osteogenesis imperfecta: Correlation to clinical findings and genotype. Am J Med Genet A 2010; 152A:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/35\">",
"      Plotkin H. Syndromes with congenital brittle bones. BMC Pediatr 2004; 4:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/36\">",
"      Smith R. Osteogenesis imperfecta. Clin Rheum Dis 1986; 12:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/37\">",
"      Carty H. Brittle or battered. Arch Dis Child 1988; 63:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/38\">",
"      Kuurila K, Kaitila I, Johansson R, Gr&eacute;nman R. Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey. Ann Otol Rhinol Laryngol 2002; 111:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/39\">",
"      Radunovic Z, Wekre LL, Diep LM, Steine K. Cardiovascular abnormalities in adults with osteogenesis imperfecta. Am Heart J 2011; 161:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/40\">",
"      Chines A, Petersen DJ, Schranck FW, Whyte MP. Hypercalciuria in children severely affected with osteogenesis imperfecta. J Pediatr 1991; 119:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/41\">",
"      Chines A, Boniface A, McAlister W, Whyte M. Hypercalciuria in osteogenesis imperfecta: a follow-up study to assess renal effects. Bone 1995; 16:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/42\">",
"      Lund AM, Hansen M, Kollerup G, et al. Collagen-derived markers of bone metabolism in osteogenesis imperfecta. Acta Paediatr 1998; 87:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/43\">",
"      Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 2000; 26:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/44\">",
"      Pedersen U. Hearing loss in patients with osteogenesis imperfecta. A clinical and audiological study of 201 patients. Scand Audiol 1984; 13:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/45\">",
"      Kuurila K, Gr&eacute;nman R, Johansson R, Kaitila I. Hearing loss in children with osteogenesis imperfecta. Eur J Pediatr 2000; 159:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/46\">",
"      Paterson CR, Monk EA, McAllion SJ. How common is hearing impairment in osteogenesis imperfecta? J Laryngol Otol 2001; 115:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/47\">",
"      Petersen K, Wetzel WE. Recent findings in classification of osteogenesis imperfecta by means of existing dental symptoms. ASDC J Dent Child 1998; 65:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/48\">",
"      Wenstrup RJ, Willing MC, Starman BJ, Byers PH. Distinct biochemical phenotypes predict clinical severity in nonlethal variants of osteogenesis imperfecta. Am J Hum Genet 1990; 46:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/49\">",
"      K&ouml;rkk&ouml; J, Ala-Kokko L, De Paepe A, et al. Analysis of the COL1A1 and COL1A2 genes by PCR amplification and scanning by conformation-sensitive gel electrophoresis identifies only COL1A1 mutations in 15 patients with osteogenesis imperfecta type I: identification of common sequences of null-allele mutations. Am J Hum Genet 1998; 62:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/50\">",
"      McPherson E, Clemens M. Bruck syndrome (osteogenesis imperfecta with congenital joint contractures): review and report on the first North American case. Am J Med Genet 1997; 70:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/51\">",
"      Beighton P, Winship I, Behari D. The ocular form of osteogenesis imperfecta: a new autosomal recessive syndrome. Clin Genet 1985; 28:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/52\">",
"      Capoen J, De Paepe A, Lauwers H. The osteoporosis pseudoglioma syndrome. J Belge Radiol 1993; 76:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/53\">",
"      Beighton P. Osteoporosis-pseudoglioma syndrome. Clin Genet 1986; 29:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/54\">",
"      Frontali M, Stomeo C, Dallapiccola B. Osteoporosis-pseudoglioma syndrome: report of three affected sibs and an overview. Am J Med Genet 1985; 22:35.",
"     </a>",
"    </li>",
"    <li>",
"     Osteoporosis-pseudoglioma syndrome; OPPG. In: Online Mendelian Inheritance in Man. Johns Hopkins University Press, Baltimore. file://www.ncbi.nlm.nih.gov/omim/259770 (Accessed on April 25, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/56\">",
"      Cole DE, Fraser FC, Glorieux FH, et al. Panostotic fibrous dysplasia: a congenital disorder of bone with unusual facial appearance, bone fragility, hyperphosphatasemia, and hypophosphatemia. Am J Med Genet 1983; 14:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/57\">",
"      Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002; 347:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/58\">",
"      Whyte MP. Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocr Rev 1994; 15:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/59\">",
"      Cole DE, Carpenter TO. Bone fragility, craniosynostosis, ocular proptosis, hydrocephalus, and distinctive facial features: a newly recognized type of osteogenesis imperfecta. J Pediatr 1987; 110:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38040/abstract/60\">",
"      Smith R. Idiopathic juvenile osteoporosis: experience of twenty-one patients. Br J Rheumatol 1995; 34:68.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2943 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38040=[""].join("\n");
var outline_f37_9_38040=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DISEASE CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mild (type I)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Moderate to severe (types III-IX)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lethal perinatal form (type II)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5114631\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Child abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Rickets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other skeletal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2943\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2943|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/43/7862\" title=\"diagnostic image 1\">",
"      Pseudofractures in osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2943|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/2/21550\" title=\"figure 1\">",
"      Tropocollagen synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2943|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/63/1014\" title=\"picture 1\">",
"      Blue sclerae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/46/36576\" title=\"picture 2\">",
"      Dentinogenesis imperfecta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2943|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/3/20541\" title=\"table 1\">",
"      OI clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/26/4525\" title=\"table 2\">",
"      OI radiographic features",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42519?source=related_link\">",
"      Bone physiology and biochemical markers of bone turnover",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15767?source=related_link\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7978?source=related_link\">",
"      Clinical manifestations and diagnosis of Paget disease of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11416?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/440?source=related_link\">",
"      Developmental defects of the teeth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11641?source=related_link\">",
"      Differential diagnosis of the orthopedic manifestations of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27494?source=related_link\">",
"      Epidemiology and etiology of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21209?source=related_link\">",
"      Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26185?source=related_link\">",
"      Osteogenesis imperfecta: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42585?source=related_link\">",
"      Prenatal diagnosis of the lethal skeletal dysplasias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/60/8137?source=related_link\">",
"      Systemic conditions associated with periodontal disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43989?source=related_link\">",
"      Transient hyperphosphatasemia of infancy and early childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29927?source=related_link\">",
"      Treatment of hearing impairment in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_9_38041="Sildenafil: Pediatric drug information";
var content_f37_9_38041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sildenafil: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"    see \"Sildenafil: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/8/27781?source=see_link\">",
"    see \"Sildenafil: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14965068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Issues Safety Recommendation Regarding Sildenafil (Revatio&reg;) Use in Children and Adolescents",
"     </span>",
"     <span class=\"collapsible-date\">",
"      August 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) is recommending to healthcare providers and their medical care organizations that Revatio&reg; (sildenafil) not be used to treat pulmonary arterial hypertension (PAH) in pediatric patients (1-17 years of age) due to a dose-dependent increased mortality risk observed in a long-term (&le;7 years) study. The Sildenafil in Treatment-Naive Children, Aged 1&ndash;17 Years, With Pulmonary Arterial Hypertension (STARTS-1, 2) study, a randomized, double-blind, international, multicenter, placebo-controlled, parallel-group trial, included 234 pediatric patients (1-17 years, weight &ge;8 kg) with PAH (mild-to-moderate symptoms) and evaluated 3 doses (low, medium, and high) of sildenafil on long-term mortality (Barst, 2012). Patients were randomized according to weight into the 3 dosage levels with doses administered 3 times daily:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <b>",
"        Low dose:",
"       </b>",
"       Weight &gt;20 kg: 10 mg per dose",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <b>",
"        Medium dose:",
"       </b>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"       Weight 8-20 kg: 10 mg per dose",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"       Weight &gt;20-45 kg: 20 mg per dose",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"       Weight &gt; 45 kg: 40 mg per dose",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <b>",
"        High dose:",
"       </b>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"       Weight 8-20 kg: 20 mg per dose",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"       Weight &gt;20-45: 40 mg per dose",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"       Weight &gt;45 kg: 80 mg per dose",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"       Low-, medium-, and high-dose levels were based upon desired steady state concentrations of 47, 140, and 373 ng/mL respectively; these concentrations are expected to inhibit 53%, 77%, and 90% of phosphodiesterase type 5 activity",
"       <i>",
"        in vitro",
"       </i>",
"       .",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"       An increased risk of death was observed after 2 years of therapy and appeared to be dose-dependent with the highest risk in the high-dose group after &ge;3 years of treatment (20% vs 9%, and 14% in the low- and medium-dose group); most deaths (74%) occurred in patients with idiopathic and hereditary PAH. The most frequent causes of death in the trial were pulmonary hypertension and heart failure which are also the most common causes of death in patients with PAH. Results did not show that low-dose sildenafil was effective at improving exercise ability.",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"       A new warning stating the use of Revatio&reg; is not recommended in pediatric patients has been added to the labeling. Revatio&reg; is indicated for the treatment of PAH by relaxing the blood vessels in the lungs to reduce blood pressure and is approved to improve exercise ability and delay clinical worsening of PAH in adult patients (WHO Group I). The FDA is requiring Pfizer, the manufacturer of Revatio&reg;, to evaluate its effect on the risk of death in adults with PAH.",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"       Patients and caregivers are advised to not change the dose or stop taking Revatio&reg; without talking with their healthcare provider. Healthcare providers were reminded that use of this product, particularly long-term use, in children is an off-label indication, is not approved by the FDA, and is not recommended.",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"       For additional information, refer to",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm317123.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm317123.htm",
"       </a>",
"       .",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Barst RJ, Ivy DD, Gaitan G, et al, &ldquo;A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Na&iuml;ve Children With Pulmonary Arterial Hypertension,&rdquo;",
"       <i>",
"        Circulation",
"       </i>",
"       , 2012, 125(2):324-34.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Revatio&reg;;",
"     </li>",
"     <li>",
"      Viagra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sildenafil&reg;;",
"     </li>",
"     <li>",
"      CO Sildenafil;",
"     </li>",
"     <li>",
"      GD-Sildenafil;",
"     </li>",
"     <li>",
"      PMS-Sildenafil;",
"     </li>",
"     <li>",
"      ratio-Sildenafil R;",
"     </li>",
"     <li>",
"      Revatio&reg;;",
"     </li>",
"     <li>",
"      Teva-Sildenafil;",
"     </li>",
"     <li>",
"      Viagra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1035851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Phosphodiesterase Type-5 (PDE5) Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In pediatric patients (1-17 years of age) with PAH, an increased mortality risk was associated with long-term use (&gt;2 years) at dosage levels of 0.88-2.5 mg/kg/dose administered three times daily (Barst, 2012); the FDA recommends against the use of sildenafil (Revatio&reg;) for treatment of PAH in children and adolescents; the mortality risk of long-term use in neonates is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pulmonary hypertension:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Limited data available; dose not established; a wide range of doses and interpatient variability has been reported; careful dose titration is necessary; most literature consists of case reports or small studies; further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: Full-term neonates: Usual range: 0.5-3 mg/kg/dose every 6-12 hours; the largest study was a double-blind, randomized, placebo-controlled trial and used an initial dose of 3 mg/kg/dose every 6 hours in 31 patients (Vargas-Origel, 2010); earlier studies used 0.3-2 mg/kg/dose every 6-24 hours; optimal duration not established (Ahsman, 2009; Baquero, 2006; Noori, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: GA &gt;34 weeks and PNA &lt;72 hours: PPHN: 0.4 mg/kg loading dose administered over 3 hours followed by continuous infusion of 1.6 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     for up to 7 days was used in four patients in an open-label, dose-escalation trial of 36 neonates with an oxygenation index (OI) &ge;15 on two occasions at least 30 minutes apart; 29 patients were also receiving iNO (Steinhorn, 2009);",
"     <b>",
"      Note:",
"     </b>",
"     The dose listed here is the dose recommended by the authors for use in future clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pulmonary hypertension, facilitation of inhaled nitric oxide (iNO) wean (in patients who previously failed iNO wean):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Limited information exists; dose not established; a wide range of doses and interpatient variability has been reported; careful dose titration is necessary; most literature consists of case reports or small studies; further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: Full-term neonates:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Single dose: ~0.3 mg/kg/dose given once 70-90 minutes prior to iNO discontinuation was used in three patients (3 days, 6 weeks, and 4 months of age) (Atz, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Multiple dose: Initial: 0.3 mg/kg/dose (range: 0.22-0.47 mg/kg/dose) every 6 hours (average duration: 28 days) was used in seven patients (median age: 12 months; range: 3 days to 21 months); optimal duration of treatment not established (Lee, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1035889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"      see \"Sildenafil: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     In pediatric patients (1-17 years of age) with PAH, an increased mortality risk was associated with long-term use (&gt;2 years) at dosage levels of 0.88-2.5 mg/kg/dose administered three times daily (Barst, 2012); the FDA recommends against the use of sildenafil (Revatio&reg;) for treatment of PAH in children and adolescents; the mortality risk of long-term use in infants is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pulmonary hypertension:",
"     </b>",
"     Limited data available; dose and duration of therapy not established; interpatient variability has been reported; further studies are needed; Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants: Initial: 0.25 mg/kg/dose every 6 hours",
"     <b>",
"      or",
"     </b>",
"     0.5 mg/kg/dose every 8 hours; titrate as needed; maximum reported dose range: 1-2 mg/kg/dose every 6-8 hours (Humpl, 2011; Mourani, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     An open-label, prospective trial of 25 pediatric patients &lt;5 years of age (median age: 6 months; age range: 10 days to 4.9 years) reported statistically significant improvement in echocardiography outcome measures; in 15 patients, sildenafil abolished rebound pulmonary hypertension following NO withdrawal; the initial dose of 0.25 mg/kg/dose four times daily was titrated as tolerated to a target of 1 mg/kg/dose four times daily; the reported median dose was 0.7 mg/kg/dose four times daily (range: 0.5-2.25 mg/kg/dose); reported duration of therapy was 9 days to 4.3 years (n=25); 11 patients were discontinued on sildenafil therapy due to clinical resolution; nine deaths were reported [severe lung hypoplasia (n=3); veno-occlusive disease post-chemotherapy (n=1); severe BPD (n=1); cause of death unrelated to pulmonary vascular disease (n=4)] (Humpl, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     A retrospective trial of 25 pediatric patients &lt;2 years of age (which included at least 16 infants) evaluated long-term safety and efficacy in patients with chronic lung disease (72% with BPD); at therapy initiation, the subject ages ranged from 14 days to 96 weeks (median: ~6 months); the initial dose of 0.5 mg/kg/dose every 8 hours was titrated as tolerated; the majority of patients were treated with 8 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     (2 mg/kg/dose four times daily); echocardiogram showed clinical improvement in 88% of patients; reported duration of therapy was 28-950 days (median: 241 days); five deaths were reported during therapy (day 25-241 of therapy; median: 135 days); causes of death included sepsis, meningitis, and refractory respiratory disease (Mourani, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children and Adolescents &lt;18 years of age:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage should not be increased; higher doses and long-term use are associated with an increased mortality risk (Barst, 2012 ).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     8-20 kg: 10 mg three times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;20 kg to 45 kg: 20 mg three times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;45 kg: 40 mg three times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Dosing based on the STARTS-1and 2 trial, a randomized, double-blind, placebo-controlled study in 235 pediatric patients (1-17 years of age) which evaluated short-term and long-term safety and efficacy of 3 dose levels (low, medium, and high-dose); results suggested that the medium dose level (shown above) is efficacious at improving exercise capacity, functional class and hemodynamic status in the short-term (16 weeks duration); the low dosage level was not shown to be efficacious. The long-term safety and efficacy data showed a dose-dependent increased risk of mortality which was highest among the high-dose group. It was estimated that the dosing presented will produce serum concentration of 140 ng/mL and would be expected to inhibit 77% of phosphodiesterase type 5 activity",
"     <i>",
"      in vitro",
"     </i>",
"     (Barst, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pulmonary hypertension, congenital heart surgery (postoperative):",
"     </b>",
"     Limited data available; dosing regimens variable:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral  (or nasogastric tube): Initial: 0.5 mg/kg/dose upon admission to ICU; increase in 0.5 mg/kg/dose increments every 4-6 hours up to a maximum dose of 2 mg/kg/dose as tolerated; upon discontinuation of mechanical ventilation, sildenafil therapy can be  tapered over 5-7 days; dosing based on a retrospective report of 100 pediatric patients (including neonates through &gt;10 years of age) which showed reduction in pulmonary arterial pressures and/or prevention of severe pulmonary hypertension (Nemoto, 2010). A lower dose of 0.35 mg/kg/dose every 4 hours for 1 week postoperatively was used in a retrospective, case-controlled trial of 38 pediatric patients (age range: 5-33 months) (Palma, 2011). In another retrospective report (n=45, median age: 32.6 months; range: 6 days to 17 years), a mean dose of 0.9 &plusmn; 0.3 mg/kg/dose four times daily was reported (Uhm, 2010). Further studies are needed.",
"     <b>",
"      Note:",
"     </b>",
"     Use of preoperative sildenafil therapy for the prevention of pulmonary hypertension following congenital heart surgery has produced variable efficacy results (Palma, 2011); a double-blind, placebo-controlled trial showed a negative impact on oxygenation and ventricular function (Vassalos, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: Infants &gt;60 days and Children: Loading dose: Range: 0.04-0.35 mg/kg administered over 5 minutes, followed by a maintenance infusion: Reported range: 0.015-0.4 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     continued for 24-72 hours was used for pulmonary hypertension occurring within 48 hours of the end of cardiac surgery in a multicenter, randomized, double-blind, placebo-controlled dose-finding trial (n=17; median age: 5 months; age range: 3 months to 14 years; neonates and infants &lt;60 days were excluded from the trial); dosages were either low, medium, or high dose (n=4 each treatment group; n=5 placebo) designed to attain serum concentrations of 40, 120, and 360 ng/mL, respectively; patients receiving sildenafil at all dosages were found to have lower pulmonary artery pressure and when compared to placebo, shorter duration of mechanical ventilation (median: 3 days vs 8 days), shorter ICU stay (median: 6 days vs 15 days), and shorter hospitalization (median: 12 days vs 21 days); study closed early due to slow patient accrual leading to underpowered results; no conclusions about dosage were able to be determined (Fraisse, 2011). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pulmonary hypertension, facilitation of inhaled nitric oxide (iNO) wean (in patients who have",
"      <span style=\"text-decoration: underline\">",
"       not",
"      </span>",
"      previously failed iNO wean):",
"     </b>",
"     Limited data available: Oral: Single dose: 0.4 mg/kg/dose (range: 0.3-0.5 mg/kg/dose) given once 60 minutes prior to iNO discontinuation; dosing based on a randomized, double-blind, placebo-controlled trial in 29 infants and young children (median age: 5.6 months; age range: 1-15 months; n=15 treatment arm) (Namachivayam, 2006). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Erectile dysfunction (Viagra&reg;): Oral: Usual: 50 mg taken as needed, ~1 hour before sexual activity (dose may be taken 30 minutes to 4 hours before sexual activity). Based on effectiveness and tolerance, may increase dose to a maximum of 100 mg or decrease to 25 mg. Maximum recommended dosing frequency: Once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pulmonary arterial hypertension (Revatio&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 20 mg 3 times daily taken at least 4-6 hours apart; no evidence for additional efficacy was observed with higher doses; treatment with higher doses is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 10 mg 3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Revatio&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment (Child Pugh class A and B): No dosage adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe hepatic impairment (Child Pugh class C): Has not been studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viagra&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Mild-to-moderate hepatic impairment (Child Pugh class A and B): Initial: 25 mg should be considered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Severe hepatic impairment (Child Pugh class C): Has not been studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Revatio&reg;: No dosage adjustments needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viagra&reg;: Severe renal impairment (creatinine clearance &lt;30 mL/minute): Initial: 25 mg should be considered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage considerations for patients taking alpha blockers:",
"     </b>",
"     Adults: Viagra&reg;: Initial: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for concomitant use of potent CYP34A inhibitors:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Revatio&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Erythromycin: No dosage adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Itraconazole, ketoconazole: Use is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Protease inhibitors: Contraindicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viagra&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Erythromycin, itraconazole, ketoconazole: Initial: 25 mg should be considered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Protease inhibitors: Maximum sildenafil dose: 25 mg every 48 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Revatio&reg;: 0.8 mg/mL (12.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Revatio&reg;: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viagra&reg;: 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1035894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Revatio&reg;: Administer doses at least 4-6 hours apart; may be administered without regard to meals; shake oral suspension well prior to use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Viagra&reg;: Administer dose ~1 hour before sexual activity (may be administered 30 minutes to 4 hours before sexual activity).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Revatio&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: In clinical trials, loading dose was administered over 3 hours, followed by a continuous I.V. infusion (Steinhorn, 2009 )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infant, Children, and Adolescents: In clinical trials, loading dose was administered as a bolus over 5 minutes, followed by a continuous I.V. infusion (Fraisse, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Administer as an I.V. bolus",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1035874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Revatio&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Powder for oral suspension: Store dry powder at &lt;30&deg;C (&lt;86&deg;F); protect from moisture. Following reconstitution, may store at &lt;30&deg;C (&lt;86&deg;F) or at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Discard unused portion after 30 days. Do not freeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Parenteral: Store at 20&deg;C to 25&deg;C (68&deg;F to77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Parenteral solution further diluted to 0.067-0.667 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W has been reported to be stable for 1 week when stored in polypropylene syringes at room temperature 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) (Al Hadithy, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Viagra&reg;: Tablets: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1035852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of WHO Group I pulmonary arterial hypertension (PAH) (Revatio&reg;: FDA approved in adults); treatment of erectile dysfunction (Viagra&reg;: FDA approved in male adults). Has also been used for treatment of persistent pulmonary hypertension of the newborn (PPHN) refractory to treatment with inhaled nitric oxide; facilitation of weaning from nitric oxide (ie, to attenuate rebound effects after discontinuing inhaled nitric oxide); secondary pulmonary hypertension following cardiac surgery;",
"     <b>",
"      Note:",
"     </b>",
"     The FDA recommends against the use of sildenafil (Revatio&reg;) for treatment of pulmonary arterial hypertension (PAH) in pediatric patients (1-17 years of age) due to a dose-dependent increased mortality risk observed in a long-term (median follow-up: 4 years; range: 0.3-7 years) study.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F221036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Revatio&reg; may be confused with ReVia&reg;, Revonto&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sildenafil may be confused with silodosin, tadalafil, vardenafil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Viagra&reg; may be confused with Allegra&reg;, Vaniqa&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F221034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Based upon normal doses for either indication or route. (Adverse effects such as flushing, diarrhea, myalgia, and visual disturbances may be increased with adult doses &gt;100 mg/24 hours.)",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, insomnia, pyrexia",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Erythema, rash",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, dyspepsia, gastritis",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Hepatic: LFTs increased",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia, paresthesia",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision (color changes, blurred vision, or increased sensitivity to light",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea exacerbated, epistaxis, nasal congestion, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, amnesia (transient global), anemia, angina pectoris, anorgasmia, asthma, AV block, cardiac arrest, cardiomyopathy, cataract, cerebral thrombosis, cerebrovascular hemorrhage, colitis, cystitis, depression, dysphagia, edema, exfoliative dermatitis, eye hemorrhage, gout, hearing decreased, hearing loss, heart failure, hematuria, hemorrhage, hyper-/hypoglycemia, hypernatremia, hyper-/hypotension, hyperuricemia, intracerebral hemorrhage, intraocular pressure increased, leukopenia, migraine, myocardial ischemia, MI, myasthenia, mydriasis, neuralgia, nonarteritic ischemic optic neuropathy (NAION), orthostatic hypotension, palpitation, priapism, pulmonary hemorrhage, rectal hemorrhage, retinal vascular disease or bleeding, seizure, shock, sickle cell crisis (vaso-occlusive crisis in patients with pulmonary hypertension associated with sickle cell disease), stomatitis, subarachnoid hemorrhage, syncope, tachycardia, tendon rupture, TIA, urinary incontinence, ventricular arrhythmia, vertigo, visual field loss, vitreous detachment/traction, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1035858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sildenafil or any component; concurrent use of organic nitrates (eg, nitroglycerin, isosorbide dinitrate) in any form (potentiates the hypotensive effects)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2930026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution in patients with resting hypotension or hypertension; cardiovascular disease, including cardiac failure, unstable angina, or a recent history (within the last 6 months) of MI, stroke, or life-threatening arrhythmia; patients with retinitis pigmentosa (subpopulation of these patients have a retinal phosphodiesterase disorder); patients receiving concurrent bosentan (efficacy has not been evaluated; bosentan decreases sildenafil serum concentrations); patients receiving alpha-blockers or other antihypertensive agents (additive hypotensive effects; symptomatic hypotension may occur). Combination therapy of sildenafil products or use with other PDE-5 inhibitors has not been evaluated and should be avoided. Use with caution in patients with hepatic or renal impairment; dosage adjustment may be needed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Use with caution in patients with anatomical deformation of the penis (angulation, cavernosal fibrosis, Peyronie's disease); conditions which may predispose patients to priapism (sickle cell anemia, multiple myeloma, leukemia). Epistaxis may occur and at a higher incidence in patients with pulmonary arterial hypertension due to connective tissue disorders or in patients receiving concurrent oral vitamin K antagonists. Use with caution in patients with bleeding disorders or with active peptic ulcer disease; safety of sildenafil is not known in these patients; may cause platelet dysfunction;",
"     <i>",
"      in vitro",
"     </i>",
"     study with human platelets indicates that sildenafil potentiates the antiaggregatory effect of nitric oxide.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1035859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The Food and Drug Administration (FDA) recommends that sildenafil (Revatio&reg;) not be used to treat pulmonary arterial hypertension (PAH) in pediatric patients (1-17 years of age) due to a dose-dependent increased mortality risk observed in a long-term study (median follow-up: 4 years; range: 0.3-7 years). The Sildenafil in Treatment-Naive Children, Aged 1&ndash;17 Years, With Pulmonary Arterial Hypertension (STARTS-1, 2) study, a randomized, double-blind, international, multicenter, placebo-controlled, parallel-group trial, included 234 pediatric patients (1-17 years, weight &ge;8 kg) with PAH (mild-to-moderate symptoms), and evaluated 3 doses (low, medium, and high) of sildenafil on efficacy and safety (eg, long-term mortality). High doses were in the range of 0.88-2.5 mg/kg/dose (rounded to the nearest 20, 40, or 80 mg fixed dose) administered three times daily and were based upon a desired steady state concentration of 373 ng/mL with the expected inhibition of 90% of phosphodiesterase type 5 activity",
"     <i>",
"      in vitro",
"     </i>",
"     . An increased risk of death was observed after 2 years of therapy and appeared to be dose-dependent with the highest risk in the high-dose group after &ge;3 years of treatment (20% vs 9% and 14% in the low- and medium-dose groups, respectively); most deaths (74%) occurred in patients with idiopathic and hereditary PAH. The most frequent causes of death in the trial were pulmonary hypertension and heart failure and were determined to be part of disease progression by the authors; pulmonary hypertension and heart failure are also the most common causes of death in patients with PAH (Barst, 2012). The FDA is requesting additional long-term studies in adult patients.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Decreases in blood pressure may occur due to vasodilator effects; the cardiovascular status of the patient should be considered prior to initiating treatment; certain patients may be adversely affected by vasodilator effects (eg, patients with resting hypotension, fluid depletion, severe left ventricular outflow obstruction, or autonomic dysfunction). Sildenafil is not recommended for use in patients with pulmonary veno-occlusive disease; consider diagnosis of pulmonary veno-occlusive disease in patients who develop pulmonary edema when receiving sildenafil. Vaso-occlusive crisis requiring hospitalization may occur in patients with PAH secondary to sickle cell disease who are treated with sildenafil; the effectiveness of sildenafil in this patient population has not been established. In the presence of increased left atrial pressure unresponsive to afterload reduction, the use of sildenafil may result in pulmonary capillary hypertension. Sildenafil may cause transient dose-related impairment of blue/green color discrimination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     A sudden decrease or loss of hearing has been reported rarely, in patients receiving sildenafil for the treatment of pulmonary arterial hypertension and for erectile dysfunction. Hearing changes may be accompanied by vestibular symptoms (eg, tinnitus, vertigo, dizziness). It is not known if PDE5 inhibitors cause this condition or if other related factors are responsible. Patients receiving sildenafil for the treatment of pulmonary arterial hypertension who experience sudden hearing changes should",
"     <b>",
"      not",
"     </b>",
"     stop taking the medication, but should contact their healthcare provider immediately. Patients receiving sildenafil for erectile dysfunction who experience a sudden hearing change should discontinue the drug and notify a healthcare provider immediately. Ritonavir or other potent CYP3A inhibitors can increase sildenafil serum concentrations; concurrent use not recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The oral suspension contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use the oral suspension containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Additional warnings for patients treated for erectile dysfunction:",
"     </b>",
"     Rare cases of sudden vision loss attributed to nonarteritic ischemic optic neuropathy (NAION) have been reported with the use of phosphodiesterase type-5 (PDE5) inhibitors when used for the treatment of male erectile dysfunction; NAION is a condition where blood flow is blocked to the optic nerve. NAION is more common in individuals with heart disease, diabetes, hypertension, certain eye problems, smokers, or those &gt;50 years of age. Vision loss in one eye has been reported in some men after taking PDE5 inhibitors. It is not known if PDE5 inhibitors cause this condition or if other related factors are responsible. Patients taking a PDE5 inhibitor and who experience vision loss should stop taking the drug and notify a healthcare provider immediately.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     A degree of cardiac risk is associated with sexual activity in patients with pre-existing cardiovascular disease; sildenafil should not generally be used to treat erectile dysfunction in men with underlying cardiovascular disease which would deem sexual activity inadvisable. Prolonged or painful erections may occur; patients should seek immediate medical assistance if erection lasts &gt;4 hours; permanent damage to the penis may occur without immediate treatment. The safety and efficacy of sildenafil with other treatments for erectile dysfunction have not been established; concurrent use is not recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     One possible case of retinopathy of prematurity  reported after treatment with I.V. sildenafil (Marsh, 2004; Pierce, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F221022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F220964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Alpha1-Blockers.  Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alprostadil: Phosphodiesterase 5 Inhibitors may enhance the adverse/toxic effect of Alprostadil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amyl Nitrite: Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Amyl Nitrite.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: Phosphodiesterase 5 Inhibitors may enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Sildenafil. Management: Avoid sildenafil when used for treatment of pulmonary arterial hypertension in patients receiving boceprevir.  Sildenafil for erectile dysfunction should be limited to 25 mg every other day with close monitoring for sildenafil toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Phosphodiesterase 5 Inhibitors may increase the serum concentration of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Sildenafil. Management: Use of sildenafil for pulmonary hypertension with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product is contraindicated.  Used for erectile dysfunction, sildenafil doses should be limited to 25 mg per 48 hrs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Sildenafil. Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Sildenafil. Management: When used for treatment of pulmonary artery hypertension, concurrent use with erythromycin is not recommended.  When used for treatment of erectile dysfunction, consider using a lower starting dose of 25 mg in patients who are also taking erythromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Management: No empiric dosage adjustments are recommended with concomitant therapy; however, dose of the phosphodiesterase inhibitor may need to be altered based on clinical response.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sildenafil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Sildenafil may decrease the metabolism of HMG-CoA Reductase Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fluvastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Sildenafil. Management: Concurrent itraconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Sildenafil. Management: Concurrent ketoconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Phosphodiesterase 5 Inhibitors. Specifically, the risk of developing priapism may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of other Phosphodiesterase 5 Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Sildenafil. Management: Concurrent posaconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent posaconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Sildenafil. Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sapropterin: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Sildenafil. Management: Concurrent use of sildenafil for treatment of pulmonary arterial hypertension is contraindicated with telaprevir.  Sildenafil for erectile dysfunction should be limited to 25 mg per 48 hours, with close monitoring for sildenafil toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vasodilators (Organic Nitrates): Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Vasodilators (Organic Nitrates).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sildenafil. Management: Concurrent voriconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent voriconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1035873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     A high fat meal decreases the rate of absorption and peak concentration. Grapefruit juice may increase serum concentrations or toxicity of sildenafil; avoid concurrent use",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F220978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Less than 0.001% appears in the semen.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2930483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Heart rate, blood pressure, oxygen saturation, PaO",
"     <sub>",
"      2",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1035876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Selective phosphodiesterase-type 5 (PDE-5) inhibitor. PDE-5 is found in the pulmonary vascular smooth muscle, vascular and visceral smooth muscle, corpus cavernosum, and platelets. PDE-5 is responsible for the degradation of cyclic guanosine monophosphate (cGMP). Normally, nitric oxide (NO) activates the enzyme guanylate cyclase, which increases the levels of cGMP; cGMP produces smooth muscle relaxation. Inhibition of PDE-5 by sildenafil increases the cellular levels of cGMP.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Increased levels of cGMP potentiate vascular smooth muscle relaxation, particularly in the lung where PDE5 is found in high concentrations. In patients with pulmonary arterial hypertension, sildenafil causes vasodilation in the pulmonary vasculature and, to a lesser extent, in the systemic circulation. Clinically, the drug decreases pulmonary arterial pressure and increases exercise capacity in these patients.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     In patients with erectile dysfunction, sildenafil does not directly cause penile erections, but affects the response to sexual stimulation. Normally, NO is released in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which increases the levels of cGMP; cGMP produces smooth muscle relaxation and allows an inflow of blood to the corpus cavernosum producing an erection. Sildenafil enhances the effect of NO by inhibiting PDE-5 and increasing the levels of cGMP in the corpus cavernosum. At recommended doses, sildenafil has no effect on erection in the absence of sexual stimulation.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F15035702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: Decrease blood pressure: Oral: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration of Action: Decrease blood pressure: &lt;8 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1035878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid; slower with a high-fat meal; tablet and suspension are bioequivalent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     total: Neonates: 22.4 L (or 456 L/70 kg) (Mukherjee, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      dss",
"     </sub>",
"     : Adults: 105 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: Sildenafil: 93.9% &plusmn; 2.5%; N-desmethyl metabolite: 92% &plusmn; 3% (Mukherjee, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Sildenafil and N-desmethyl metabolite: ~96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via the liver via cytochrome P450 isoenzyme CYP3A4 (major route) and CYP2C9 (minor route). Major metabolite (UK-103320 or desmethylsildenafil) is formed via N-desmethylation pathway and has 50% of the activity as sildenafil.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Mean: 41%; range: 25% to 63%; may be higher in patients with PAH compared to healthy volunteers;",
"     <b>",
"      Note:",
"     </b>",
"     A 10 mg dose of the injection is predicted to have an effect equal to a 20 mg oral dose taking into consideration the parent drug and active metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life (terminal):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sildenafil:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates: PNA 1 day: 55.9 hours (Mukherjee, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates: PNA 7 days: 47.7 hours (Mukherjee, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Active N-desmethyl metabolite:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates: 11.9 hours (Mukherjee, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Fasting: 30-120 minutes (median 60 minutes); delayed by 60 minutes with a high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted as metabolites; 80% of dose excreted in feces, 13% in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Decreased in patients with hepatic cirrhosis or severe renal impairment; clearance may be lower in patients with PAH compared to normal volunteers. Sildenafil clearance in newborns is significantly decreased compared to adults, but approaches adult (allometrically scaled) values by the first week of life (Mukherjee, 2009). Clearance of N-desmethyl active metabolite is decreased in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not likely to be beneficial due to high protein binding",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1035898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/8/27781?source=see_link\">",
"      see \"Sildenafil: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take nitroglycerin or other nitrate medications while using sildenafil (serious side effects may occur). Do not take Revatio&reg; with Viagra&reg; or other PDE-5 inhibitors. Avoid grapefruit juice and the herbal medicine, St John's wort. Certain other medications should not be taken with sildenafil or may require a dosage adjustment of sildenafil; report to healthcare provider the use of other medications, including nonprescription medications, and herbal or natural products.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Headache, flushing, or abnormal vision (color changes, blurred or increased sensitivity to light) may occur; use caution when driving at night or in poorly lit environments. Seek immediate medical attention if a sudden vision loss in one or both eyes occurs or if a sudden decrease or loss of hearing occurs. Report immediately acute allergic reactions; chest pain or palpitations; persistent dizziness; signs of urinary tract infection; skin rash; respiratory difficulty; genital swelling; or other adverse reactions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Do not combine sildenafil with other approaches to treating erectile dysfunction without consulting prescriber. If erection lasts longer than 4 hours, contact prescriber immediately; permanent damage to the penis can occur.",
"     <b>",
"      Note:",
"     </b>",
"     Sildenafil provides no protection against sexually-transmitted diseases, including HIV.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1035900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sildenafil is ~10 times more selective for PDE-5 as compared to PDE-6. PDE-6 is found in the retina and is involved in phototransduction. At higher plasma levels, inhibition of PDE-6 may occur and may account for the abnormalities in color vision noted in some patients.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F2619373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 2.5 mg/mL sildenafil citrate oral suspension may be made with tablets and either a 1:1 mixture of methylcellulose 1% and simple syrup NF or a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;. Crush thirty sildenafil 25 mg tablets (Viagra&reg;) in a mortar and reduce to a fine powder. Add small portions of chosen vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     300 mL; transfer to a graduated cylinder, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 300 mL. Store in amber plastic bottles and label \"shake well\". Stable for 90 days at room temperature or refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Morosco RS, and Brady MT, &ldquo;Extemporaneous Sildenafil Citrate Oral Suspensions for the Treatment of Pulmonary Hypertension in Children,&rdquo;",
"     <i>",
"      Am J Health-Syst Pharm",
"     </i>",
"     , 2006, 63(3):254-7.",
"     <span class=\"pubmed-id\">",
"      16434784",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Al Hadithy AF, de Goede AL, Eckhardt M, et al, \"Stability of Sildenafil (Revatio&reg;) Dilutions in Dextrose 5%,\"",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2011, 37(11):1899.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/21946926/pubmed\" id=\"21946926\" target=\"_blank\">",
"        21946926",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ahsman MJ, Witjes BC, Wildschut ED, et al, \"Sildenafil Exposure in Neonates With Pulmonary Hypertension After Administration Via a Nasogastric Tube,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 2010, 95(2):F109-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/19949232/pubmed\" id=\"19949232\" target=\"_blank\">",
"        19949232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Apitz C, Reyes JT, Holtby H, et al, \"Pharmacokinetic and Hemodynamic Responses to Oral Sildenafil During Invasive Testing in Children With Pulmonary Hypertension,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2010, 55(14):1456-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/20359596/pubmed\" id=\"20359596\" target=\"_blank\">",
"        20359596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Atz AM and Wessel DL, \"Sildenafil Ameliorates Effects of Inhaled Nitric Oxide Withdrawal,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1999, 91(1):307-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/10422958/pubmed\" id=\"10422958\" target=\"_blank\">",
"        10422958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baquero H, Soliz A, Neira F, et al, \"Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(4):1077-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/16585301/pubmed\" id=\"16585301\" target=\"_blank\">",
"        16585301",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barst RJ, Ivy DD, Gaitan G, et al, \"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 125(2):324-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/22128226/pubmed\" id=\"22128226\" target=\"_blank\">",
"        22128226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carroll WD and Dhillon R, \"Sildenafil as a Treatment for Pulmonary Hypertension,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2003, 88(9):827-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/12937112 /pubmed\" id=\"12937112 \" target=\"_blank\">",
"        12937112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erickson S, Reyes J, Bohn D, et al, \"Sildenafil (Viagra) in Childhood and Neonatal Pulmonary Hypertension,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2002, 39(Suppl):S402.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fraisse A and Wessel DL, \"Acute Pulmonary Hypertension in Infants and Children: cGMP-Related Drugs,\"",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2010, 11(2 Suppl):S37-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/20216161/pubmed\" id=\"20216161\" target=\"_blank\">",
"        20216161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haworth SG and Hislop AA, \"Treatment and Survival in Children With Pulmonary Arterial Hypertension: The UK Pulmonary Hypertension Service for Children 2001-2006,\"",
"      <i>",
"       Heart",
"      </i>",
"      , 2009, 95(4):312-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/18952635/pubmed\" id=\"18952635\" target=\"_blank\">",
"        18952635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Humpl T, Reyes JT, Erickson S, et al, \"Sildenafil Therapy for Neonatal and Childhood Pulmonary Hypertensive Vascular Disease,\"",
"      <i>",
"       Cardiol Young",
"      </i>",
"      , 2011, 21(2):187-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/21138617/pubmed\" id=\"21138617\" target=\"_blank\">",
"        21138617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Humpl T, Reyes JT, Holtby H, et al, \"Beneficial Effect of Oral Sildenafil Therapy on Childhood Pulmonary Arterial Hypertension: Twelve-Month Clinical Trial of a Single-Drug, Open-Label, Pilot Study,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(24):3274-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/15956137/pubmed\" id=\"15956137\" target=\"_blank\">",
"        15956137",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karatza AA, Bush A, and Magee AG, \"Safety and Efficacy of Sildenafil Therapy in Children With Pulmonary Hypertension,\"",
"      <i>",
"       Int J Cardiol",
"      </i>",
"      , 2005, 100(2):267-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/15823634/pubmed\" id=\"15823634\" target=\"_blank\">",
"        15823634",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karatza AA, Narang I, Rosenthal M, et al, \"Treatment of Primary Pulmonary Hypertension With Oral Sildenafil,\"",
"      <i>",
"       Respiration",
"      </i>",
"      , 2004, 71(2):192-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/15031578/pubmed\" id=\"15031578\" target=\"_blank\">",
"        15031578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      K&ouml;nig K and Henschke P, \"Successful Weaning of Nitric Oxide Facilitated by a Single Dose of Sildenafil in a Baby With Persistent Pulmonary Hypertension of the Newborn,\"",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 2009, 44(8):837.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/19598230/pubmed\" id=\"19598230\" target=\"_blank\">",
"        19598230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kothari SS and Duggal B, \"Chronic Oral Sildenafil Therapy in Severe Pulmonary Artery Hypertension,\"",
"      <i>",
"       Indian Heart J",
"      </i>",
"      , 2002, 54(4):404-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/12462669/pubmed\" id=\"12462669\" target=\"_blank\">",
"        12462669",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krishnan U, Krishnan S, and Gewitz M, \"Treatment of Pulmonary Hypertension in Children With Chronic Lung Disease With Newer Oral Therapies,\"",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 2008, 29(6):1082-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/18594787/pubmed\" id=\"18594787\" target=\"_blank\">",
"        18594787",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lammers AE, Haworth SG, and Pierce CM, \"Intravenous Sildenafil as an Effective Treatment of Pulmonary Hypertensive Crises During Acute Intestinal Malabsorption,\"",
"      <i>",
"       Cardiol Young",
"      </i>",
"      , 2006, 16(1):84-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/16454884/pubmed\" id=\"16454884\" target=\"_blank\">",
"        16454884",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee JE, Hillier SC, and Knoderer CA, \"Use of Sildenafil to Facilitate Weaning From Inhaled Nitric Oxide in Children With Pulmonary Hypertension Following Surgery for Congenital Heart Disease,\"",
"      <i>",
"       J Intensive Care Med",
"      </i>",
"      , 2008, 23(5):329-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/18701525/pubmed\" id=\"18701525\" target=\"_blank\">",
"        18701525",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marsh CS, Marden B, and Newsom R, \"Severe Retinopathy of Prematurity (ROP) in a Premature Baby Treated With Sildenafil Acetate (Viagra) for Pulmonary Hypertension,\"",
"      <i>",
"       Br J Ophthalmol",
"      </i>",
"      , 2004, 88(2):306-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/14736800 /pubmed\" id=\"14736800 \" target=\"_blank\">",
"        14736800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mourani PM, Sontag MK, Ivy DD, et al, \"Effects of Long-Term Sildenafil Treatment for Pulmonary Hypertension in Infants With Chronic Lung Disease,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2009, 154(3):379-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/18950791/pubmed\" id=\"18950791\" target=\"_blank\">",
"        18950791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mukherjee A, Dombi T, Wittke B, et al, \"Population Pharmacokinetics of Sildenafil in Term Neonates: Evidence of Rapid Maturation of Metabolic Clearance in the Early Postnatal Period,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2009, 85(1):56-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/18800037/pubmed\" id=\"18800037\" target=\"_blank\">",
"        18800037",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nagdyman N, Fleck T, Bitterling B, et al, \"Influence of Intravenous Sildenafil on Cerebral Oxygenation Measured by Near-Infrared Spectroscopy in Infants After Cardiac Surgery,\"",
"      <i>",
"       Pediatr Res",
"      </i>",
"      , 2006, 59(3):462-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/16492990/pubmed\" id=\"16492990\" target=\"_blank\">",
"        16492990",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Namachivayam P, Theilen U, Butt WW, et al, \"Sildenafil Prevents Rebound Pulmonary Hypertension After Withdrawal of Nitric Oxide in Children,\"",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2006, 174(9):1042-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/16917115/pubmed\" id=\"16917115\" target=\"_blank\">",
"        16917115",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nemoto S, Sasaki T, Ozawa H, et al, \"Oral Sildenafil for Persistent Pulmonary Hypertension Early After Congenital Cardiac Surgery in Children,\"",
"      <i>",
"       Eur J Cardiothorac Surg",
"      </i>",
"      , 2010, 38(1):71-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/    20206543/pubmed\" id=\"    20206543\" target=\"_blank\">",
"        20206543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Noori S, Friedlich P, Wong P, et al, \"Cardiovascular Effects of Sildenafil in Neonates and Infants With Congenital Diaphragmatic Hernia and Pulmonary Hypertension,\"",
"      <i>",
"       Neonatology",
"      </i>",
"      , 2007, 91(2):92-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/17344658/pubmed\" id=\"17344658\" target=\"_blank\">",
"        17344658",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palma G, Giordano R, Russolillo V, et al, \"Sildenafil Therapy for Pulmonary Hypertension Before and After Pediatric Congenital Heart Surgery,\"",
"      <i>",
"       Tex Heart Inst J",
"      </i>",
"      , 2011, 38(3):238-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/21720460/pubmed\" id=\"21720460\" target=\"_blank\">",
"        21720460",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pierce CM, Petros AJ, and Fielder AR, \"No Evidence for Severe Retinopathy of Prematurity Following Sildenafil,\"",
"      <i>",
"       Br J Ophthalmol",
"      </i>",
"      , 2005, 89(2):250.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/15665374/pubmed\" id=\"15665374\" target=\"_blank\">",
"        15665374",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raja SG, Danton MD, MacArthur KJ, et al, \"Effects of Escalating Doses of Sildenafil on Hemodynamics and Gas Exchange in Children With Pulmonary Hypertension and Congenital Cardiac Defects,\"",
"      <i>",
"       J Cardiothorac Vasc Anesth",
"      </i>",
"      , 2007, 21(2):203-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/17418732/pubmed\" id=\"17418732\" target=\"_blank\">",
"        17418732",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raposo-Sonnenfeld I, Otero-Gonz&aacute;lez I, Blanco-Aparicio M, et al, \"Treatment With Sildenafil, Bosentan, or Both in Children and Young People With Idiopathic Pulmonary Arterial Hypertension and Eisenmenger's Syndrome,\"",
"      <i>",
"       Rev Esp Cardiol",
"      </i>",
"      , 2007, 60(4):366-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/17521545/pubmed\" id=\"17521545\" target=\"_blank\">",
"        17521545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Samada K, Shiraishi H, Aoyagi J, et al, \"Cerebral Hemorrhage Associated With Sildenafil (Revatio) in an Infant,\"",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 2009, 30(7):998-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/19582500/pubmed\" id=\"19582500\" target=\"_blank\">",
"        19582500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh TP, Rohit M, Grover A, et al, \"A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Efficacy of Oral Sildenafil Therapy in Severe Pulmonary Artery Hypertension,\"",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2006, 151(4):851.e1-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/16569546/pubmed\" id=\"16569546\" target=\"_blank\">",
"        16569546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spillers J, \"PPHN: Is Sildenafil the New Nitric? A Review of the Literature,\"",
"      <i>",
"       Adv Neonatal Care",
"      </i>",
"      , 2010, 10(2):69-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/20386371/pubmed\" id=\"20386371\" target=\"_blank\">",
"        20386371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steinhorn RH, Kinsella JP, Pierce C, et al, \"Intravenous Sildenafil in the Treatment of Neonates With Persistent Pulmonary Hypertension,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2009, 155(6):841-847.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/19836028/pubmed\" id=\"19836028\" target=\"_blank\">",
"        19836028",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Uhm JY, Jhang WK, Park JJ, et al, \"Postoperative Use of Oral Sildenafil in Pediatric Patients With Congenital Heart Disease,\"",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 2010, 31(4):515-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/20054528/pubmed\" id=\"20054528\" target=\"_blank\">",
"        20054528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vargas-Origel A, G&oacute;mez-Rodr&iacute;guez G, Aldana-Valenzuela C, et al, \"The Use of Sildenafil in Persistent Pulmonary Hypertension of the Newborn,\"",
"      <i>",
"       Am J Perinatol",
"      </i>",
"      , 2010, 27(3):225-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/19866403/pubmed\" id=\"19866403\" target=\"_blank\">",
"        19866403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vassalos A, Peng E, Young D, et al, \"Pre-Operative Sildenafil and Pulmonary Endothelial-Related Complications Following Cardiopulmonary Bypass: A Randomised Trial in Children Undergoing Cardiac Surgery,\"",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2011, 66(6):472-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/9/38041/abstract-text/21457152/pubmed\" id=\"21457152\" target=\"_blank\">",
"        21457152",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13000 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-17F8E0A872-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38041=[""].join("\n");
var outline_f37_9_38041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965068\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220995\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220996\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035851\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445030\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035889\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220969\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220955\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035894\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035874\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035852\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221036\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221034\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035858\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930026\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035859\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221022\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220964\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035873\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220966\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220978\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930483\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035876\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15035702\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035878\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035898\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035900\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2619373\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13000\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13000|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=related_link\">",
"      Sildenafil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/8/27781?source=related_link\">",
"      Sildenafil: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_9_38042="Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy";
var content_f37_9_38042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/9/38042/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/9/38042/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/9/38042/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/9/38042/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/9/38042/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/9/38042/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/9/38042/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorectal cancer (CRC) is a common and lethal disease. CRC is the second leading cause of cancer death, and accounts for approximately 9 percent of cancer deaths overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately one in three people who develop CRC die of this disease. Removal of premalignant adenomas can prevent the cancer and removal of localized cancer may prevent CRC-related death.",
"   </p>",
"   <p>",
"    Multiple test options are available for screening, to detect either early stage cancer or precancerous polyps. This topic will review characteristics of the individual tests that are used for colorectal cancer screening. Screening strategies for patients with average colon cancer risk and with increased risk, as well as management of patients with colon polyps, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3224?source=see_link\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCREENING RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most colorectal cancers arise from adenomatous polyps that progress from small to large (&gt;1.0 cm) polyps and then to dysplasia and cancer. The progression from adenoma to carcinoma is believed to take at least 10 years on average [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/2\">",
"     2",
"    </a>",
"    ], although this estimate is imprecise because polyps are ordinarily removed when found.",
"   </p>",
"   <p>",
"    Most colorectal polyps are either adenomatous or hyperplastic. These cannot be distinguished reliably by gross appearance and therefore biopsy is required for diagnosis. Hyperplastic polyps usually do not progress to cancer.",
"   </p>",
"   <p>",
"    Two-thirds of polyps are adenomas. Adenomas are more common in men than women and prevalence increases with age. In an Australian population of 44,350 participants (average age 61 years) undergoing colonoscopy screening, adenomas were found in 25 percent of men and 15 percent of women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/3\">",
"     3",
"    </a>",
"    ]. Large adenomatous polyps (&gt;1.0 cm) are more likely to progress to cancer than smaller ones but are less common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/4\">",
"     4",
"    </a>",
"    ]. Some colon cancers arise from non-polypoid adenomas that are flat or depressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The slow transition from polyps to colorectal cancer in most patients allows opportunities to prevent cancer by removing polyps and to prevent cancer death by finding and removing early cancers. Multiple tests are available as options for colorectal cancer screening (",
"    <a class=\"graphic graphic_table graphicRef71954 \" href=\"mobipreview.htm?31/15/31996\">",
"     table 1",
"    </a>",
"    ). While stool-based tests improve disease prognosis by detecting early stage treatable cancers (and possibly advanced adenomas), endoscopic or radiologic tests that visualize the bowel mucosa have the potential to also prevent cancer by detecting polyps that can be removed prior to malignant transformation.",
"   </p>",
"   <p>",
"    Older tests, including guaiac-based fecal occult blood tests (gFOBT), flexible sigmoidoscopy (FS), double-contrast",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema (DCBE), and colonoscopy with direct visualization (optical colonoscopy) have been recommended as screening options for many years. Newer tests, including fecal immunochemical tests, computed tomographic colonography (CTC), and a panel test for stool DNA (sDNA) are also available. Guidelines do not agree on the screening role for CTC, double contrast barium enema, and sDNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STOOL-BASED TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Guaiac-based fecal occult blood test (gFOBT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guaiac testing of stool samples identifies hemoglobin by the presence of a peroxidase reaction, which turns the guaiac-impregnated paper blue. Several guaiac reagents are marketed; Hemoccult-SENSA is more sensitive than Hemoccult, Hemoccult-II, or Hemoccult-R.",
"   </p>",
"   <p>",
"    The first clinical trial of gFOBT screening randomly assigned 46,551 participants ages 50 to 80 years in Minnesota to screening with gFOBT (Hemoccult II) once a year or every two years or to a control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients assigned to screening were asked to follow a high fiber diet for two days with no red meat, vitamin C, or gastric irritant medications and then to submit two specimens from three consecutive stools for guaiac testing. Most stools were rehydrated with distilled water before testing, increasing sensitivity and decreasing specificity. Participants who tested positive underwent a diagnostic evaluation, usually with colonoscopy. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cumulative CRC mortality was reduced by 33 percent at 13 years and by 21 percent at 18 years in the annual and biennial screening groups respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two percent of patients with a positive test had cancer. Thus, for every patient with cancer, approximately 50 patients were subjected to anxiety and further testing (typically colonoscopy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Slightly lower mortality reductions (15 to 18 percent) have been reported with other randomized trials of biennial screening with nonrehydrated specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. Twenty-year follow-up of a large trial in Nottingham, England, also using non-rehydrated specimens, found a 13 percent decrease in CRC mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/16\">",
"     16",
"    </a>",
"    ]. Whereas 28 percent of the screened subjects in the Minnesota trial underwent colonoscopy, only 5 percent of the screened subjects in the Nottingham trial had a colonoscopy; the difference in test characteristics (sensitivity) with rehydration likely contributed to the difference in colonoscopy rates. &nbsp;",
"   </p>",
"   <p>",
"    An Italian population based study, comparing mortality rates in regions that implemented FOBT screening at different times, found a 13 percent reduction in CRC mortality related to screening implementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/17\">",
"     17",
"    </a>",
"    ]. Similarly, a population-based study in the United Kingdom found a 10 percent relative reduction in CRC mortality for invitees to screening and a 27 percent reduction in CRC mortality for those who participated in screening, compared to matched controls in regions where screening was not offered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/18\">",
"     18",
"    </a>",
"    ]. These studies have reported little effect on all cause mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity of a single gFOBT for colorectal cancer, using an older guaiac method, is only about 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/20\">",
"     20",
"    </a>",
"    ]; a program of repeated testing has a higher sensitivity of about 80 to 92 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is disagreement about the extent to which cancers found after a positive FOBT were discovered by chance, because of the test's high false positive rate, rather than a specific effect of gFOBT screening itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The effectiveness of gFOBT in reducing mortality from CRC may be in part a consequence of implementing colonoscopy in a relatively random sample of the population.",
"   </p>",
"   <p>",
"    A restrictive diet during testing may not be necessary. A systematic review found that advice to follow a restrictive diet did not reduce the gFOBT positivity rate, and restrictive diets decreased screening compliance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/24\">",
"     24",
"    </a>",
"    ]. Additionally, it is not necessary to avoid oral iron supplements when performing gFOBT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Large doses of vitamin C cause false-negative tests, and intake of vitamin C should be restricted to &lt;250 mg per day (less than the dose in common multivitamins) for at least three days prior to sampling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11336?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of occult gastrointestinal bleeding\", section on 'Testing for occult blood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is general consensus that gFOBT samples should not be rehydrated prior to processing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/29\">",
"     29",
"    </a>",
"    ]. Hydration increases test sensitivity but leads to an increased number of false positive results.",
"   </p>",
"   <p>",
"    FOBT screening has some disadvantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is not a good test for the detection of polyps, which usually do not bleed. The sensitivity for advanced adenomas is substantially less than for cancers.",
"     </li>",
"     <li>",
"      It is necessary to work up many false positive results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A single stool specimen obtained during a rectal examination is",
"    <strong>",
"     not",
"    </strong>",
"    an adequate screen for colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/30\">",
"     30",
"    </a>",
"    ]. The sensitivity for advanced neoplasia was much lower than with a six-sample home test (5 versus 24 percent) in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/31\">",
"     31",
"    </a>",
"    ]. Screening by gFOBT should be performed on three consecutive stool specimens (applying two samples per card for each specimen).",
"   </p>",
"   <p>",
"    Despite lack of support from evidence or guidelines recommendations, a single stool specimen from digital rectal examination remains a common approach to screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/32\">",
"     32",
"    </a>",
"    ]. We do not advise screening by guaiac testing on samples obtained in the course of a rectal examination performed in an asymptomatic patient, although such examinations have their place in the evaluation of abnormalities such as anemia. Nevertheless, if an office gFOBT is obtained during a rectal examination and found to be positive in an asymptomatic patient, further workup with colonoscopy is indicated. Repeat stool testing is not an appropriate test once a positive guaiac is noted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11336?source=see_link\">",
"     \"Evaluation of occult gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Sensitive gFOBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoccult SENSA, also a guaiac-based test, is more sensitive than Hemoccult II, although has lower specificity. In a head-to-head comparison, sensitivity of Hemoccult SENSA for colorectal cancer was reported as 64 to 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/21,33\">",
"     21,33",
"    </a>",
"    ] compared to 25 to 38 percent for nonrehydrated Hemoccult II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/34\">",
"     34",
"    </a>",
"    ]; specificity was 87 to 90 percent for Hemoccult SENSA and 98 to 99 percent for Hemoccult II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of concerns that compliance with a program of repeated annual testing is low, one major consensus guideline in 2008 did not endorse screening tests that have less than 50 percent sensitivity for cancer detection as individual tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/8\">",
"     8",
"    </a>",
"    ]. The consensus panel therefore recommends that FOBT screening should only be performed using the more sensitive guaiac reagent, such as Hemoccult SENSA (or an immunochemical test) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immunochemical tests for fecal blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fecal immunochemical tests (FIT or iFOBT) for hemoglobin are more specific than guaiac tests because they respond only to human globin and do not detect upper gastrointestinal bleeding (since the globin is digested in transit) or foods with peroxidase activity.",
"   </p>",
"   <p>",
"    A variety of immunochemical FOBTs are marketed around the world, some with qualitative results (normal or abnormal) and others with quantitative results. Several qualitative immunochemical tests are commercially available in the US. They appear to be somewhat more sensitive and more specific than Hemoccult II for CRC and advanced neoplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/8,21,35,36\">",
"     8,21,35,36",
"    </a>",
"    ]. Representative studies comparing guaiac and immunochemical testing include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study comparing Hemoccult SENSA (guaiac-based) and Hemoccult ICT (immunochemical) for screening, sensitivity for cancer was higher for the immunochemical test (81.9 versus 64.3 percent) but sensitivity for advanced adenomas was higher for the guaiac test (41.3 versus 29.5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, six qualitative immunochemical tests were compared; all performed better than a guaiac test for detecting adenoma but specificities and sensitivities varied [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/37\">",
"       37",
"      </a>",
"      ]. The two best performing tests had sensitivities of 25 and 27 percent for advanced adenoma and specificities of 97 and 93 percent.",
"     </li>",
"     <li>",
"      A population of 20,322 average risk subjects aged 50 to 74 years was screened by both Hemoccult II (guaiac-based) and Magstream I-FOBT (immunochemical) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/36\">",
"       36",
"      </a>",
"      ]. Patients with either test positive were advised to have colonoscopy. Among 1277 colonoscopies, 43 invasive cancers and 270 advanced adenomas were found. Immunochemical testing showed greater sensitivity than Hemoccult II, especially for advanced adenomas (ratio of sensitivities, RSN 3.32, 95% CI 2.70-4.07) and for rectal cancer (RSN 2.09, 1.36-3.20).",
"     </li>",
"     <li>",
"      In a randomized trial in the Netherlands comparing Hemoccult II (guaiac-based), a quantitative fecal immunochemical test (FIT), and flexible sigmoidoscopy for screening, the participation rate was higher for the FIT compared to the guaiac test (61.5 versus 49.5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/38\">",
"       38",
"      </a>",
"      ]. This likely reflects the greater convenience of immunochemical testing, which does not require dietary restrictions or sampling of three consecutive stools.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sensitivity of the immunochemical FOBT declines with delay in mailing or processing after sampling, because of hemoglobin degradation. In one study, delayed return of the FOBT more than five days after sampling, compared to no delay, was associated with a decreased rate of adenoma detection (OR 0.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunochemical tests have the advantage over guaiac-based tests of requiring fewer stool samples (one or two, compared to three) and automated analysis. The immunochemical test itself is more expensive than guaiac-based tests, but has the potential to be more cost-effective if fewer colonoscopies are needed for follow-up.",
"   </p>",
"   <p>",
"    The optimal interval for FIT screening is not known. In a randomized trial in the Netherlands, screening by FIT (one sample) every three years, compared to annual or biennial screening, resulted in the same positivity rate and a slightly higher participation rate in the second round screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/40\">",
"     40",
"    </a>",
"    ]. The authors concluded that screening intervals could be tailored to local resources (including colonoscopy capacity and funding).",
"   </p>",
"   <p>",
"    In one study (2310 subjects), the sensitivity of an immunochemical stool test for advanced adenoma was significantly greater for left-sided than right-sided lesions (33 versus 20 percent, at a specificity of 95 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/41\">",
"     41",
"    </a>",
"    ]. This finding was not confirmed in another study of 1226 participants who underwent both FIT testing and colonoscopy in which the sensitivity of FIT was the same for proximal and distal advanced neoplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/42\">",
"     42",
"    </a>",
"    ]. This issue is of concern because it has been suggested that colonoscopy screening is also more effective for the detection of left-sided than right-sided lesions. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Evidence of effectiveness'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Quantitative immunochemical stool tests offer the ability to adjust the defined cutoff point for an abnormal result, based on population characteristics and resources for follow-up testing. Currently it is difficult to compare results between different tests, as comparable units have not been standardized though there are proposals to do so [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/43\">",
"     43",
"    </a>",
"    ]. In one study, sensitivity and specificity of the immunochemical test for cancer were 94 and 86 percent respectively, and for advanced neoplasia were 67 and 91 percent at a hemoglobin threshold of 75",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    buffer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/44\">",
"     44",
"    </a>",
"    ]. Another study evaluated test characteristics at a variety of cut-off values and found 75",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    provided a good compromise between detection rates of advanced neoplasia or colon cancer and the number of colonoscopies needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/45\">",
"     45",
"    </a>",
"    ]. The quantitative test is not commercially available in the US. A European consensus panel has recommended use of a quantitative iFOBT with automated high throughput analysis as the fecal test of choice for centers that will be initiating colon cancer screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for primary or secondary prevention is increasingly prevalent among people who are in the age range for CRC screening. Aspirin increases the risk for both upper and lower gastrointestinal bleeding and can decrease the positive predictive value of guaiac FOBTs for significant colon disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/46\">",
"     46",
"    </a>",
"    ]. However, FITs are more specific than guaiac-based tests for lower gastrointestinal sources of bleeding. In one German observational study, the performance (higher sensitivity with only slightly lower specificity) of a quantitative FIT in detecting advanced colorectal neoplasia was better for patients who took low dose aspirin, compared to those who did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COLON IMAGING AND DIRECT VISUALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of radiologic and endoscopic options are available to detect adenomatous polyps and cancer. As noted above, such tests offer the potential to remove polyps that might progress to invasive cancer, as well as the potential to identify early stage treatable cancer. Bowel preparation recommendations for bowel imaging procedures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/39/27258?source=see_link\">",
"     \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36632?source=see_link&amp;anchor=H2#H2\">",
"     \"Computed tomographic colonography\", section on 'Patient preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Double-contrast barium enema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Double contrast",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema (DCBE) involves coating the lower intestinal mucosa with barium and inserting air through a rectal catheter to distend the colon, with multiple radiographs taken under fluoroscopy. Patients must undergo bowel preparation. Sedation is not ordinarily given. Patients experience some cramping during the procedure but can return to work after the examination.",
"   </p>",
"   <p>",
"    DCBE detects only about half of adenomas larger than 1.0 cm and 39 percent of all polyps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/48\">",
"     48",
"    </a>",
"    ]. Retrospective studies have found that DCBE may miss 15 to 22 percent of colorectal cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormalities must be followed by colonoscopy for biopsy or excision. False-positive findings can result from retained stool, air, and other causes of mucosal irregularity. Potential advantages of DCBE are that it can be used to examine the entire colon and rectum, and it is relatively safe.",
"   </p>",
"   <p>",
"    There are no studies evaluating the effectiveness of DCBE in the prevention of CRC deaths. It can be reasonably inferred that DCBE is effective, however, since it is more sensitive than FOBT, which has been shown to lower CRC mortality. DCBE may perform less well in the rectosigmoid than in the rest of the colon, but this has not been rigorously tested.",
"   </p>",
"   <p>",
"    Use of DCBE has been declining, with increasing use of endoscopic and CT procedures, and is now infrequently used for screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/8\">",
"     8",
"    </a>",
"    ]. This may affect the availability of adequately trained radiologists and technicians in DCBE technique. DCBE may be of particular value where colonoscopy resources are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sigmoidoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 60 cm flexible sigmoidoscope can reach to the splenic flexure. One study demonstrated that 66 percent of advanced colon lesions in men could be detected with sigmoidoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/50\">",
"     50",
"    </a>",
"    ]. Colon lesions (cancers or polyps) are more likely to be proximal in women. A study in 1463 women found that only 35 percent of women with advanced neoplasia would have had their lesions identified if they had undergone flexible sigmoidoscopy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/51\">",
"     51",
"    </a>",
"    ]. If colonoscopy is performed to follow-up polyps found on sigmoidoscopy, an additional 20 percent of neoplasms might be found, but lesions that were only present in the proximal colon would still be missed.",
"   </p>",
"   <p>",
"    Primary care physicians, nurse practitioners, and physicians assistants can become proficient in the technique of sigmoidoscopy with proper training [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/52\">",
"     52",
"    </a>",
"    ]. The patient preparation is less onerous than for colonoscopy or CT colonography, and the procedure can be performed without sedation in the office. The most important complication is perforation. In a Medicare population, perforation rates were 0.88 per 1000 sigmoidoscopies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/53\">",
"     53",
"    </a>",
"    ]. This rate was about half that of colonoscopy (OR 0.55). Comorbidities and increasing age increased the risk of perforation, and patients who experienced a perforation had an increased risk of death (OR 8.8, 95% CI 1.6-48.5). Small adenomas can be biopsied during the procedure. However, excision of larger lesions (&gt;1.0 cm) is usually done during a subsequent colonoscopy.",
"   </p>",
"   <p>",
"    Technical difficulties preventing sigmoidoscopy from reaching an adequate depth (at least 40 cm) are more common in women and older people. A study in 15,406 people aged &ge;50 years who underwent screening flexible sigmoidoscopy found that an examination to less than 50 cm occurred in 10 percent of men and 19 percent of women aged 50 to 59 years, and in 22 percent of men and 32 percent of women aged &ge;80 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Evidence of effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized trials of screening sigmoidoscopy have shown a decrease in cancer incidence and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/55-59\">",
"     55-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of five randomized trials (&gt;410,000 subjects) comparing colorectal cancer screening by flexible sigmoidoscopy with no screening or with usual care, found that sigmoidoscopy reduced the incidence of CRC (RR 0.82, 95% CI 0.73-0.81) and CRC mortality (RR 0.72, 95% CI 0.65-0.80) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/59\">",
"       59",
"      </a>",
"      ]. When results were analyzed to include only those who underwent screening, sigmoidoscopy screening reduced the incidence of CRC by 32 percent and mortality from CRC by 50 percent.",
"     </li>",
"     <li>",
"      Two randomized trials, one in the United Kingdom and one in Italy, evaluated one-time screening in participants between the ages of 55 and 64 years who had indicated that they would accept screening prior to trial recruitment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. In the larger trial involving 170,432 participants, patients were randomly assigned to control or sigmoidoscopy groups; polypectomy, when indicated, was performed during sigmoidoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/56\">",
"       56",
"      </a>",
"      ]. In the group invited to undergo sigmoidoscopy, 71 percent underwent the procedure and 5 percent had a subsequent colonoscopy for large or multiple adenomatous polyps, abnormal histology, or &gt;20 hyperplastic polyps. At 11 year follow-up, the intention-to-treat analysis found significant decreases in the incidence of CRC and overall mortality for the group randomly assigned to sigmoidoscopy (HR 0.77, 95% CI 0.70-0.84 and HR 0.69, 95% CI 0.59-0.82 for incidence of CRC and mortality, respectively). Differences were even more striking when the comparison was made between those who underwent sigmoidoscopy and the control group (HR 0.67, 95% CI 0.60-0.76 for CRC incidence, HR 0.57, 0.45-0.72 for overall mortality). Similar results were reported in a subsequent trial of 34,292 participants randomly assigned to flexible sigmoidoscopy or control (no further contact) groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/57\">",
"       57",
"      </a>",
"      ]. The incidence of CRC at 10.5 year follow-up was reduced in the intervention group compared to the controls (RR 0.82, 95% CI 0.69-0.96). The mortality rate at 11.4 year follow-up for the intervention group showed a trend towards reduction (RR 0.78, 95% CI 0.56-1.08) when analyzed by intention-to-treat but was significantly decreased in the per-protocol analysis (RR 0.62, 95% CI 0.40-0.96).",
"     </li>",
"     <li>",
"      The Norwegian Colorectal Cancer Prevention (NORCCAP) trial reported interim results at six to seven year follow-up, with planned further follow-up at 10 and 15 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/55\">",
"       55",
"      </a>",
"      ]. Individuals aged 55 to 64 years were randomly assigned to screening (n = 13,823) or no screening (n = 41,913). One half of those assigned to sigmoidoscopy screening were also assigned to an immunochemical FOBT. There was no difference in the cumulative incidence of colorectal cancer at seven years. Colorectal cancer mortality showed a trend toward reduction in those who were assigned to screening and was significantly reduced for those who underwent screening (HR 0.41, 95% CI 0.21-0;82 for any CRC and HR 0.24, 0.08-0.76 for rectosigmoid cancer).",
"     </li>",
"     <li>",
"      Results of the flexible sigmoidoscopy arm of the Prostate Lung Colorectal and Ovarian (PLCO) Screening Trial have been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/58\">",
"       58",
"      </a>",
"      ]. A total of 154,900 men and women aged 55 to 74 were randomly assigned to screening with flexible sigmoidoscopy (repeated at three or five years) or to usual care, with median follow-up of 11.9 years. Polyps were not removed at sigmoidoscopy and patients with positive findings were advised to undergo colonoscopy. There was a 21 percent reduction (RR 0.79, 95% CI 0.72-0.85) in the relative risk of colorectal cancer, comparing the screening arm with usual care, and a 26 percent reduction (RR 0.74, 95% CI 0.63-0.87) in the relative risk of death from colorectal cancer. Per 10,000 person-years, there were 11.9 cases of CRC and 2.9 CRC deaths in the screening arm, compared with 15.2 cases and 3.9 CRC deaths in the usual care arm. Although the incidence of both proximal and distal CRC significantly decreased, a reduction in mortality was seen only for distal cancer. The effectiveness of screening sigmoidoscopy followed by colonoscopy for positive findings may be even greater than these study results suggest, since there was significant contamination in the usual care group (among whom 47 percent underwent either sigmoidoscopy or colonoscopy) and 20 percent of the patients found to have a polyp in the study sigmoidoscopy group did not proceed to colonoscopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Case-control studies have found that sigmoidoscopy reduces overall CRC mortality by about two-thirds in the half of the bowel examined, which is about one-third overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have looked at the rates of advanced lesions and cancer after a negative sigmoidoscopy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Participants in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Trial who had a negative initial screening sigmoidoscopy were offered a follow-up sigmoidoscopy examination at three or five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/63\">",
"       63",
"      </a>",
"      ]. After the first screening, colorectal cancer or advanced adenoma (size &ge;1.0 cm, villous elements, or high-grade dysplasia) was found in 37.8 per 1000 persons. After the second sigmoidoscopy, the yield of colorectal cancer or advanced adenoma increased by an additional 26 percent in women and 34 percent in men. Overall, a second screening examination identified 1 additional cancer and 17 advanced adenomas for every 1000 re-screenings. For all colorectal cancers diagnosed by screening (177 by the first screen, 46 by the second, total 223), 64.6 percent were stage 1 and 17.5 percent stage 2.",
"     </li>",
"     <li>",
"      A cohort study from Kaiser Permanente that included 72,483 adults who had undergone a negative screening sigmoidoscopy found that the age-adjusted incidence of colorectal cancer per 100,000 people increased from 2.8 during the first year of follow-up to 13.0 during the fourth year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/64\">",
"       64",
"      </a>",
"      ]. The authors pointed out that these rates are much lower than the expected age-adjusted incidence in the general population of 70.6 cancers per 100,000 person-years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The British randomized trial provides evidence that a single sigmoidoscopic examination reduces colorectal mortality for at least 11 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/56\">",
"     56",
"    </a>",
"    ]. Whether there is additional effectiveness if the examination is repeated at five year intervals was not studied in this trial, but seems to be suggested by results of the PCLO. Current screening guidelines in the United States recommend sigmoidoscopy screening at five-year intervals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Follow-up of positive sigmoidoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is consensus that risk of advanced neoplasia in the proximal colon is increased when sigmoidoscopy discloses a large adenoma (&gt;1.0 cm), an adenoma of any size with tubulovillous or villous histology, or multiple adenomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/65\">",
"     65",
"    </a>",
"    ]. Sigmoidoscopy should be followed by colonoscopy in these circumstances.",
"   </p>",
"   <p>",
"    Hyperplastic polyps, in small numbers, are not associated with proximal neoplasia and do not indicate a need for colonoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/66\">",
"     66",
"    </a>",
"    ]. Patients found to have a single, small (&lt;0.6 cm) tubular adenoma of the distal colon are probably not at increased risk and should continue average risk screening without additional testing.",
"   </p>",
"   <p>",
"    Opinions differ regarding the need for colonoscopy for patients with single tubular adenomas 0.6 to 1.0 cm. The issue is not whether some proximal adenomas are missed by sigmoidoscopy, but rather how many proximal adenomas would be missed if small distal adenomas were not followed up with colonoscopy. Results of studies of this question are mixed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study reported findings in 10,850 colonoscopies for participants who had a polyp found at screening sigmoidoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/67\">",
"       67",
"      </a>",
"      ]. Small (&lt;1 cm) advanced adenomas (villous histology or high grade dysplasia) were identified in 5.5 percent of colonoscopies performed as follow-up for sigmoidoscopy findings of polyps 0.5 to 0.9 cm; proximal adenomas &ge;1 cm were found in another 9.9 percent.",
"     </li>",
"     <li>",
"      A study of 2972 screening sigmoidoscopies followed by colonoscopy found that the rates of proximal advanced adenomas were no different in patients with no, small, or large tubular adenomas on sigmoidoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taking a cautious approach, guidelines from the Multisociety Task force recommend colonoscopy for polyps &gt;0.5 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/8\">",
"     8",
"    </a>",
"    ]. However, there is no definitive evidence regarding optimal management of these patients, and the decision to perform colonoscopy should be individualized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     FOBT plus sigmoidoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are theoretical reasons for combining FOBT and sigmoidoscopy. Three randomized trials have shown that the yield of flexible sigmoidoscopy plus FOBT was greater than with FOBT alone, but no trials had colorectal cancer mortality as an end-point [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/69\">",
"     69",
"    </a>",
"    ]. FOBT plus sigmoidoscopy misses a number of invasive cancers. In a study of 2885 asymptomatic men aged 50 to 75 years, one time screening with FOBT (with rehydration of slides) and sigmoidoscopy failed to detect advanced colonic neoplasia in 24 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/50\">",
"     50",
"    </a>",
"    ]. Sensitivity may be improved with repeated screening at suggested intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy in this section refers to optical colonoscopy, to be distinguished from \"virtual colonoscopy\" that is an earlier term for CT colonography.",
"   </p>",
"   <p>",
"    Colonoscopy has become increasingly popular for screening. There is a strong biologic argument that colonoscopy, with direct visualization of the colonic mucosa and the ability to biopsy or excise polyps and localized cancers, can prevent colorectal cancers and deaths. The American College of Gastroenterology now considers colonoscopy the \"preferred\" screening test when it is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/70\">",
"     70",
"    </a>",
"    ], but other expert groups simply list it as an option.",
"   </p>",
"   <p>",
"    Colonoscopy has the added benefit that lesions can be removed during the same procedure. Furthermore, colonoscopy has the potential to detect proximal lesions that would be missed by screening sigmoidoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. In a study of screening colonoscopy in 1994 asymptomatic adults, 5.7 percent had advanced neoplasms; 1.6 percent had only a proximal advanced neoplasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/71\">",
"     71",
"    </a>",
"    ]. Thus, if screening colonoscopy effectively detected proximal lesions, it would be necessary to screen 64 patients with colonoscopy rather than sigmoidoscopy to find one additional person with an advanced neoplasm.",
"   </p>",
"   <p>",
"    The risk associated with screening colonoscopy is higher than the risk with sigmoidoscopy (OR 1.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/53\">",
"     53",
"    </a>",
"    ]. The rate of major complications (perforation and major bleeding) is about 1 per 1000 colonoscopy procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Comorbidities, increasing age, polypectomy, and less experienced endoscopists increase the risk of perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. In a series of over 16,000 diagnostic colonoscopies in one health care system, serious complications occurred at a rate of 0.8 per 1000 procedures without biopsy and 7.0 per 1000 colonoscopies with biopsy or polypectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an earlier report of a Medicare population, the risk of perforation was 1.96 per 1000 procedures, including both inpatient and outpatient colonoscopies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/53\">",
"     53",
"    </a>",
"    ]. A perforation rate of 0.6 per 1000 outpatient procedures in a sample of Medicare patients (age 65 to 95 years) was reported more recently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/76\">",
"     76",
"    </a>",
"    ]. In this report, the risk of perforation was four times greater for patients who had a polypectomy. The risk of bleeding was 8.7 per 1000 colonoscopies in which polypectomy was performed. Adverse events within 30 days of colonoscopy occurred more frequently in patients who were older or had a history of diabetes mellitus, stroke, chronic obstructive pulmonary disease, atrial fibrillation, or heart failure.",
"   </p>",
"   <p>",
"    Colonoscopy is expensive. Patients usually receive conscious sedation for comfort and must be accompanied home after the test and cannot return directly to their usual activities. Many patients find the rigorous bowel preparation worse than the procedure itself. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/39/27258?source=see_link\">",
"     \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A multidisciplinary panel has developed a set of criteria by which a referring clinician can assess the quality of the colonoscopy service used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/78\">",
"     78",
"    </a>",
"    ]. Components of this quality assessment include adequacy of reports received (including notes of procedure details, patient tolerance, pathology results, and recommendations for follow-up); the colonoscopist&rsquo;s rate of cecal intubation and rate of adenoma detection; and a safe setting for the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Evidence of effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no published randomized trials of the effectiveness of screening colonoscopy in average risk patients. Two randomized trials are currently underway in Europe, and another is being sponsored by the US Veterans Administration, but results are not expected for many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The National Polyp Study (NPS), a study of 2602 patients with polyps in which the colon was cleared of polyps by colonoscopy, showed a large reduction in the development of advanced lesions (76 to 90 percent) compared with patients in other studies who did not have polyps removed or compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/82\">",
"     82",
"    </a>",
"    ]. Long-term follow-up of the NPS population found that, at an average follow-up of 16 years, there was a 53 percent reduction in CRC mortality (mortality ratio 0.47, 95% CI 0.26-0.80) in patients who had adenomas removed compared to the expected CRC mortality rate in the general population (based on data from the SEER program) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/83\">",
"     83",
"    </a>",
"    ]. CRC mortality in the NPS for the first 10 years following polypectomy was the same for patients found to have adenomatous or nonadenomatous polyps. Although not a randomized trial, this is the first study to strongly indicate a CRC mortality benefit for colonoscopy. The magnitude of the results of this study may not be generalizable to community practice, because NPS colonoscopies were performed by a small number of trained endoscopists and reported rates of CRC following polypectomy were lower for the NPS than reported in other studies. Rates of postpolypectomy surveillance colonoscopies (81 percent in the NPS) may also be higher than is common in the community.",
"   </p>",
"   <p>",
"    A case-control study in four health plans in the United States compared rates of screening colonoscopy in average-risk patients prior to diagnosis of late stage (IIb or higher) colorectal cancer with screening colonoscopy rates in matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/84\">",
"     84",
"    </a>",
"    ]. Although rates of screening colonoscopy were low in both cases and controls (reflecting practice patterns as early as 1996), the rate of screening colonoscopy performed between 3 months and 10 years prior to the late stage cancer diagnosis was significantly lower than for the matched controls (2.8 and 9.0 percent respectively; adjusted odds ratio [AOR] 0.29 [95% CI 0.15-0.58]). The comparative rate of screening sigmoidoscopy was also lower for the index patients than matched controls (19.5 versus 34.0 percent; AOR 0.50, 95% CI 0.36-0.70).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22320183\">",
"    <span class=\"h4\">",
"     Proximal lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of colonoscopy performed in the community settings in detecting proximal (right-sided) lesions has been called into question, however.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case control study in Canada compared colonoscopy rates for 10,292 patients who died of colorectal cancer and 52,450 matched controls. Completed colonoscopy was associated with decreased deaths from left-sided colorectal cancer (OR 0.33, 95% CI 0.28-0.39) but not from right-sided cancer (OR 0.99, 0.86-1.14) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/85\">",
"       85",
"      </a>",
"      ]. Limitations in this study include inability to distinguish screening and diagnostic colonoscopies and uncertain quality of the colonoscopies.",
"     </li>",
"     <li>",
"      Findings were similar for a cohort study in Manitoba, in which standardized CRC mortality for people who had an initial colonoscopy was compared with CRC mortality in the general population using standardized mortality ratios (SMR) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/86\">",
"       86",
"      </a>",
"      ]. A 47 percent reduction in CRC mortality was reported for distal CRC (SMR 0.53, 95% CI 0,42-9.67), but no reduction was found for proximal CRC (SMR 0.94, 0.77-1.17). This study focused on screening examinations by excluding patients who had known colon disease (prior sigmoidoscopy, inflammatory bowel disease, colorectal surgery, or CRC) and patients younger than 50 or greater than 80 years of age.",
"     </li>",
"     <li>",
"      Another community-based study of 3287 German participants undergoing screening colonoscopy found a lower incidence of left-sided (prevalence ratio 0.33, 95% CI 0.21-0.53), but not right-sided, advanced colorectal neoplasia comparing participants who had undergone prior colonoscopy within the previous 10 years with those who had not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two case control studies found that colonoscopy in the preceding 10 years was effective for decreasing the incidence of both left and right sided CRC. One study from Germany (1688 cases, 1932 controls) found that risk reduction was greater for left sided cancer (84 versus 56 percent reduction; OR 0.16, 95% CI 0.12-0.20 for left sided cancer and OR 0.44, CI 0.35 to 0.55 for right sided cancer) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/88\">",
"       88",
"      </a>",
"      ]. Overall risk reduction was 77 percent. Specific training and quality assurance measures accompanied introduction of screening colonoscopy at the outset of this study, and more than 90 percent of the examinations reached the cecum. A case control study in four US health centers (471 cases with late stage colorectal cancer, 509 controls) also found an association between colonoscopy and reduction of both right and left sided late stage cancers, with an OR 0.36 (CI 0.16-0.80) for right colon cancer and OR 0.26 (CI 0.06-1.11) for left colon cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The finding that right-sided lesions may not be as readily detected may reflect bias in these observational studies, incomplete colonoscopic examination of the right colon, or biologic differences in right-sided tumors, such as more flat or rapidly growing neoplasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/5,89\">",
"     5,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22320331\">",
"    <span class=\"h4\">",
"     Sensitivity of colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sensitivity of colonoscopy for detection of adenomas and carcinomas is dependent upon the experience and technique of the colonoscopist. One study found the risk of developing an interval cancer between screening and surveillance colonoscopy was significantly associated with the endoscopist's rate of adenoma detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/90\">",
"     90",
"    </a>",
"    ], and a case control study found that decreased colon cancer mortality was more strongly associated with prior colonoscopy performed by a gastroenterologist than by another type of clinician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/91\">",
"     91",
"    </a>",
"    ]. One study of screening colonoscopies by 12 experienced gastroenterologists in a community-based practice found the detection rate for adenomas to range from 9.4 to 32.7 percent among clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/92\">",
"     92",
"    </a>",
"    ]. Detection rates for neoplasms were significantly higher for clinicians who, on average, took longer than six minutes for withdrawal of the colonoscope, compared to those who took less than six minutes. However, a subsequent study of nearly 24,000 colonoscopies (42 percent for screening or surveillance), performed by 42 endoscopists in an academic center, did not find an increase in polyp detection rate after an institutional policy was instituted (with almost 100 percent compliance) requiring a minimal withdrawal time of seven minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity of colonoscopy has typically been estimated by using it as its own reference standard (results of two colonoscopies performed shortly after one another). A systematic review of studies of tandem colonoscopies (n = 465 patients) found a miss rate of 2 percent for adenomas &ge;10 mm, 13 percent for adenomas 5 to 10 mm, and 25 percent for adenomas &lt;5 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/94\">",
"     94",
"    </a>",
"    ]. The overall miss rate for polyps of any size was 22 percent.",
"   </p>",
"   <p>",
"    In contrast, a large study (n = 614) of patients at high risk for colon lesions found the sensitivity of colonoscopy to be 98 to 99 percent for lesions &ge;6 mm in size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/95\">",
"     95",
"    </a>",
"    ]. In this study, the reference standard was an aggregate view of the colon based on double-contrast",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema (DCBE), two-dimensional computed tomographic colonography (CTC), and repeat colonoscopy of the involved bowel segment if a lesion was found on imaging that was not seen on the initial colonoscopy. Colonoscopy sensitivity in this study was substantially higher than reported in other studies.",
"   </p>",
"   <p>",
"    Some polyps and cancers may be difficult to detect because of their location, and thus may be missed on both initial and subsequent colonoscopy studies, making repeat colonoscopy less than an ideal gold standard. It appears that flat or depressed lesions occur more commonly than previously thought, are at least as likely to represent advanced neoplasia even if small, and can be difficult to detect by either optical colonoscopy or CTC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of patients receiving both CTC and colonoscopy, 14 of 15 nonrectal neoplasms missed by colonoscopy were located on a fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/96\">",
"     96",
"    </a>",
"    ]. Five of six missed rectal lesions were located within 10 cm of the anal verge. The authors estimated that when state-of-the-art three-dimensional CTC was used as a reference standard, the miss rate of colonoscopy for large adenomas (&ge;10 mm) was 12 percent, significantly higher than the previous estimates discussed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Frequency of testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence to determine the optimal frequency for screening with colonoscopy. If the colonoscopy is negative, the usual advice is to repeat the colonoscopy in 10 years and to not screen with other tests during this interval. If the colonoscopy is positive, the interval until the next colonoscopy depends on the specific findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link&amp;anchor=H27#H27\">",
"     \"Approach to the patient with colonic polyps\", section on 'Surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No cancers were found in follow-up colonoscopy testing in a group of 1256 average risk patients who had had an initial screening colonoscopy five years earlier (detection rate 0 percent; 95% CI 0-0.24%) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/97\">",
"       97",
"      </a>",
"      ]. Nineteen advanced adenomas were found among 16 persons (1.3 percent), with risk greater in men. In a similar study, no cancers were found at colonoscopy performed an average of 11.5 years after the initial screening study in a group of 553 patients in Germany [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study from Canada followed a cohort of patients who had a negative colonoscopy (n = 35,975) and compared the subsequent incidence of colorectal cancer in this cohort to the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/99\">",
"       99",
"      </a>",
"      ]. The subsequent incidence of colorectal cancer following a negative colonoscopy was 31 percent lower than expected at six months, and remained reduced beyond 10 years (72 percent lower than expected).",
"     </li>",
"     <li>",
"      Follow-up of over 100,00 patients who had a negative colonoscopy (either screening or diagnostic) found a decreased risk of distal colorectal cancer at 14 years, compared to the general population (RR 0.21, 95% CI 0.05-0.36), and a decreased risk for proximal colorectal cancer that persisted for seven years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that a 10 year interval for colonoscopy following an initial negative study is an acceptable strategy. When an adequate screening colonoscopy is accomplished, additional screening with intercurrent stool tests between colonoscopy examinations is not necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Computed tomographic colonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomographic colonography (CTC, formerly \"virtual colonoscopy\") involves obtaining multiple, thin slice CT data and using computers to construct images of the bowel mucosa in two and three dimensions, with other enhancements to assist in interpretation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36632?source=see_link\">",
"     \"Computed tomographic colonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For most studies, patients prepare for CTC with aggressive bowel preparation, the same as used for optical colonoscopy. Alternative non-cathartic preparation protocols have been introduced in which oral iodinated contrast medium is taken to &rdquo;tag&rdquo; stool and fluid in the bowel; bowel contents are then electronically subtracted from final images.",
"   </p>",
"   <p>",
"    Patients are not sedated during the procedure and may return to work after they leave the radiology suite. An intravenous catheter may be inserted to allow administration of drugs such as glucagon to relax the smooth muscle of the bowel, if needed. Air or carbon dioxide are introduced into the rectum via a rubber catheter and typically cause some cramping, more severe with air which is less rapidly absorbed. Images are obtained during a single 32 second breath hold.",
"   </p>",
"   <p>",
"    Computer reconstruction and reading often take place after the patient has left, although optimally might be done immediately. Ideally, when CTC indicates need for follow-up colonoscopy and a cathartic preparation has been used, patients should proceed directly to optical colonoscopy for biopsy and excision, and thus avoid the need for a second bowel cleansing. Though difficult to arrange, special effort should be undertaken to accomplish same day or next day colonoscopy whenever possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technology for CTC is rapidly evolving and it is not reasonable to combine results from studies of old and new technologies. The best current techniques involve tagging bowel contents with oral contrast, distending the colon with carbon dioxide, using CT scanners with multidetector rows and thin collimation, dedicated CTC software with 2D and 3D polyp detection, and interpretation by readers with special training [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Test characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of CTC has been compared to that of colonoscopy by doing both procedures in tandem.",
"   </p>",
"   <p>",
"    Sensitivity of CTC for the detection of cancers and adenomas &ge;10 mm has been reported to range between 84 to 94 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. Sensitivity was 90 percent and specificity 86 percent in the largest study, a multicenter CTC screening study of 2600 patients age 50 and older using state-of-the-art technology and trained readers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/102\">",
"     102",
"    </a>",
"    ]. In a study of CTC in participants at increased risk for colorectal cancer (family history, personal history of adenomas, or positive fecal occult blood), sensitivity and specificity were 85 and 88 percent, respectively, for lesions 6 mm or larger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/105\">",
"     105",
"    </a>",
"    ]. In a study of laxative-free CTC, in which stool was tagged by orally-ingested contrast material and software was used to &ldquo;electronically cleanse&rdquo; the bowel images, sensitivity and specificity for adenomas &ge;10 mm were 91 and 85 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/106\">",
"     106",
"    </a>",
"    ], and comparable to the performance of CTC with laxatives.",
"   </p>",
"   <p>",
"    A randomized trial in the Netherlands compared outcomes for two screening strategies: invitation for colonoscopy or invitation for screening CTC (for which patients did not use a cathartic preparation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/107\">",
"     107",
"    </a>",
"    ]. The diagnostic yield for advanced neoplasia was greater for individuals who underwent colonoscopy than for CT colonography (RR 1.46, 95% CI 1.06-2.03). However, participation rates were significantly higher for those invited for colonography than for colonoscopy (34 versus 22 percent), so that the diagnostic yield for advanced neoplasia per 100 invitees was essentially the same for both strategies.",
"   </p>",
"   <p>",
"    While the diagnostic yield for advanced neoplasia by CTC and colonoscopy is roughly equivalent, the number of biopsies obtained when colonoscopy is performed is often higher, with consequent increased risk for perforation. In one study of parallel programs of CTC or colonoscopy screening in the same institution, over four times as many polyps in total were removed in the colonoscopy group despite no difference in the number of large adenomas and small advanced adenomas removed in the CTC and colonoscopy groups (100 and 107 lesions among 3120 and 3163 patients, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advantages of CTC are that it is non-invasive, visualizes the entire bowel, and detects large adenomas about as well as optical colonoscopy. Patients who experienced both procedures report mixed preferences, but tend to prefer CTC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/103,109,110\">",
"     103,109,110",
"    </a>",
"    ]. Patients who underwent both CTC (without or with laxatives) and optical colonoscopy responded that they would prefer CTC for future examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/106,111\">",
"     106,111",
"    </a>",
"    ]. The predicted mortality from CT-induced cancer was less than the mortality related to complications of colonoscopy in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several disadvantages of CTC. Abnormal results need to be followed up by colonoscopy for excision and tissue diagnosis, or, for smaller lesions, surveillance with CTC. Flat adenomas may have greater malignant potential than polypoid lesions and are more likely to be missed on CTC than colonoscopy. The risk of radiation exposure with CTC is less than a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/72,113,114\">",
"     72,113,114",
"    </a>",
"    ], but the cumulative radiation exposure risks with testing every five years are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Extracolonic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;CTC can identify extracolonic neoplasms and abdominal aortic aneurysms (AAA), but it is uncertain whether this is an advantage or disadvantage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/115\">",
"     115",
"    </a>",
"    ]. Such findings have the potential to identify asymptomatic early disease that allows treatment with improved outcomes when compared to treatment at a later symptomatic stage. However, potential disadvantages are overdiagnosis (identifying disease that would not cause problems in a patient's lifetime), the cost and risk of additional evaluations, and the worry associated with abnormal findings. Additional tests or procedures were recommended in 6 to 24 percent of CTCs in several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/102,108,116,117\">",
"     102,108,116,117",
"    </a>",
"    ]. In one cohort of 2869 women, an indeterminate adnexal mass was found in 118 (4.1 percent), leading to further evaluation in 80; no ovarian cancers were prospectively identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormal CTC tests will generate anxiety and cost and may have a low yield of clinically important pathology. Extracolonic cancers were identified in 36 of 10,286 patients (0.35 percent) undergoing screening CT colonography in one prospective series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/117\">",
"     117",
"    </a>",
"    ]; it is unknown if detection of these malignancies, however, will improve outcomes or represents overdiagnosis. One modeling study found that identification of AAA and decrease in AAA-related deaths led to an additional gain in life-years for CTC compared with colonoscopy or combined",
"    <span class=\"nowrap\">",
"     colonoscopy/ultrasound",
"    </span>",
"    strategies (1458 and 462 life years respectively per 100,000 hypothetical persons) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31791528\">",
"    <span class=\"h3\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness and cost-effectiveness of CTC performed every five years were compared to other screening strategies in a population 65 years and older, as a study to provide information to the Centers for Medicare and Medicaid Services (CMS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/119\">",
"     119",
"    </a>",
"    ]. Using three simulation models as part of the National Cancer Institute's Cancer Intervention and Surveillance Modeling Network (CISNET), the analysis found that CTC every five years for individuals 65 years and older, with colonoscopy for polyps &gt;6 mm, resulted in slightly fewer life-years gained compared to optical colonoscopy, but was comparable to flexible sigmoidoscopy with FOBT. CTC was the least cost-effective strategy with reimbursement at costs equivalent to the cost of colonoscopy plus polypectomy, and became cost effective at reimbursement rates about 60 percent lower. Relative cost effectiveness for CTC improves if it significantly increases patient adherence to screening over other strategies. Excess risks of CTC related to radiation exposure and the detection of extracolonic findings were not considered in the analysis. An analogous simulation was performed for screening individuals 50 years old every 5 or 10 years with CT colonography, compared with guideline-concordant colonoscopy, flexible sigmoidoscopy plus fecal blood testing, and with no screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/120\">",
"     120",
"    </a>",
"    ]. CT colonography was more costly and less effective than the other screening strategies evaluated, but CT colonography every five years had net benefit compared with no screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194078445\">",
"    <span class=\"h2\">",
"     Fecal DNA tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorectal neoplasms shed DNA in the stool where it can be isolated and tested for the presence of mutations acquired during carcinogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/33,121-125\">",
"     33,121-125",
"    </a>",
"    ]. One previously commercially-available test is no longer available in 2012, and newer panels are under development. In one pre-commercial test, a gene amplification technique allows for detection of lower abundance mutations with increased sensitivity for advanced adenomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/126\">",
"     126",
"    </a>",
"    ]. Not all genetic abnormalities associated with colorectal cancer can be included in the stool DNA test (sDNA), however, and false negative results occur.",
"   </p>",
"   <p>",
"    The implications of &ldquo;false positives,&rdquo; abnormal DNA testing in patients who are not found to have colonic lesions on colonoscopy, is uncertain. Such positive tests may indicate upper gastrointestinal neoplasms or premalignant genetic abnormalities somewhere in the gastrointestinal tract.",
"   </p>",
"   <p>",
"    The sensitivity of a single sDNA test has been reported from 62 to 100 percent for colorectal cancer, and 27 to 82 percent for advanced adenoma, with specificity ranges from 82 to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/125,127\">",
"     125,127",
"    </a>",
"    ]. Two multicenter studies have compared fecal DNA tests, occult blood testing, and screening colonoscopy in average risk asymptomatic adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      sDNA was compared to gFOBT (using nonrehydrated Hemoccult II) in 2507 asymptomatic adults 50 years of age; all subjects underwent colonoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/128\">",
"       128",
"      </a>",
"      ]. sDNA testing was more sensitive than gFOBT for cancer (52 versus 13 percent) and for advanced neoplasia (18 versus 11 percent). Both tests missed the majority of cancers and advanced polyps that were detected by colonoscopy.",
"     </li>",
"     <li>",
"      A similar study compared two stool DNA tests (one with DNA markers not used in the commercial test) with guaiac tests and colonoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/125\">",
"       125",
"      </a>",
"      ]. The sensitivity of the commercial sDNA was lower in this study than the study above and was no better than Hemoccult SENSA (20 percent and 21 percent respectively) for screen-relevant neoplasms (advanced adenomas and curable cancers). Sensitivity for the second generation stool DNA panel was improved (46 percent compared to 24 percent for Hemoccult SENSA); this sDNA test, however, was also positive in 16 percent of patients who had a negative colonoscopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An entire bowel movement must be collected for fecal DNA testing, and specimens must be shipped with an ice pack. The test is expensive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/27\">",
"     27",
"    </a>",
"    ]. The appropriate interval between screening sDNA tests is unknown; a five-year interval has been proposed.",
"   </p>",
"   <p>",
"    A cost-effectiveness analysis found that at 2010 pricing in the United States ($350 per test), fecal DNA testing every three to five years would be more costly and lead to fewer life-years gained than other screening options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/129\">",
"     129",
"    </a>",
"    ]. A sensitivity analysis found that the fecal DNA test could be cost-effective at a significantly lower price ($40-60 per test) or, at current pricing, if it increased testing adherence by &gt;50 percent compared to other screening options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194078472\">",
"    <span class=\"h3\">",
"     Hypermethylation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypermethylation of genes associated with colorectal cancer has led to the study of fecal DNA methylation patterns as a marker of cancer. Assays to detect aberrant methylation in stool may be more readily performed than other gene marker assays, but are in the early stages of investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Capsule endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A special adaptation of capsule endoscopy has been developed to obtain images of the colon using tiny video cameras embedded in the two ends of an ingested capsule that take images as the capsule traverses the colon. This technique, while less invasive than optical colonoscopy, requires a more rigorous patient preparation regimen. Colonic capsule endoscopy does not allow for biopsy or polyp removal, so patients with lesions detected during the examination typically require subsequent colonoscopy for further evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17178?source=see_link\">",
"     \"Wireless video capsule endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17178?source=see_link&amp;anchor=H20#H20\">",
"     \"Wireless video capsule endoscopy\", section on 'Colon capsule endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies of colon capsule endoscopy have found a relatively low sensitivity for polyp detection with this technique, when compared with colonoscopy. A meta-analysis found that the sensitivity for significant polyps (&gt;6 mm or three or more polyps) was 69 percent with a specificity of 89 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/131\">",
"     131",
"    </a>",
"    ]. In a subsequent study in 545 patients undergoing screening, two of the five cancers detected by colonoscopy were not identified by capsule endoscopy, and the sensitivity of capsule endoscopy for significant polyps was only 39 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/132\">",
"     132",
"    </a>",
"    ]. These findings suggest that the current technique is not sufficiently accurate for screening.",
"   </p>",
"   <p>",
"    Capsule endoscopy for the colon is not commercially available in the United States, but is marketed in Europe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15240639\">",
"    <span class=\"h2\">",
"     Serum markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current serum markers are not sufficiently sensitive or specific to be used for screening. The potential to utilize a combination of six serum markers to improve the test has been reported in a feasibility study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/133\">",
"     133",
"    </a>",
"    ], but validation studies in screening populations are needed before clinical relevance can be determined.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      One blood test that detects Septin 9 hypermethylation in DNA from plasma (ColoVantage&trade;) has been approved in 2011 by the New York State Health Department for colon cancer. In one study of an assay for Septin 9 (SEPT9), the sensitivities for adenomas (1 to 5 cm), for stage I to III CRC, and for stage IV CRC were 14, 50, and 88 percent respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/127\">",
"       127",
"      </a>",
"      ]. The false-positive rate was 27 percent. These test characteristics suggest that a serum Septin 9 assay is not sufficiently sensitive for identifying cancer or cancer precursors at a treatable stage, but would lead to many false-positive findings.",
"     </li>",
"     <li>",
"      The New York State Department of Health also approved a seven-gene test (ColonSentry&trade;) in February 2012 to be used to identify patients at increased risk of colorectal cancer in order to target such patients for monitoring to assure compliance with regular colonoscopy. However, it has not been shown that the test can detect early-stage cancers, for which screening would be most effective, and test sensitivity (61 to 82 percent) and specificity (64 to 77 percent) were only fair for CRC at any stage when tested in populations that included a substantial proportion of patients with known CRC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/134,135\">",
"       134,135",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a study that compared the performance of serum markers (C-reactive protein, serum CD26 [sCD26], complement C3a anaphylatoxin, and tissue inhibitor of metalloproteinases [TIMP-1]) with stool fecal occult blood tests for the detection of colon cancer and advanced adenomas among patients with known and no known colon disease, at a specificity of 97.7 percent, the sensitivity of the four serum markers was less than 20 percent compared with 40 percent for gFOBT and 66 percent for iFOBT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/9/38042/abstract/136\">",
"       136",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, until further evidence is available, we do not recommend serum tests for colorectal cancer screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other technologies have been used in various clinical settings, but their value in screening for colorectal cancer has yet to be established.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chromoendoscopy involves the application of stains or pigment to improve the identification of abnormal mucosal tissue. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15370?source=see_link\">",
"       \"Chromoendoscopy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Magnification endoscopy, with or without staining, allows the endoscopist to better visualize mucosal details with 80- to 100-fold image enhancement. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4248?source=see_link\">",
"       \"Magnification endoscopy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Narrow band imaging optical colonoscopy modifies the bandwidth and wavelength of the light used in colonoscopy, allowing better visualization of vascular changes in superficial lesions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4248?source=see_link\">",
"       \"Magnification endoscopy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/34/25123?source=see_link\">",
"       \"Patient information: Colon and rectal cancer screening (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7541?source=see_link\">",
"       \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/30/9698?source=see_link\">",
"       \"Patient information: Colonoscopy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/12/42176?source=see_link\">",
"       \"Patient information: Flexible sigmoidoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of the slow transition from polyps to colorectal cancer, screening with tests that identify early-stage disease can prevent cancer death and removal of large adenomatous polyps can prevent transformation to cancer. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Screening rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guaiac-based fecal occult blood testing (gFOBT) of stool samples identifies hemoglobin by the presence of a peroxidase reaction. Screening with gFOBT has been shown in multiple randomized controlled trials to reduce mortality from CRC. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Guaiac-based fecal occult blood test (gFOBT)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sensitive gFOBT tests (eg, Hemoccult SENSA) or FIT (below) are preferred to older reagents. Current guidelines recommend that samples not be rehydrated prior to testing. Restrictive diets are not necessary. Any positive result requires follow-up with visualization of the colon. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Guaiac-based fecal occult blood test (gFOBT)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Sensitive gFOBT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunochemical tests for fecal blood are more specific for colon-related occult blood than guaiac tests and require fewer stool samples. A quantitative immunochemical stool test may be more useful but is not commercially available in the United States. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Immunochemical tests for fecal blood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effectiveness of screening sigmoidoscopy in preventing colorectal cancer deaths has been established by randomized controlled trials. Sigmoidoscopy can identify lesions up to the splenic flexure; proximal lesions are more common in women and in older individuals. Patient preparation for the procedure is less than for procedures that examine the entire colon. Colonoscopy is indicated for follow-up of multiple or large adenomas (&ge;1.0 cm) and for adenomas with villous histology. Colonoscopy is not indicated for single, small (&lt;0.6 cm), tubular adenomas. The decision to perform colonoscopy should be individualized for patients with a single tubular adenoma 0.6 to 1.0 cm. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Sigmoidoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effectiveness of screening colonoscopy in preventing colorectal cancer deaths is strongly suggested by long-term follow-up data of patients undergoing polypectomy at colonoscopy. The overall reported sensitivity of colonoscopy is over 95 percent for lesions 6 mm or greater. The sensitivity of colonoscopy for detection of adenomas and carcinomas is dependent on the experience and technique of the colonoscopist. Major complications (perforation and major bleeding) occur in about 1 per 1000 colonoscopy procedures, although the rate is likely lower for screening studies. A rigorous bowel preparation and conscious sedation for the procedure is required. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Colonoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computed tomographic colonography (CTC, formerly \"virtual colonoscopy\") involves obtaining multiple, thin slice CT data and using computers to construct images of the bowel mucosa in two and three dimensions, with other enhancements to assist in interpretation. CTC detects large (&gt;1 cm) polyps about as well as colonoscopy but is less sensitive for the detection of smaller polyps. Abnormal results need to be followed up by optical colonoscopy for excision and tissue diagnosis. The disadvantages of CTC are that it requires a rigorous bowl preparation, finds extra-colonic lesions that may be followed up and may not be treatable, and exposes patients to radiation. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Computed tomographic colonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A commercially-available stool DNA test is not currently available in 2012. In previously-available stool DNA tests, the sensitivity of the test, dependent on the DNA panel used, appeared to be greater than for stool guaiac testing. The fecal DNA test was expensive and required shipping an entire bowel movement. (See",
"      <a class=\"local\" href=\"#H194078445\">",
"       'Fecal DNA tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/1\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/2\">",
"      Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/3\">",
"      Ferlitsch M, Reinhart K, Pramhas S, et al. Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA 2011; 306:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/4\">",
"      O'Brien MJ, Winawer SJ, Zauber AG, et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990; 98:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/5\">",
"      Soetikno RM, Kaltenbach T, Rouse RV, et al. Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA 2008; 299:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/6\">",
"      Rembacken BJ, Fujii T, Cairns A, et al. Flat and depressed colonic neoplasms: a prospective study of 1000 colonoscopies in the UK. Lancet 2000; 355:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/7\">",
"      Saitoh Y, Waxman I, West AB, et al. Prevalence and distinctive biologic features of flat colorectal adenomas in a North American population. Gastroenterology 2001; 120:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/8\">",
"      Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/9\">",
"      U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/10\">",
"      Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/11\">",
"      Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/12\">",
"      Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/13\">",
"      J&oslash;rgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002; 50:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/14\">",
"      Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/15\">",
"      Faivre J, Dancourt V, Lejeune C, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004; 126:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/16\">",
"      Scholefield JH, Moss SM, Mangham CM, et al. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 2012; 61:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/17\">",
"      Costantini AS, Martini A, Puliti D, et al. Colorectal cancer mortality in two areas of Tuscany with different screening exposures. J Natl Cancer Inst 2008; 100:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/18\">",
"      Libby G, Brewster DH, McClements PL, et al. The impact of population-based faecal occult blood test screening on colorectal cancer mortality: a matched cohort study. Br J Cancer 2012; 107:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/19\">",
"      Moayyedi P, Achkar E. Does fecal occult blood testing really reduce mortality? A reanalysis of systematic review data. Am J Gastroenterol 2006; 101:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/20\">",
"      Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993; 85:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/21\">",
"      Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/22\">",
"      Lang CA, Ransohoff DF. Fecal occult blood screening for colorectal cancer. Is mortality reduced by chance selection for screening colonoscopy? JAMA 1994; 271:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/23\">",
"      Ederer F, Church TR, Mandel JS. Fecal occult blood screening in the Minnesota study: role of chance detection of lesions. J Natl Cancer Inst 1997; 89:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/24\">",
"      Pignone M, Campbell MK, Carr C, Phillips C. Meta-analysis of dietary restriction during fecal occult blood testing. Eff Clin Pract 2001; 4:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/25\">",
"      Coles EF, Starnes EC. Use of HemoQuant assays to assess the effect of oral iron preparations on stool hemoccult tests. Am J Gastroenterol 1991; 86:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/26\">",
"      Anderson GD, Yuellig TR, Krone RE Jr. An investigation into the effects of oral iron supplementation on in vivo Hemoccult stool testing. Am J Gastroenterol 1990; 85:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/27\">",
"      McDonnell WM, Ryan JA, Seeger DM, Elta GH. Effect of iron on the guaiac reaction. Gastroenterology 1989; 96:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/28\">",
"      Jaffe RM, Kasten B, Young DS, MacLowry JD. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). Ann Intern Med 1975; 83:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/29\">",
"      Duffy MJ, van Rossum LG, van Turenhout ST, et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer 2011; 128:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/30\">",
"      Sox HC. Office-based testing for fecal occult blood: do only in case of emergency. Ann Intern Med 2005; 142:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/31\">",
"      Collins JF, Lieberman DA, Durbin TE, et al. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005; 142:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/32\">",
"      Nadel MR, Shapiro JA, Klabunde CN, et al. A national survey of primary care physicians' methods for screening for fecal occult blood. Ann Intern Med 2005; 142:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/33\">",
"      Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/34\">",
"      Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/35\">",
"      Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/36\">",
"      Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer 2009; 100:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/37\">",
"      Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009; 150:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/38\">",
"      Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/39\">",
"      van Rossum LG, van Rijn AF, van Oijen MG, et al. False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening. Int J Cancer 2009; 125:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/40\">",
"      van Roon AH, Goede SL, van Ballegooijen M, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 2013; 62:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/41\">",
"      Haug U, Kuntz KM, Knudsen AB, et al. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. Br J Cancer 2011; 104:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/42\">",
"      de Wijkerslooth TR, Stoop EM, Bossuyt PM, et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol 2012; 107:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/43\">",
"      Fraser CG, Allison JE, Halloran SP, et al. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst 2012; 104:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/44\">",
"      Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007; 146:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/45\">",
"      Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009; 100:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/46\">",
"      Sawhney MS, McDougall H, Nelson DB, Bond JH. Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci 2010; 55:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/47\">",
"      Brenner H, Tao S, Haug U. Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA 2010; 304:2513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/48\">",
"      Winawer SJ, Stewart ET, Zauber AG, et al. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. N Engl J Med 2000; 342:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/49\">",
"      Toma J, Paszat LF, Gunraj N, Rabeneck L. Rates of new or missed colorectal cancer after barium enema and their risk factors: a population-based study. Am J Gastroenterol 2008; 103:3142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/50\">",
"      Lieberman DA, Weiss DG, Veterans Affairs Cooperative Study Group 380. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/51\">",
"      Schoenfeld P, Cash B, Flood A, et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med 2005; 352:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/52\">",
"      Fletcher RH. Rationale for combining different screening strategies. Gastrointest Endosc Clin N Am 2002; 12:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/53\">",
"      Gatto NM, Frucht H, Sundararajan V, et al. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst 2003; 95:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/54\">",
"      Walter LC, de Garmo P, Covinsky KE. Association of older age and female sex with inadequate reach of screening flexible sigmoidoscopy. Am J Med 2004; 116:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/55\">",
"      Hoff G, Grotmol T, Skovlund E, et al. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 2009; 338:b1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/56\">",
"      Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/57\">",
"      Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. J Natl Cancer Inst 2011; 103:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/58\">",
"      Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012; 366:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/59\">",
"      Elmunzer BJ, Hayward RA, Schoenfeld PS, et al. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 2012; 9:e1001352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/60\">",
"      Newcomb PA, Norfleet RG, Storer BE, et al. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992; 84:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/61\">",
"      M&uuml;ller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med 1995; 155:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/62\">",
"      Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/63\">",
"      Weissfeld JL, Schoen RE, Pinsky PF, et al. Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J Natl Cancer Inst 2012; 104:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/64\">",
"      Doria-Rose VP, Levin TR, Selby JV, et al. The incidence of colorectal cancer following a negative screening sigmoidoscopy: implications for screening interval. Gastroenterology 2004; 127:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/65\">",
"      Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/66\">",
"      Lin OS, Schembre DB, McCormick SE, et al. Risk of proximal colorectal neoplasia among asymptomatic patients with distal hyperplastic polyps. Am J Med 2005; 118:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/67\">",
"      Schoen RE, Weissfeld JL, Pinsky PF, Riley T. Yield of advanced adenoma and cancer based on polyp size detected at screening flexible sigmoidoscopy. Gastroenterology 2006; 131:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/68\">",
"      Levin TR, Palitz A, Grossman S, et al. Predicting advanced proximal colonic neoplasia with screening sigmoidoscopy. JAMA 1999; 281:1611.",
"     </a>",
"    </li>",
"    <li>",
"     Pignone M, Rich M, Teutsch SM, et al. Screening for colorectal cancer in adults. Systematic Evidence Reviews, No. 7. Agency for Healthcare Research and Quality, Rockville, MD 2002. Available at: www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat3.chapter.2359 (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/70\">",
"      Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009; 104:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/71\">",
"      Imperiale TF, Wagner DR, Lin CY, et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000; 343:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/72\">",
"      Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/73\">",
"      Lewis JD, Ng K, Hung KE, et al. Detection of proximal adenomatous polyps with screening sigmoidoscopy: a systematic review and meta-analysis of screening colonoscopy. Arch Intern Med 2003; 163:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/74\">",
"      Iqbal CW, Cullinane DC, Schiller HJ, et al. Surgical management and outcomes of 165 colonoscopic perforations from a single institution. Arch Surg 2008; 143:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/75\">",
"      Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 2008; 135:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/76\">",
"      Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med 2009; 150:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/77\">",
"      Levin TR, Zhao W, Conell C, et al. Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med 2006; 145:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/78\">",
"      Fletcher RH, Nadel MR, Allen JI, et al. The quality of colonoscopy services--responsibilities of referring clinicians: a consensus statement of the Quality Assurance Task Group, National Colorectal Cancer Roundtable. J Gen Intern Med 2010; 25:1230.",
"     </a>",
"    </li>",
"    <li>",
"     file://ClinicalTrials.gov/ct2/show/NCT00906997 (Accessed on February 04, 2010).",
"    </li>",
"    <li>",
"     www.kreftregisteret.no/en/Research/Projects/NordICC (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT01239082 (Accessed on October 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/82\">",
"      Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/83\">",
"      Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012; 366:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/84\">",
"      Doubeni CA, Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med 2013; 158:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/85\">",
"      Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009; 150:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/86\">",
"      Singh H, Nugent Z, Demers AA, et al. The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology 2010; 139:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/87\">",
"      Brenner H, Hoffmeister M, Arndt V, et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 2010; 102:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/88\">",
"      Brenner H, Chang-Claude J, Seiler CM, et al. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 2011; 154:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/89\">",
"      Azzoni C, Bottarelli L, Campanini N, et al. Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis. Int J Colorectal Dis 2007; 22:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/90\">",
"      Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010; 362:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/91\">",
"      Baxter NN, Warren JL, Barrett MJ, et al. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol 2012; 30:2664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/92\">",
"      Barclay RL, Vicari JJ, Doughty AS, et al. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 2006; 355:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/93\">",
"      Sawhney MS, Cury MS, Neeman N, et al. Effect of institution-wide policy of colonoscopy withdrawal time &gt; or = 7 minutes on polyp detection. Gastroenterology 2008; 135:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/94\">",
"      van Rijn JC, Reitsma JB, Stoker J, et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006; 101:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/95\">",
"      Rockey DC, Paulson E, Niedzwiecki D, et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet 2005; 365:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/96\">",
"      Pickhardt PJ, Nugent PA, Mysliwiec PA, et al. Location of adenomas missed by optical colonoscopy. Ann Intern Med 2004; 141:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/97\">",
"      Imperiale TF, Glowinski EA, Lin-Cooper C, et al. Five-year risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med 2008; 359:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/98\">",
"      Brenner H, Haug U, Arndt V, et al. Low risk of colorectal cancer and advanced adenomas more than 10 years after negative colonoscopy. Gastroenterology 2010; 138:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/99\">",
"      Singh H, Turner D, Xue L, et al. Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA 2006; 295:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/100\">",
"      Lakoff J, Paszat LF, Saskin R, Rabeneck L. Risk of developing proximal versus distal colorectal cancer after a negative colonoscopy: a population-based study. Clin Gastroenterol Hepatol 2008; 6:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/101\">",
"      Morrin MM, LaMont JT. Screening virtual colonoscopy--ready for prime time? N Engl J Med 2003; 349:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/102\">",
"      Johnson CD, Chen MH, Toledano AY, et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 2008; 359:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/103\">",
"      Pickhardt PJ, Choi JR, Hwang I, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003; 349:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/104\">",
"      Johnson CD, Fletcher JG, MacCarty RL, et al. Effect of slice thickness and primary 2D versus 3D virtual dissection on colorectal lesion detection at CT colonography in 452 asymptomatic adults. AJR Am J Roentgenol 2007; 189:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/105\">",
"      Regge D, Laudi C, Galatola G, et al. Diagnostic accuracy of computed tomographic colonography for the detection of advanced neoplasia in individuals at increased risk of colorectal cancer. JAMA 2009; 301:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/106\">",
"      Zalis ME, Blake MA, Cai W, et al. Diagnostic accuracy of laxative-free computed tomographic colonography for detection of adenomatous polyps in asymptomatic adults: a prospective evaluation. Ann Intern Med 2012; 156:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/107\">",
"      Stoop EM, de Haan MC, de Wijkerslooth TR, et al. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol 2012; 13:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/108\">",
"      Kim DH, Pickhardt PJ, Taylor AJ, et al. CT colonography versus colonoscopy for the detection of advanced neoplasia. N Engl J Med 2007; 357:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/109\">",
"      Walter LC, Lewis CL, Barton MB. Screening for colorectal, breast, and cervical cancer in the elderly: a review of the evidence. Am J Med 2005; 118:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/110\">",
"      Lin OS, Kozarek RA, Gluck M, et al. Preference for colonoscopy versus computerized tomographic colonography: a systematic review and meta-analysis of observational studies. J Gen Intern Med 2012; 27:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/111\">",
"      Pooler BD, Baumel MJ, Cash BD, et al. Screening CT colonography: multicenter survey of patient experience, preference, and potential impact on adherence. AJR Am J Roentgenol 2012; 198:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/112\">",
"      Hassan C, Pickhardt PJ, Pickhardt P, et al. Computed tomographic colonography to screen for colorectal cancer, extracolonic cancer, and aortic aneurysm: model simulation with cost-effectiveness analysis. Arch Intern Med 2008; 168:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/113\">",
"      Kay CL, Evangelou HA. A review of the technical and clinical aspects of virtual endoscopy. Endoscopy 1996; 28:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/114\">",
"      Brenner DJ, Georgsson MA. Mass screening with CT colonography: should the radiation exposure be of concern? Gastroenterology 2005; 129:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/115\">",
"      Fletcher RH, Pignone M. Extracolonic findings with computed tomographic colonography: asset or liability? Arch Intern Med 2008; 168:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/116\">",
"      Kimberly JR, Phillips KC, Santago P, et al. Extracolonic findings at virtual colonoscopy: an important consideration in asymptomatic colorectal cancer screening. J Gen Intern Med 2009; 24:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/117\">",
"      Pickhardt PJ, Kim DH, Meiners RJ, et al. Colorectal and extracolonic cancers detected at screening CT colonography in 10,286 asymptomatic adults. Radiology 2010; 255:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/118\">",
"      Pickhardt PJ, Hanson ME. Incidental adnexal masses detected at low-dose unenhanced CT in asymptomatic women age 50 and older: implications for clinical management and ovarian cancer screening. Radiology 2010; 257:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/119\">",
"      Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst 2010; 102:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/120\">",
"      Vanness DJ, Knudsen AB, Lansdorp-Vogelaar I, et al. Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations. Radiology 2011; 261:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/121\">",
"      Calistri D, Rengucci C, Bocchini R, et al. Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol 2003; 1:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/122\">",
"      Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001; 93:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/123\">",
"      Lenhard K, Bommer GT, Asutay S, et al. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol 2005; 3:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/124\">",
"      Levin B. Molecular screening testing for colorectal cancer. Clin Cancer Res 2006; 12:5014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/125\">",
"      Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008; 149:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/126\">",
"      Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012; 142:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/127\">",
"      Ahlquist DA, Taylor WR, Mahoney DW, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol 2012; 10:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/128\">",
"      Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351:2704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/129\">",
"      Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, et al. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med 2010; 153:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/130\">",
"      Nagasaka T, Tanaka N, Cullings HM, et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst 2009; 101:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/131\">",
"      Rokkas T, Papaxoinis K, Triantafyllou K, Ladas SD. A meta-analysis evaluating the accuracy of colon capsule endoscopy in detecting colon polyps. Gastrointest Endosc 2010; 71:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/132\">",
"      Sacher-Huvelin S, Coron E, Gaudric M, et al. Colon capsule endoscopy vs. colonoscopy in patients at average or increased risk of colorectal cancer. Aliment Pharmacol Ther 2010; 32:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/133\">",
"      Wild N, Andres H, Rollinger W, et al. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res 2010; 16:6111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/134\">",
"      Marshall KW, Mohr S, Khettabi FE, et al. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer 2010; 126:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/135\">",
"      Yip KT, Das PK, Suria D, et al. A case-controlled validation study of a blood-based seven-gene biomarker panel for colorectal cancer in Malaysia. J Exp Clin Cancer Res 2010; 29:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/9/38042/abstract/136\">",
"      Tao S, Haug U, Kuhn K, Brenner H. Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening. Br J Cancer 2012; 106:1424.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7576 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-8539BEA455-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38042=[""].join("\n");
var outline_f37_9_38042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCREENING RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STOOL-BASED TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Guaiac-based fecal occult blood test (gFOBT)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Sensitive gFOBT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immunochemical tests for fecal blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COLON IMAGING AND DIRECT VISUALIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Double-contrast barium enema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sigmoidoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Evidence of effectiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Follow-up of positive sigmoidoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      FOBT plus sigmoidoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Evidence of effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22320183\">",
"      Proximal lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22320331\">",
"      Sensitivity of colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Frequency of testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Computed tomographic colonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Test characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Extracolonic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31791528\">",
"      - Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      INVESTIGATIONAL TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194078445\">",
"      Fecal DNA tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H194078472\">",
"      - Hypermethylation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Capsule endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15240639\">",
"      Serum markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7576\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7576|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/15/31996\" title=\"table 1\">",
"      Screening tests for CRC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=related_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/39/27258?source=related_link\">",
"      Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36632?source=related_link\">",
"      Computed tomographic colonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11336?source=related_link\">",
"      Evaluation of occult gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4248?source=related_link\">",
"      Magnification endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7541?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/34/25123?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/12/42176?source=related_link\">",
"      Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3224?source=related_link\">",
"      Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17178?source=related_link\">",
"      Wireless video capsule endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_9_38043="Screen eating disorders obesity";
var content_f37_9_38043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Screening for eating disorders and obesity in adolescent patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Eating disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Further assessment is necessary for any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Weight loss greater than 10 percent of previous weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recurrent dieting when not overweight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distorted body image",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Body mass index below the 5th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Further assessment is necessary for any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Body mass index &ge;95th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Body mass index &ge;85th and &lt;95th percentile",
"        <strong>",
"         AND",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Family history of premature heart disease, obesity, hypertension, or diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        High blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        High total cholesterol (&gt;200 mg/dL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Increase of &ge;two points in body mass index in 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Concern about weight by adolescent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Story M, Neumark-Sztainer D. Adolesc Med 1999; 10:109.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38043=[""].join("\n");
var outline_f37_9_38043=null;
var title_f37_9_38044="Dx criteria panic disorder";
var content_f37_9_38044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for panic attack and panic disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Panic attack (summary of DSM-IV criteria)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A discrete period of intense fear or discomfort, in which four (or more) of the following symptoms develop abruptly and reach a peak within ten minutes:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Cardiopulmonary symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chest pain or discomfort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sensations of shortness of breath or smothering",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Palpitations, pounding heart, or accelerated heart rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Neurological symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trembling or shaking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parasthesias (numbness or tingling sensation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Feeling dizzy, unsteady, light-headed or faint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Psychiatric symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Derealization (feelings of unreality) or depersonalization (being detached from oneself)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fear of losing control or going crazy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fear of dying",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Autonomic symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sweating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chills or hot flushes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Gastrointestinal symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Feeling of choking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nausea or abdominal distress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Panic disorder (summary of DSM-IV criteria)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        With agoraphobia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A. Recurrent, unexpected panic attacks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B. At least one of the attacks has been followed by a month or more of: persistent concern about having additional attacks; worry about the implications of the attack or its consequences; a significant change in behavior related to the attacks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C. The presence of agoraphobia, ie, anxiety about being in places or situations in which escape might be difficult (or embarrassing) or in which help might not be available in the event of having a panic attack.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Without agoraphobia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A. Both A and B above",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B. Absence of agoraphobia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Diagnostic and Statistical Manual of Mental Disorders, 4th Ed, Primary Care Version (DSM-IV-PC). American Psychiatric Association, Washington, DC 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38044=[""].join("\n");
var outline_f37_9_38044=null;
var title_f37_9_38045="Exudative pleural effusions";
var content_f37_9_38045=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of exudative pleural effusions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infectious",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bacterial pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tuberculous pleurisy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Parasites",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fungal disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atypical pneumonias (viral, mycoplasma)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nocardia, Actinomyces",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Subphrenic abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatic abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Splenic abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spontaneous esophageal rupture",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Iatrogenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Central venous catheter misplacement/migration",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug-induced",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Esophageal perforation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Esophageal sclerotherapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Enteral feeding tube in pleural space",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Radiofrequency ablation of pulmonary neoplasms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Malignancy-related",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mesothelioma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leukemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chylothorax",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paraproteinemia (multiple myeloma, Waldenstrom's macroglobulinemia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other inflammatory disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis (acute, chronic)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Benign asbestos pleural effusion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary embolism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Radiation therapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Uremic pleurisy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postcardiac injury syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemothorax",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute respiratory distress syndrome (ARDS)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Increased negative intrapleural pressure with accompanying pleural malignancy or inflammation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lung entrapment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cholesterol effusion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Connective tissue disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lupus pleuritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatoid pleurisy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mixed connective tissue disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Churg-Strauss syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Granulomatosis with polyangiitis (Wegener's)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Familial mediterranean fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Endocrine dysfunction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypothyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ovarian hyperstimulation syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Lymphatic abnormalities",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malignancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chylothorax",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Yellow nail syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphangiomyomatosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphangiectasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Movement of fluid from abdomen to pleural space",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatic pseudocyst",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meigs' syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chylous ascites",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malignant ascites",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Subphrenic abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatic abscess (bacterial, amebic)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Splenic abscess, infarction",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38045=[""].join("\n");
var outline_f37_9_38045=null;
var title_f37_9_38046="Immune clearance of red cells";
var content_f37_9_38046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Immune-mediated clearance of erythrocytes in autoimmune hemolytic anemia (AIHA)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 337px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In warm-reactive AIHA, IgG autoantibodies are bound to erythrocytes but typically do not fix complement efficiently. IgG-coated cells enter the spleen and other parts of the reticuloendothelial system (RES), where they interact with Fc receptors on macrophages. Erythrocytes may be completely engulfed and destroyed by this interaction or may have only a portion of their membrane removed. In the latter case, the red cells will reshape into spherocytes, which are then destroyed on their next pasage through the spleen. In cold-reactive disease, complement is typically fixed very efficiently and intravascular lysis by the complement cascade can occur. Alternatively, the presence of surface-bound complement (C3) can lead to extravascular red cell destruction by the spleen and other portions of the RES, such as the liver.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ware RE. Autoimmune Hemolytic Anemia. In: Nathan and Oski's Hematology of Infancy and Childhood, 5th Ed, Nathan DG, Orkin SH (Eds), WB Saunders Company. Philadelphia 1998. p.508.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38046=[""].join("\n");
var outline_f37_9_38046=null;
var title_f37_9_38047="Major food groups";
var content_f37_9_38047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major food groups",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Grains",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Dairy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Whole grains",
"       </td>",
"       <td class=\"subtitle2_single\">",
"        Milk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brown rice",
"       </td>",
"       <td class=\"indent1\">",
"        Fat-free (skim)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Buckwheat",
"       </td>",
"       <td class=\"indent1\">",
"        Low fat (1 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bulgur (cracked wheat)",
"       </td>",
"       <td class=\"indent1\">",
"        Reduced fat (2 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oatmeal",
"       </td>",
"       <td class=\"indent1\">",
"        Whole milk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Popcorn",
"       </td>",
"       <td class=\"indent1\">",
"        Flavored milks (eg, chocolate, strawberry)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole grain barley",
"       </td>",
"       <td class=\"indent1\">",
"        Lactose reduced milks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole grain cornmeal",
"       </td>",
"       <td class=\"indent1\">",
"        Lactose free milks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole rye",
"       </td>",
"       <td class=\"subtitle2_single\">",
"        Milk-based desserts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole wheat bread",
"       </td>",
"       <td class=\"indent1\">",
"        Puddings made with milk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole wheat crackers",
"       </td>",
"       <td class=\"indent1\">",
"        Ice milk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole wheat pasta",
"       </td>",
"       <td class=\"indent1\">",
"        Frozen yogurt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole wheat sandwich buns and rolls",
"       </td>",
"       <td class=\"indent1\">",
"        Ice cream",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole wheat tortillas",
"       </td>",
"       <td class=\"subtitle2_single\">",
"        Cheese",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wild rice",
"       </td>",
"       <td class=\"indent1\">",
"        Cheddar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Less common whole grains",
"        </em>",
"       </td>",
"       <td class=\"indent1\">",
"        Mozzarella",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Amaranth",
"       </td>",
"       <td class=\"indent1\">",
"        Swiss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Millet",
"       </td>",
"       <td class=\"indent1\">",
"        Parmesan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Quinoa",
"       </td>",
"       <td class=\"indent1\">",
"        Ricotta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Sorghum",
"       </td>",
"       <td class=\"indent1\">",
"        Cottage cheese",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Triticale",
"       </td>",
"       <td class=\"indent1\">",
"        American",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Ready-to-eat breakfast cereals",
"        </em>",
"       </td>",
"       <td class=\"subtitle2_single\">",
"        Yogurt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Whole wheat cereal flakes",
"       </td>",
"       <td class=\"indent1\">",
"        Fat-free",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Muesli",
"       </td>",
"       <td class=\"indent1\">",
"        Low fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Refined grains",
"       </td>",
"       <td class=\"indent1\">",
"        Reduced fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cornbread",
"       </td>",
"       <td class=\"indent1\">",
"        Whole milk yogurt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Corn tortillas",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Couscous",
"       </td>",
"       <td class=\"subtitle2_single\">",
"        Meats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Crackers",
"       </td>",
"       <td class=\"indent1\">",
"        <em>",
"         Lean cuts of:",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flour tortillas",
"       </td>",
"       <td class=\"indent2\">",
"        Beef",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grits",
"       </td>",
"       <td class=\"indent2\">",
"        Ham",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Noodles",
"       </td>",
"       <td class=\"indent2\">",
"        Lamb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        White bread",
"       </td>",
"       <td class=\"indent2\">",
"        Pork",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        White sandwich buns and rolls",
"       </td>",
"       <td class=\"indent2\">",
"        Veal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        White rice",
"       </td>",
"       <td class=\"indent2\">",
"        Lean luncheon meats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pitas",
"       </td>",
"       <td class=\"indent1\">",
"        <em>",
"         Game meats",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pretzels",
"       </td>",
"       <td class=\"indent2\">",
"        Bison",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Pasta",
"        </em>",
"       </td>",
"       <td class=\"indent2\">",
"        Rabbit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Spaghetti",
"       </td>",
"       <td class=\"indent2\">",
"        Venison",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Macaroni",
"       </td>",
"       <td class=\"indent1\">",
"        <em>",
"         Lean ground meats",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Ready-to-eat breakfast cereals",
"        </em>",
"       </td>",
"       <td class=\"indent2\">",
"        Beef",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Corn flakes",
"       </td>",
"       <td class=\"indent2\">",
"        Pork",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Vegetables",
"       </td>",
"       <td class=\"indent2\">",
"        Lamb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Artichokes",
"       </td>",
"       <td class=\"indent1\">",
"        <em>",
"         Organ meats",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asparagus",
"       </td>",
"       <td class=\"indent2\">",
"        Liver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bean sprouts",
"       </td>",
"       <td class=\"indent2\">",
"        Giblets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beets",
"       </td>",
"       <td class=\"subtitle2_single\">",
"        Poultry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brussels sprouts",
"       </td>",
"       <td class=\"indent1\">",
"        Chicken",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cabbage",
"       </td>",
"       <td class=\"indent1\">",
"        Duck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cauliflower",
"       </td>",
"       <td class=\"indent1\">",
"        Goose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Celery",
"       </td>",
"       <td class=\"indent1\">",
"        Turkey",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cucumbers",
"       </td>",
"       <td class=\"indent1\">",
"        Ground chicken and turkey",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eggplant",
"       </td>",
"       <td class=\"subtitle2_single\">",
"        Eggs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Green beans",
"       </td>",
"       <td class=\"indent1\">",
"        Chicken eggs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Green or red peppers",
"       </td>",
"       <td class=\"indent1\">",
"        Duck eggs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iceberg (head) lettuce",
"       </td>",
"       <td class=\"subtitle2_single\">",
"        Dry beans and peas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mushrooms",
"       </td>",
"       <td class=\"indent1\">",
"        Black beans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Okra",
"       </td>",
"       <td class=\"indent1\">",
"        Black-eyed peas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onions",
"       </td>",
"       <td class=\"indent1\">",
"        Chickpeas (garbanzo beans)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parsnips",
"       </td>",
"       <td class=\"indent1\">",
"        Falafel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tomatoes",
"       </td>",
"       <td class=\"indent1\">",
"        Kidney beans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tomato juice",
"       </td>",
"       <td class=\"indent1\">",
"        Lentils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vegetable juice",
"       </td>",
"       <td class=\"indent1\">",
"        Lima beans (mature)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Turnips",
"       </td>",
"       <td class=\"indent1\">",
"        Navy beans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wax beans",
"       </td>",
"       <td class=\"indent1\">",
"        Pinto beans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zucchini",
"       </td>",
"       <td class=\"indent1\">",
"        Soy beans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Dark green vegetables",
"       </td>",
"       <td class=\"indent1\">",
"        Split peas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bok choy",
"       </td>",
"       <td class=\"indent1\">",
"        Tofu (bean curd made from soy beans)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Broccoli",
"       </td>",
"       <td class=\"indent1\">",
"        White beans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Collard greens",
"       </td>",
"       <td class=\"indent1\">",
"        <em>",
"         Bean burgers",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dark green leafy lettuce",
"       </td>",
"       <td class=\"indent2\">",
"        Garden burgers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kale",
"       </td>",
"       <td class=\"indent2\">",
"        Veggie burgers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mesclun",
"       </td>",
"       <td class=\"subtitle2_single\">",
"        Nuts and seeds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mustard greens",
"       </td>",
"       <td class=\"indent1\">",
"        Almonds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Romaine lettuce",
"       </td>",
"       <td class=\"indent1\">",
"        Cashews",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spinach",
"       </td>",
"       <td class=\"indent1\">",
"        Hazelnuts (filberts)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Turnip greens",
"       </td>",
"       <td class=\"indent1\">",
"        Mixed nuts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Watercress",
"       </td>",
"       <td class=\"indent1\">",
"        Peanuts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Orange vegetables",
"       </td>",
"       <td class=\"indent1\">",
"        Peanut butter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acorn squash",
"       </td>",
"       <td class=\"indent1\">",
"        Pecans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Butternut squash",
"       </td>",
"       <td class=\"indent1\">",
"        Pistachios",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carrots",
"       </td>",
"       <td class=\"indent1\">",
"        Pumpkin seeds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hubbard squash",
"       </td>",
"       <td class=\"indent1\">",
"        Sesame seeds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pumpkin",
"       </td>",
"       <td class=\"indent1\">",
"        Sunflower seeds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sweet potatoes",
"       </td>",
"       <td class=\"indent1\">",
"        Walnuts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Starchy vegetables",
"       </td>",
"       <td class=\"subtitle2_single\">",
"        Fish",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Corn",
"       </td>",
"       <td class=\"indent1\">",
"        <em>",
"         Finfish such as:",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Green peas",
"       </td>",
"       <td class=\"indent2\">",
"        Catfish",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lima beans (green)",
"       </td>",
"       <td class=\"indent2\">",
"        Cod",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Potatoes",
"       </td>",
"       <td class=\"indent2\">",
"        Flounder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fruits",
"       </td>",
"       <td class=\"indent2\">",
"        Haddock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apples",
"       </td>",
"       <td class=\"indent2\">",
"        Halibut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apricots",
"       </td>",
"       <td class=\"indent2\">",
"        Herring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avocado",
"       </td>",
"       <td class=\"indent2\">",
"        Mackerel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bananas",
"       </td>",
"       <td class=\"indent2\">",
"        Pollock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cherries",
"       </td>",
"       <td class=\"indent2\">",
"        Porgy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grapes",
"       </td>",
"       <td class=\"indent2\">",
"        Salmon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kiwi fruit",
"       </td>",
"       <td class=\"indent2\">",
"        Sea bass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mangoes",
"       </td>",
"       <td class=\"indent2\">",
"        Snapper",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nectarines",
"       </td>",
"       <td class=\"indent2\">",
"        Swordfish",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peaches",
"       </td>",
"       <td class=\"indent2\">",
"        Trout",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pears",
"       </td>",
"       <td class=\"indent2\">",
"        Tuna",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papaya",
"       </td>",
"       <td class=\"indent1\">",
"        <em>",
"         Shellfish such as:",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pineapple",
"       </td>",
"       <td class=\"indent2\">",
"        Clams",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plums",
"       </td>",
"       <td class=\"indent2\">",
"        Crab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prunes",
"       </td>",
"       <td class=\"indent2\">",
"        Crayfish",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Raisins",
"       </td>",
"       <td class=\"indent2\">",
"        Lobster",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fruit cocktail",
"       </td>",
"       <td class=\"indent2\">",
"        Mussels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Berries",
"       </td>",
"       <td class=\"indent2\">",
"        Octopus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Strawberries",
"       </td>",
"       <td class=\"indent2\">",
"        Oysters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blueberries",
"       </td>",
"       <td class=\"indent2\">",
"        Scallops",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Raspberries",
"       </td>",
"       <td class=\"indent2\">",
"        Squid (calamari)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Melons",
"       </td>",
"       <td class=\"indent2\">",
"        Shrimp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cantaloupe",
"       </td>",
"       <td class=\"indent1\">",
"        <em>",
"         Canned fish such as:",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Honeydew",
"       </td>",
"       <td class=\"indent2\">",
"        Anchovies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Watermelon",
"       </td>",
"       <td class=\"indent2\">",
"        Clams",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Citrus",
"       </td>",
"       <td class=\"indent2\">",
"        Tuna",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grapefruit",
"       </td>",
"       <td class=\"indent2\">",
"        Sardines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lemons",
"       </td>",
"       <td class=\"indent2\" rowspan=\"9\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Limes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oranges",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tangerines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        100 percent fruit juice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Orange",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apple",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grape",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grapefruit",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from:",
"     <a href=\"file://www.mypyramid.gov\" target=\"_blank\">",
"      www.mypyramid.gov",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_9_38047=[""].join("\n");
var outline_f37_9_38047=null;
